Partnerre (PREJF) 20-F 21 Mar 23 2022 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2022 shares
Entity Listings [Line Items]
Document type	20-F
Amendment flag	false
Document Registration Statement	false
Document Annual Report	true
Document period end date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-14536
Entity registrant name	PartnerRe Ltd.
Entity Incorporation, State or Country Code	D0
Entity Address, Address Line One	90 Pitts Bay Road
Entity Address, City or Town	Pembroke
Entity Address, Country	BM
Entity Address, Postal Zip Code	HM08
Title of 12(b) Security	4.875% Series J Fixed Rate Non-Cumulative Preferred Shares, $1.00 par value
Trading Symbol	PRE-J
Security Exchange Name	NYSE
Entity well known seasoned issuer	No
Entity voluntary filers	No
Entity current reporting status	Yes
Entity Interactive Data Current	Yes
Entity filer category	Non-accelerated Filer
Entity emerging growth company	false
ICFR Auditor Attestation Flag	false
Document Accounting Standard	U.S. GAAP
Entity shell company	false
Document Fiscal Year Focus	2022
Current fiscal year end date	--12-31
Entity central index key	0000911421
Business Contact
Entity Listings [Line Items]
Contact Personnel Name	Abina Kealy
Entity Address, Address Line One	90 Pitts Bay Road
Entity Address, City or Town	Pembroke
Entity Address, Country	BM
Entity Address, Postal Zip Code	HM 08
Contact Personnel Email Address	abina.kealy@partnerre.com
Common shares
Entity Listings [Line Items]
Entity common stock shares outstanding	100,000,000
Common Class C
Entity Listings [Line Items]
Entity common stock shares outstanding	7,666

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers Ltd.	Ernst & Young Ltd.
Auditor Location	Hamilton, Bermuda	Hamilton, Bermuda
Auditor Firm ID	1403	1277

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Fixed maturities, at fair value (amortized cost: 2022, $14,925,319; 2021, $14,181,310)	$ 13,021,914	$ 14,071,274
Short-term investments, at fair value (amortized cost: 2022, $536,139; 2021, $213,047)	523,510	205,146
Equities, at fair value (cost: 2022, $586,107; 2021, $903,314)	929,886	1,751,584
Investments in real estate	57,984	67,539
Other invested assets	3,355,106	3,601,245
Total investments	17,888,400	19,696,788
Cash and cash equivalents (restricted: 2022, $137,782; 2021: $104,971)	1,251,596	660,897
Accrued investment income	103,752	94,997
Reinsurance balances receivable	3,342,612	3,063,153
Reinsurance recoverable on paid and unpaid losses	1,959,652	1,787,493
Prepaid reinsurance premiums	247,276	216,338
Funds held by reinsured companies	471,570	561,576
Deferred acquisition costs	1,012,850	920,779
Deposit assets	81,053	109,528
Net tax assets	164,384	154,472
Goodwill	456,380	456,380
Intangible assets	89,769	98,818
Other assets	203,119	208,652
Total assets	27,272,413	28,029,871
Liabilities
Non-life reserves	12,725,631	12,047,792
Life and health reserves	2,510,293	2,638,086
Unearned premiums	2,745,371	2,501,161
Other reinsurance balances payable	632,336	744,735
Debt	1,848,003	1,897,499
Deposit liabilities	4,681	5,077
Net tax liabilities	29,154	90,974
Accounts payable, accrued expenses and other	488,594	560,561
Total liabilities	20,984,063	20,485,885
Shareholders’ Equity
Common shares (par value $0.00000001; issued and outstanding: 100,000,000 shares)	0	0
Preferred shares (par value $1.00; issued and outstanding: 8,000,000 shares; aggregate liquidation value: $200,000)	8,000	8,000
Additional paid-in capital	1,929,934	1,929,934
Accumulated other comprehensive loss	(7,669)	(29,706)
Retained earnings	4,358,085	5,635,758
Total shareholders’ equity	6,288,350	7,543,986
Total liabilities and shareholders’ equity	$ 27,272,413	$ 28,029,871

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Amortized cost of trading securities, debt	$ 14,925,319	$ 14,181,310
Short-term investments, amortized cost	536,139	213,047
Equities, at cost	586,107	903,314
Restricted cash and cash equivalents	$ 137,782	$ 104,971
Common shares, par value	$ 0.00	$ 0.00
Common shares, shares issued	100,000,000	100,000,000
Common stock, shares outstanding	100,000,000	100,000,000
Preferred shares, par value per share	$ 1	$ 1
Preferred shares, shares issued	8,000,000	8,000,000
Preferred shares, shares outstanding	8,000,000	8,000,000
Aggregate liquidation value	$ 200,000	$ 200,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Gross premiums written	$ 8,689,279	$ 8,203,925	$ 6,875,925
Net premiums written	7,544,195	7,134,018	6,300,858
(Increase) decrease in unearned premiums	(287,078)	(177,496)	235,968
Net premiums earned	7,257,117	6,956,522	6,536,826
Net investment income	398,348	376,469	360,668
Net realized and unrealized investment (losses) gains	(1,969,014)	37,797	454,319
Other income	40,492	28,748	13,491
Total revenues	5,726,943	7,399,536	7,365,304
Expenses
Losses and loss expenses	4,747,403	4,883,984	5,334,900
Acquisition costs	1,540,681	1,386,832	1,356,118
Other expenses	414,876	398,542	355,647
Interest expense	55,185	55,606	39,200
Amortization of intangible assets	8,912	8,861	9,988
Net foreign exchange losses	29,402	30,883	51,964
Total expenses	6,796,459	6,764,708	7,147,817
(Loss) income before taxes and interest in earnings of equity method investments	(1,069,516)	634,828	217,487
Income tax (expense) benefit	(31,334)	(38,219)	13,091
Interest in earnings of equity method investments	10,821	126,795	23,611
Net (loss) income	(1,090,029)	723,404	254,189
Preferred dividends	9,750	22,693	45,990
Loss on redemption of preferred shares	0	21,234	2,341
Net (loss) income attributable to common shareholder	(1,099,779)	679,477	205,858
Comprehensive (loss) income
Net (loss) income	(1,090,029)	723,404	254,189
Change in currency translation adjustment	9,464	43,120	(5,884)
Change in unfunded pension obligation, net of tax	12,573	23,307	(14,383)
Change in unrealized gains or losses on investments, net of tax	0	(128)	187
Other comprehensive income (loss)	22,037	66,299	(20,080)
Comprehensive (loss) income	$ (1,067,992)	$ 789,703	$ 234,109

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common shares	Preferred shares	Additional paid-in capital	Accumulated other comprehensive loss	Currency translation adjustment	Unfunded pension obligation	Unrealized gain (loss) on investments	Retained earnings	Retained earnings Cumulative effect of adoption of accounting guidance
Balance at beginning of year at Dec. 31, 2019		$ 0	$ 28,169	$ 2,396,530	$ (75,925)	$ (59,904)	$ (15,988)	$ (33)	$ 4,921,395	$ (14,305)
Issuance of preferred shares			0	0
Redemption of preferred shares			(2,679)	(61,966)
Change in currency translation adjustment	$ (5,884)					(5,884)
Change in unfunded pension obligation, net of tax	(14,383)						(14,383)
Change in unrealized gains or losses on investments, net of tax	187							187
Net (loss) income	254,189								254,189
Dividends on common shares									(50,000)
Dividends on preferred shares	(45,990)								(45,990)
Loss on redemption of preferred shares	(2,341)								(2,341)
Balance at end of year at Dec. 31, 2020	7,326,997	0	25,490	2,334,564	(96,005)	(65,788)	(30,371)	154	5,062,948	0
Balance at end of period, tax impact							7,559	0
Issuance of preferred shares			8,000	185,887
Redemption of preferred shares			(25,490)	(590,517)
Change in currency translation adjustment	43,120					43,120
Change in unfunded pension obligation, net of tax	23,307						23,307
Change in unrealized gains or losses on investments, net of tax	(128)							(128)
Net (loss) income	723,404								723,404
Dividends on common shares									(106,667)
Dividends on preferred shares	(22,693)								(22,693)
Loss on redemption of preferred shares	(21,234)								(21,234)
Balance at end of year at Dec. 31, 2021	$ 7,543,986	0	8,000	1,929,934	(29,706)	(22,668)	(7,064)	26	5,635,758	$ 0
Accounting Standards Update	Accounting Standards Update 2016-13
Balance at end of period, tax impact							1,840	0
Issuance of preferred shares			0	0
Redemption of preferred shares			0	0
Change in currency translation adjustment	$ 9,464					9,464
Change in unfunded pension obligation, net of tax	12,573						12,573
Change in unrealized gains or losses on investments, net of tax	0							0
Net (loss) income	(1,090,029)								(1,090,029)
Dividends on common shares									(177,894)
Dividends on preferred shares	(9,750)								(9,750)
Loss on redemption of preferred shares	0								0
Balance at end of year at Dec. 31, 2022	$ 6,288,350	$ 0	$ 8,000	$ 1,929,934	$ (7,669)	$ (13,204)	5,509	26	$ 4,358,085
Balance at end of period, tax impact							$ 1,230	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net (loss) income		$ (1,090,029)	$ 723,404	$ 254,189
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of net premium on investments		78,162	57,900	34,708
Amortization of intangible assets		8,912	8,861	9,988
Net realized and unrealized investment losses (gains)		1,969,014	(37,797)	(454,319)
Changes in:
Reinsurance balances, net		(381,838)	19,366	274,506
Reinsurance recoverable on paid and unpaid losses, net of ceded premiums payable		(325,409)	(637,908)	16,026
Funds held by reinsured companies		53,335	113,626	175,272
Deferred acquisition costs		(131,236)	(122,739)	74,871
Net tax assets and liabilities		(72,452)	3,256	(23,647)
Non-life and life and health reserves		1,009,439	903,324	944,263
Unearned premiums, net of prepaid reinsurance premiums		287,078	177,496	(235,968)
Other net changes in operating assets and liabilities		63,433	23,801	55,004
Net cash provided by operating activities		1,468,409	1,232,590	1,124,893
Cash flows from investing activities
Sales of fixed maturities		623,929	3,693,365	5,518,588
Redemptions of fixed maturities		1,216,920	2,381,821	1,821,934
Purchases of fixed maturities		(2,940,597)	(8,141,246)	(8,962,066)
Sales of short-term investments		308,622	252,527	3,637,532
Redemptions of short-term investments		227,118	321,609	1,971,826
Purchases of short-term investments		(867,605)	(372,901)	(5,006,397)
Sales of equities		915,583	161,501	143,932
Purchases of equities		(78,425)	(144,537)	(151,292)
Sales and redemptions of other invested assets		545,411	1,106,211	1,300,591
Purchases of other invested assets		(627,460)	(1,555,569)	(930,827)
Other, net		11,679	(31,903)	23,431
Net cash used in investing activities		(664,825)	(2,329,122)	(632,748)
Cash flows from financing activities
Dividends paid to common and preferred shareholders		(187,644)	(129,360)	(95,990)
Issuance of unrestricted Class B common shares	[1]	0	0	2,257
Redemption of Class B common shares	[1]	(6,346)	(581)	(5,157)
Issuance of preferred shares		0	193,887	0
Redemption of preferred shares		0	(637,241)	(66,985)
Issuance of debt		0	0	494,237
Redemption of debt		(560)	0	0
Net cash (used in) provided by financing activities		(194,550)	(573,295)	328,362
Effect of foreign exchange rate changes on cash		(18,335)	(20,109)	45,863
Increase (decrease) in cash and cash equivalents		590,699	(1,689,936)	866,370
Cash and cash equivalents—beginning of year		660,897	2,350,833	1,484,463
Cash and cash equivalents—end of year		1,251,596	660,897	2,350,833
Supplemental cash flow information:
Taxes paid		216,467	100,222	64,288
Interest paid		$ 54,867	$ 56,177	$ 33,164
[1]Class B shares are liability-accounted on the Company's Consolidated Balance Sheet. See Note 13 for further details.

Organization

Organization	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization PartnerRe Ltd. primarily provides reinsurance on a worldwide basis through its principal wholly-owned subsidiaries, including Partner Reinsurance Company Ltd. (PartnerRe Bermuda), Partner Reinsurance Europe SE (PartnerRe Europe), Partner Reinsurance Company of the U.S. (PartnerRe U.S.), Partner Reinsurance Asia Pte. Ltd. (PartnerRe Asia) and PartnerRe Life Reinsurance Company of Canada (PartnerRe Canada). Non-life risks reinsured include agriculture, aviation/space, casualty, catastrophe, energy, engineering, financial risks, marine, motor, multiline, property and U.S. health. Life and health risks include mortality, morbidity, longevity and financial reinsurance solutions. Reinsurance of alternative risk products include weather and credit protection to financial, industrial and service companies on a worldwide basis. PartnerRe Ltd. and it subsidiaries are collectively referred to hereinafter as PartnerRe, the Company or the Group. The Company was incorporated in August 1993 under the laws of Bermuda. The Company commenced operations in November 1993 upon completion of the sale of common shares and warrants pursuant to subscription agreements and an initial public offering. The Company completed the acquisition of Societe Anonyme Francaise de Reassurances (SAFR) in 1997, the acquisition of Winterthur Re in 1998, the acquisition of PARIS RE Holdings Limited (Paris Re) in 2009, the acquisition of Presidio Reinsurance Group, Inc. (Presidio) in 2012 and the acquisition of Aurigen Capital Limited (Aurigen) in 2017. On March 18, 2016, the Company's publicly held common shares were acquired by Exor N.V. (subsequently renamed to EXOR Nederland N.V), whose ultimate parent is EXOR N.V. (Exor), which is listed on the Milan Stock Exchange. As a result of the acquisition, PartnerRe's publicly issued common shares were cancelled and are no longer publicly traded. On December 16, 2021, Exor announced that it had signed a definitive agreement with Covéa Coopérations S.A. (Covéa), under which Covéa would acquire PartnerRe's common shares. Preferred shares issued by PartnerRe were not included in the proposed transaction. Consummation of this transaction occurred on July 12, 2022. The Company’s preferred shares continue to be traded on the New York Stock Exchange (NYSE).

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies The Company’s Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. While management believes that the amounts included in the Consolidated Financial Statements reflect its best estimates and assumptions, actual results could differ from those estimates. The Company’s principal estimates include: • Non-life reserves; • Life and health reserves; • Reinsurance recoverable for unpaid losses; • Gross and net premiums written and net premiums earned; • Recoverability of deferred acquisition costs; • Recoverability of deferred tax assets; • Fair value measurements of financial instrument assets; and • Valuation of goodwill and intangible assets. The following are the Company’s significant accounting policies: (a) Premiums Gross premiums written and earned are based upon reports received from ceding companies, supplemented by the Company’s own estimates of premiums written and earned for which ceding company reports have not been received. The determination of premium estimates requires a review of the Company’s experience with cedants, familiarity with each market, an understanding of the characteristics of each line of business and management’s assessment of the impact of various other factors on the volume of business written and ceded to the Company. Premium estimates are updated as new information is received from cedants and differences between such estimates and actual amounts are recorded in the period in which the estimates are changed or the actual amounts are determined. Net premiums written and earned are presented net of ceded premiums. Premiums related to non-life business are earned on a basis that is consistent with the risks covered under the terms of the reinsurance contracts, which is generally one to two years. Reinstatement premiums are recognized as written and earned at the time a loss event occurs, where coverage limits for the remaining life of the contract are reinstated under pre-defined contract terms. The accrual of reinstatement premiums is based on management’s estimate of losses and loss expenses associated with the loss event. Unearned premiums represent the portion of premiums written which is applicable to the unexpired risks under contracts in force. Premiums related to life and annuity business are recorded over the premium-paying period on the underlying policies. Premiums on contracts for which there is no significant mortality or critical illness risk are accounted for in a manner consistent with accounting for interest-bearing financial instruments and are not reported as revenues, but rather as direct deposits to the contract. Amounts assessed against annuity and universal life policyholders are recognized as revenue in the period assessed. (b) Losses and Loss Expenses The reserves for non-life business include amounts determined from loss reports on individual treaties (case reserves), additional case reserves when the Company’s loss estimate is higher than reported by the cedants (ACRs) and amounts for losses incurred but not yet reported to the Company (IBNR). Such reserves are estimated by management based upon reports received from ceding companies, supplemented by the Company’s own actuarial estimates of reserves for which ceding company reports have not been received, and based on the Company’s own historical experience. To the extent that the Company’s own historical experience is inadequate for estimating reserves, such estimates may be determined based upon industry experience and management’s judgment. The estimates are regularly reviewed and the ultimate liability may be materially in excess of, or less than, the amounts provided. Any adjustments are reflected in the periods in which they are determined, which may affect the Company’s operating results in future periods. See Note 7(a) for further details. The life and health reserves have been established based upon information reported by ceding companies, supplemented by the Company’s actuarial estimates, which for life include mortality, morbidity, critical illness, persistency and future investment income, with appropriate provision to reflect uncertainty. For traditional and limited payment long-duration contracts, the assumptions are locked in at contract inception and are subject to annual loss recognition testing. Future policy benefit reserves for annuity and universal life contracts are carried at their accumulated values. Reserves for policy claims and benefits include both mortality, morbidity and critical illness claims in the process of settlement, and claims that have been incurred but not yet reported. See Note 7(b) for further details. (c) Deferred Acquisition Costs Acquisition costs, comprising primarily incremental brokerage fees, commissions and excise taxes, which vary directly with, and are related to, the successful acquisition of reinsurance contracts, are capitalized and charged to expense as the related premium is earned. All other acquisition related costs, including indirect costs, are expensed as incurred. Acquisition costs are shown net of commissions earned on ceded reinsurance. Acquisition costs related to individual life and annuity contracts are deferred and amortized over the premium-paying periods in proportion to anticipated premium income, allowing for lapses, terminations and anticipated investment income. Acquisition costs related to universal life and single premium annuity contracts for which there is no significant mortality or critical illness risk are deferred and amortized over the lives of the contracts as a percentage of the estimated gross profits expected to be realized on the contracts. The Company establishes a premium deficiency reserve to the extent the deferred acquisition costs are insufficient to cover the excess of expected losses and loss expenses, settlement costs and deferred acquisition costs over the related unearned premiums. Actual and anticipated losses and loss expenses, other costs, and investment income related to underlying premiums are considered in determining the recoverability of deferred acquisition costs for the Company’s short-duration contracts. Actual and anticipated loss experience, together with the present value of future gross premiums, the present value of future benefits, and settlement and maintenance costs are considered in determining the recoverability of deferred acquisition costs related to the Company’s life and annuity business. (d) Reinsurance The Company purchases retrocessional contracts to reduce its exposure to risk of losses on reinsurance assumed. Ceded premiums, which represent the cost of retrocessional protection purchased by the Company, are expensed over the coverage period. Prepaid reinsurance premiums represent the portion of premiums ceded applicable to the unexpired term of policies in force. Reinsurance recoverable on paid and unpaid losses involves actuarial estimates consistent with those used to establish the associated liabilities for non-life and life and health reserves and are recorded net of a valuation allowance for estimated uncollectible recoveries. Retroactive reinsurance reimburses a ceding company for liabilities incurred as a result of past insurable events covered under contracts subject to the reinsurance. Premiums payable for retroactive reinsurance coverage meeting the conditions of reinsurance accounting are reported as reinsurance recoverables. To the extent that recorded liabilities on an underlying reinsurance contract exceed premiums payable for retroactive coverage, a deferred gain is recognized in Accounts payable, accrued expenses and other on the Company's Consolidated Balance Sheets and amortized over estimated remaining settlement period of the underlying contract. Any such amortization is included in Loss and loss expenses in the Consolidated Statements of Operations. (e) Funds Held by Reinsured Companies The Company writes certain business on a funds held basis. Under such contractual arrangements, the cedant retains the premiums that would have otherwise been paid to the Company and the Company is credited with investment income on these funds. The Company generally earns investment income on the funds held balances based upon a predetermined interest rate, either fixed contractually at the inception of the contract or based upon a recognized index (e.g. LIBOR, SOFR). However, in certain circumstances, the Company may receive an investment return based upon either the result of a pool of assets held by the cedant, generally used to collateralize the funds held balance, or the investment return earned by the cedant on its entire investment portfolio. In these arrangements, investment returns are typically reflected in Net investment income in the Company’s Consolidated Statements of Operations. In these arrangements, the Company is exposed, to a limited extent, to the underlying credit risk of the pool of assets inasmuch as the underlying policies may have guaranteed minimum returns. In such cases, an embedded derivative exists and its fair value is recorded by the Company as an increase or decrease to the funds held balance. (f) Deposit Assets and Liabilities In the normal course of its operations, the Company writes certain contracts that do not meet the risk transfer provisions of U.S. GAAP. While these contracts do not meet risk transfer provisions for accounting purposes, there is a remote possibility that the Company will suffer a loss. The Company accounts for these contracts using the deposit accounting method originally recording deposit assets or liabilities for an amount equivalent to the consideration paid or received, respectively. The difference between the consideration received and the estimated liability for unpaid losses is determined upon entering into the contract and, if a loss, recognized into income immediately, and if a gain, the gain is deferred and earned over the expected settlement period of the contract, with the unearned portion recorded as a component of deposit liabilities. Actuarial studies are used to estimate the liabilities under these contracts and the appropriate accretion rates to increase or decrease the liabilities over the term of the contracts. The change in the estimated liability for the period is recorded in Other income or loss in the Consolidated Statements of Operations. Under some of these contracts, cedants retain the assets on a funds-held basis. In those cases, the Company records those assets as deposit assets and records the related income in Net investment income in the Consolidated Statements of Operations. Also included in Deposit assets are receivables included as an element of certain life reinsurance agreements that do not meet risk transfer. (g) Investments The Company elects the fair value option for Fixed maturities, Short-term investments and Equities with changes in fair value recorded in Net realized and unrealized investment gains or losses in the Consolidated Statements of Operations. Short-term investments comprise securities with a maturity greater than three months but less than one year from the date of purchase. Investments in real estate includes real estate that is directly held by the Company, which is recorded at cost less any write down for impairment, where applicable. Real estate assets held for investment are reviewed for impairment at least annually, or more frequently when events or changes in circumstances indicate the carrying value may not be recoverable and exceeds its estimated fair value. The Company recognizes Other invested assets at fair value, except for those that are accounted for using the equity method of accounting. Other invested assets consist of equity investments in non-publicly traded companies such as limited liability companies and limited partnerships (or similar structures); privately placed corporate loans, notes and loans receivable and notes securitization; and derivative financial instruments. Non-publicly traded entities in which the Company has significant influence, including an ownership of more than 20% and less than 50% of the voting rights, and limited partnerships (or similar structures) in which the Company has more than a minor interest (typically more than 3 to 5%), are accounted for using either the equity method or the fair value option. Where the equity method is used, the Company's share of profits or losses of the investee are recorded in Interest in earnings or losses of equity method investees in the Consolidated Statements of Operations. The Company has not elected the fair value option for these equity method investees as the carrying values already approximate fair value. Where the fair value option is elected, the investment is recognized in the Consolidated Balance Sheets at fair value with changes in fair value recorded in Net realized and unrealized investment gains or losses in the Consolidated Statements of Operations. See Note 2(n) below for significant accounting policy for derivatives. The Company defines fair value as the price received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company measures the fair value of financial instruments according to a fair value hierarchy that prioritizes the information used to measure fair value into three broad levels. The Company’s policy is to recognize transfers between the hierarchy levels at the beginning of the period. Refer to Note 3 for the valuation techniques used by the Company. The Company invests in various funds where the net asset value (NAV) is used as a basis for determining fair value. The Company applies the practical expedient relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of these fund investments based on that NAV per share, or its equivalent. Refer to Note 3 for the valuation methods and assumptions used by the Company. Net investment income includes interest and dividend income, amortization of premiums and discounts on fixed maturities and short-term investments, and is net of investment expenses and withholding taxes. Investment income is recognized when earned and accrued to the balance sheet date. Realized gains or losses on the disposal of investments are determined on a first-in, first-out basis. Investment purchases and sales are recorded on a trade-date basis. (h) Cash and Cash Equivalents Cash equivalents are carried at fair value and include fixed income securities that, from the date of purchase, have a maturity of three months or less. (i) Business Combinations The Company accounts for transactions in which it obtains control over one or more businesses using the acquisition method. The purchase price is allocated to identifiable assets and liabilities, including any intangible assets, based on their estimated fair value at the acquisition date. The estimates of fair values for assets and liabilities acquired are determined based on various market and income analyses and appraisals. Any excess of the purchase price over the fair value of net assets acquired is recorded as Goodwill in the Company’s Consolidated Balance Sheets, while any excess of the fair value of net assets acquired over the purchase price is recorded as a gain in the Consolidated Statements of Operations. All costs associated with an acquisition are expensed as incurred. (j) Goodwill Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in a business combination. The Company assesses the appropriateness of its valuation of goodwill on an annual basis (as of December 31) or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. If, as a result of the assessment, the Company determines that the value of its goodwill is impaired, goodwill will be written down in the period in which the determination is made. (k) Intangible Assets Intangible assets represent the fair value adjustments related to renewal rights, and customer relationships; value of life business acquired; and U.S. licenses arising from acquisitions. Definite-lived intangible assets are amortized over their useful lives and the Amortization of intangible assets is recorded in the Consolidated Statement of Operations. Indefinite-lived intangible assets are not subject to amortization. The carrying values of indefinite-lived intangible assets are reviewed for indicators of impairment on an annual basis (as of December 31) or more frequently if events or changes in circumstances indicate that impairment may exist. Impairment is recognized if the carrying values of the intangible assets are not recoverable from their undiscounted cash flows and is measured as the difference between the carrying value and the fair value. (l) Income Taxes Certain subsidiaries and branches of the Company operate in jurisdictions where they are subject to taxation. Current and deferred income taxes are charged or credited to Net income or loss or, in certain cases, to Accumulated other comprehensive income or loss, based upon enacted tax laws and rates applicable in the relevant jurisdiction in the period in which the tax becomes accruable or realizable. Deferred income taxes are provided for all temporary differences between the bases of assets and liabilities used in the Consolidated Balance Sheets and those used in the various jurisdictional tax returns. When management’s assessment indicates that it is more likely than not that deferred tax assets will not be realized, a valuation allowance is recorded against the deferred tax assets. Where appropriate, the valuation allowance assessment considers tax planning strategies. The Company recognizes a tax benefit relating to uncertain tax positions only where the position is more likely than not to be sustained assuming examination by tax authorities. A liability is recognized for any tax benefit (along with any interest and penalty, if applicable) claimed in a tax return in excess of the amount recognized in the financial statements under U.S. GAAP. Any changes in amounts recognized are recorded in the period in which they are determined. (m) Foreign Exchange In recording foreign currency transactions, revenue and expense items in a currency other than the functional currency are converted into the functional currency at the average rates of exchange for the period. Monetary assets and liabilities originating in currencies other than the functional currency are remeasured into the functional currency at the rates of exchange in effect at the balance sheet dates. The resulting foreign exchange transaction gains or losses are included in Net foreign exchange gains or losses in the Consolidated Statements of Operations. Non-monetary assets and liabilities denominated in foreign currency are not subsequently remeasured. The reporting currency of the Company is the U.S. dollar. The national currencies of the Company’s subsidiaries and branches are generally their functional currencies, except for the Company’s Bermuda subsidiaries, its branches in Switzerland and the United Kingdom and its Singapore subsidiary and branches, whose functional currency is the U.S. dollar. In translating the financial statements of those subsidiaries or branches whose functional currency is other than the U.S. dollar, assets and liabilities are converted into U.S. dollars using the rates of exchange in effect at the balance sheet dates, and revenues and expenses are converted using the average foreign exchange rates for the period. The effect of translation adjustments are reported in the Consolidated Balance Sheets as Currency translation adjustment, a separate component of Accumulated other comprehensive income or loss. The change in currency translation adjustment is reflected in Other comprehensive income or loss. (n) Derivatives The Company’s investment strategy allows for the use of certain derivative instruments, subject to strict limitations. The Company may use derivative financial instruments such as foreign exchange forward contracts, foreign currency option contracts, futures contracts, to-be-announced mortgage-backed securities (TBAs), total return swaps, interest rate swaps, insurance-linked securities, and credit default swaps for the purpose of managing overall currency risk, market exposures and portfolio duration, for hedging certain investments, or for enhancing investment performance that would be allowed under the Company’s investment policy if implemented in other ways. On the date the Company enters into a derivative contract, management determines whether or not the derivative is to be used and designated as a hedge of an identified underlying risk exposure (a designated hedge). The Company’s derivative instruments are recorded in Other invested assets in the Consolidated Balance Sheets at fair value, with gains and losses associated with changes in fair value recognized in either Net realized and unrealized investment gains or losses or Net foreign exchange gains or losses in the Consolidated Statements of Operations, or in Other comprehensive income or loss, depending on the nature and designation of the derivative instrument (see also Note 5). The Company formally documents all relationships between designated hedging instruments and hedged items, as well as its risk management objectives and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the asset or liability that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally measures effectiveness of its designated hedging relationships both at the hedge inception and on an ongoing basis. The Company will discontinue hedge accounting prospectively if it is determined that the derivative is no longer effective in hedging the exposure to variability in expected future cash flows that is attributable to the risk it was meant to hedge; if the derivative instrument expires, is sold, or is otherwise terminated; or if the Company removes the designation of the hedge. To the extent that the Company discontinues hedge accounting because, based on management’s assessment, the derivative no longer qualifies as an effective hedge, or the Company otherwise de-designates the hedge, the derivative will continue to be carried in the Consolidated Balance Sheet at its fair value, with changes in its fair value recognized in in the Consolidated Statements of Operations, or in Other comprehensive income or loss, depending on the type of derivative held. (o) Pensions The Company recognizes an asset or a liability in the Consolidated Balance Sheets for the funded status of its defined benefit plans that are overfunded or underfunded, respectively, measured as the difference between the fair value of plan assets and the pension obligation and recognizes changes in the funded status of defined benefit plans in the year in which the changes occur as a component of Accumulated other comprehensive income or loss, net of tax. (p) Variable Interest Entities The Company is involved in the normal course of business with variable interest entities (VIEs). An assessment is performed as of the date the Company becomes initially involved in the VIE followed by a reassessment upon certain events related to its involvement in the VIE. The Company consolidates a VIE when it is the primary beneficiary having a controlling financial interest as a result of having the power to direct the activities that most significantly impact the economic performance of the VIE and the obligation to absorb losses, or right to receive benefits, that could potentially be significant to the VIE. (q) Segment Reporting The Company monitors the performance of its operations in three segments: Property & Casualty (P&C), Specialty and Life and Health. Segments represent markets that are reasonably homogeneous in terms of client types, buying patterns, underlying risk patterns or approach to risk management. Since the Company does not manage its assets by segment, neither assets nor net investment income are allocated to the P&C and Specialty segments. However, because of the interest-sensitive nature of some of the Company’s life products, allocated net investment income is considered in management’s assessment of the profitability of the Life and Health segment. The following items are not considered in evaluating the results of the P&C, Specialty and Life and Health segments: Net realized and unrealized investment gains or losses, Interest expense, Loss on redemption of debt, Amortization of intangible assets, Net foreign exchange gains or losses, Income tax expense or benefit and Interest in earnings and losses of equity method investments. These items are included in the Corporate and Other component, which is comprised of the Company’s investment and corporate activities, including other expenses. (r) Share-Based Incentives The Company is authorized to issue Class C common shares and restricted share units to certain executives and directors. Prior to the adoption of the new Class C common shares and related restricted share unit plan in 2021, the Company was authorized to issue restricted Class B common shares. The compensation cost for grants of Class B and C common shares and restricted share units is measured at fair value and expensed over the period for which the employee is required to provide services in exchange for the award, up to three years from the date of grant. The Company has elected to recognize forfeitures as they occur. Class B and C common shares and restricted share units are accounted for as liabilities and included in Accounts payable, accrued expenses and other on the Consolidated Balance Sheets. See Note 13 for further details. (s) Recent Accounting Pronouncements Recently adopted In October 2020, the FASB issued updated guidance to clarify that callable debt securities should be reevaluated each reporting period to determine if the amortized cost exceeds the amount repayable by the issuer at the next earliest call date and, if so, the excess should be amortized to the next call date. This guidance is effective for fiscal years beginning after December 15, 2020, and the Company adopted this guidance effective January 1, 2021 on a prospective basis for existing or newly purchased callable debt securities. The adoption did not have a material impact on the Company's Consolidated Financial Statements. In March 2020, the U.S. Securities and Exchange Commission (the SEC) adopted amendments to the financial disclosure requirements related to certain debt securities, including registered debt securities issued by a wholly-owned, operating subsidiary that are fully and unconditionally guaranteed by the parent company. In October 2020, the FASB issued updated guidance to reflect the SEC's new disclosure requirements. This new guidance narrows the circumstances that require separate financial statements of subsidiary issuers and guarantors and streamlines the alternative disclosures required in lieu of those statements. The amended SEC rules became effective on January 4, 2021, and the Company adopted the new disclosure requirements at that time. As the guidance is disclosure-related only, it did not have a material impact on the Company's Consolidated Financial Statements. In January and April 2017, the FASB issued updated guidance on the accounting for goodwill impairment. This update removes the second step of the goodwill impairment test and requires entities to apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The guidance is effective for annual impairment tests in fiscal years beginning after December 15, 2019, and the Company adopted the guidance effective January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements. In August 2018, the FASB issued updated guidance to the disclosure requirements for fair value measurement as part of the disclosure framework project. The updated guidance allows for the removal and modification of certain disclosures to improve the effectiveness of disclosures in the notes to financial statements. This guidance is effective for fiscal years beginning after December 15, 2019, and the Company adopted this guidance effective January 1, 2020. As the guidance is disclosure-related only, it did not have a material impact on the Company's Consolidated Financial Statements. Refer to Note 3 for the relevant disclosures. In August 2018, the FASB issued updated guidance to improve the effectiveness of disclosures for defined benefit plans, as part of the disclosure framework project. The updated guidance allows for the removal and modification of certain disclosures to improve the effectiveness of disclosures in the notes to financial statements. This guidance is effective for fiscal years beginning after December 15, 2019, and the Company adopted the guidance effective January 1, 2020. As the guidance is disclosure-related only, it did not have a material impact on the Company's Consolidated Financial Statements. Refer to Note 14 for the relevant disclosures. In June 2016, the FASB issued updated guidance on the recognition of credit losses by replacing the incurred loss impairment methodology with new accounting models related to how credit losses on financial instruments are determined. The new guidance is applicable to financial assets measured at amortized cost such as loans, reinsurance receivables, trade receivables, debt securities, off-balance sheet credit exposures and other financial assets that have a contractual right to receive cash. The Company's investments, except for certain Other invested assets that are accounted for using the equity method of accounting and Investments in real estate, are measured at fair value through net income, and therefore those investments are not impacted by the adoption of this guidance. The guidance is effective for annual periods beginning after December 15, 2019. The Company adopted the guidance on January 1, 2020 and recorded an after-tax cumulative effect adjustment as a decrease to retained earnings of $14 million upon adoption. Refer to Notes 8(a) and 15(a) for further information regarding the impacts of adoption of this guidance. Not yet adopted Targeted Improvements to the Accounting for Long-duration Contracts In August 2018, the FASB issued updated guidance to improve financial reporting for insurance companies that issue long-duration contracts such as life insurance and annuities. The updated guidance changes how insurers account for long-duration contracts, including recognition, measurement, presentation and disclosure requirements. The objective of the new guidance is to improve, simplify, and enhance the financial reporting for long-duration contracts. These updates amend four key areas pertaining to the accounting and disclosures for long-duration insurance contracts: • Cash flow assumptions and liability for future policy benefits: The update requires cash flow assumptions used to measure the liability for future policy benefits to be reviewed at least annually and updated, if necessary, with the effect of changes in those assumptions remeasured retrospectively and reflected in current period Net income or loss. Assumptions no longer allow a provision for adverse deviation. Loss recognition testing is eliminated for traditional and limited-payment contracts. Upon adoption, there will be an adjustment to Retained earnings as a result of capping the net premium ratio at 100% and eliminating negative reserves on certain cohorts. The update also requires the discount rate used in measuring the liability to be an upper

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value	Fair Value (a) Fair Value of Financial Instrument Assets The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The level in the hierarchy within which a given fair value measurement falls is determined based on the lowest level input that is significant to the measurement. The Company determines the appropriate level in the hierarchy for each financial instrument that it measures at fair value. In determining fair value, the Company uses various valuation approaches, including market, income and cost approaches. The hierarchy is broken down into three levels based on the observability of inputs as follows: • Level 1 inputs—Unadjusted, quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The Company’s financial instruments that it measures at fair value using Level 1 inputs generally include equities listed on a major exchange. • Level 2 inputs—Quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in inactive markets and significant directly or indirectly observable inputs, other than quoted prices, used in industry accepted models. The Company’s financial instruments that it measures at fair value using Level 2 inputs generally include: U.S. government issued bonds; U.S. government sponsored enterprises bonds; certain U.S. state, territory and municipal entities bonds; non-U.S. sovereign government, supranational and government related bonds; investment grade and high yield corporate bonds; mortgage-backed and certain asset-backed securities; short-term investments; certain preferred equities; certain privately placed corporate loans; and certain derivative assets and liabilities. • Level 3 inputs—Unobservable inputs. The Company’s financial instruments that it measures at fair value using Level 3 inputs generally include: inactively traded fixed maturities including U.S. state, territory and municipal bonds; special purpose financing asset-backed bonds; certain short-term investments; unlisted equity securities; certain privately placed corporate loans, notes and loans receivable and notes securitizations; certain real estate company investments; certain fund investments included in Other invested assets; and certain other derivatives, including weather derivatives, longevity insurance-linked securities; options and warrants; and total return swaps included in Other invested assets. At December 31, 2022 and 2021, the Company’s financial instruments measured at fair value were classified between Levels 1, 2 and 3 as follows (in thousands of U.S. dollars): December 31, 2022 Quoted prices in Significant Significant Fair value based on NAV as practical expedient Total Fixed maturities U.S. government and government sponsored enterprises $ — $ 1,797,934 $ — $ — $ 1,797,934 U.S. states, territories and municipalities — 10,126 48,747 — 58,873 Non-U.S. sovereign government, supranational and government related — 1,654,532 — — 1,654,532 Corporate bonds — 5,759,149 — — 5,759,149 Asset-backed securities — 12,434 15,930 — 28,364 Residential mortgage-backed securities — 3,723,062 — — 3,723,062 Fixed maturities $ — $ 12,957,237 $ 64,677 $ — $ 13,021,914 Short-term investments $ — $ 516,603 $ 6,907 $ — $ 523,510 Equities Real estate $ 61,754 $ — $ 1,814 $ — $ 63,568 Consumer non-cyclical — — 10,081 — 10,081 Diversified — — 9,667 — 9,667 Consumer cyclical 4,449 — 28 — 4,477 Energy 3 — 1,514 — 1,517 Finance — — 120 — 120 Industrials 20 — 76 — 96 Insurance — 42 — — 42 Fund investments — — — 840,318 840,318 Equities $ 66,226 $ 42 $ 23,300 $ 840,318 $ 929,886 Other invested assets Derivative assets Foreign exchange forward contracts $ — $ 13,705 $ — $ — $ 13,705 Interest rate swaps — 258 — — 258 Insurance-linked securities — — 6,657 — 6,657 Options and warrants — — 8,691 — 8,691 TBAs — 578 — — 578 Other Corporate loans (1) — 1,015,529 287,278 — 1,302,807 Notes and loans receivable and notes securitization — — 3,166 — 3,166 Real estate company investment — — 491,602 — 491,602 Fund investments — — 36,274 1,271,612 1,307,886 Derivative liabilities Foreign exchange forward contracts — (17,336) — — (17,336) Interest rate swaps — (153) — — (153) Other invested assets $ — $ 1,012,581 $ 833,668 $ 1,271,612 $ 3,117,861 Total $ 66,226 $ 14,486,463 $ 928,552 $ 2,111,930 $ 17,593,171 (1) Corporate loans includes a portfolio of third-party, individually managed privately issued corporate loans that are managed under an externally managed mandate with a fair value of $1.0 billion and $1.0 billion at December 31, 2022 and 2021, respectively. The mandate primarily invests in U.S. floating rate, first lien, senior secured broadly syndicated loans with a focus on facility sizes greater than $300 million. Corporate loans also includes $0.3 billion and $0.4 billion of other privately issued corporate loans at December 31, 2022 and 2021, respectively . December 31, 2021 Quoted prices in Significant Significant Fair value based on NAV practical expedient Total Fixed maturities U.S. government and government sponsored enterprises $ — $ 2,118,772 $ — $ — $ 2,118,772 U.S. states, territories and municipalities — 12,878 95,181 — 108,059 Non-U.S. sovereign government, supranational and government related — 2,181,127 — — 2,181,127 Corporate bonds — 5,441,908 — — 5,441,908 Asset-backed securities — — 16,764 — 16,764 Residential mortgage-backed securities — 4,204,644 — — 4,204,644 Fixed maturities $ — $ 13,959,329 $ 111,945 $ — $ 14,071,274 Short-term investments $ — $ 205,146 $ — $ — $ 205,146 Equities Real estate $ 97,854 $ — $ 2,097 $ — $ 99,951 Consumer non-cyclical 343 — 10,081 10,424 Consumer cyclical 7,341 — 1,394 — 8,735 Diversified 4 — 7,468 — 7,472 Energy 1,112 — 2,368 — 3,480 Industrials 137 — 220 — 357 Finance — — 128 — 128 Insurance — 18 — — 18 Fund investments (1) — — — 1,621,019 1,621,019 Equities $ 106,791 $ 18 $ 23,756 $ 1,621,019 $ 1,751,584 Other invested assets Derivative assets Foreign exchange forward contracts $ — $ 8,841 $ — $ — $ 8,841 Total return swaps — — 153 — 153 Insurance-linked securities — — 5,663 — 5,663 Other — — 3,059 — 3,059 Other Corporate loans (1) — 1,104,444 287,527 — 1,391,971 Notes and loans receivable and notes securitization — — 6,575 — 6,575 Real estate company investment (2) — — 560,687 — 560,687 Fund investments (1) — — 11,739 1,346,797 1,358,536 Derivative liabilities Foreign exchange forward contracts — (6,657) — — (6,657) Total return swaps — — (1,079) — (1,079) Interest rate swaps — (10,489) — — (10,489) Other invested assets $ — $ 1,096,139 $ 874,324 $ 1,346,797 $ 3,317,260 Total $ 106,791 $ 15,260,632 $ 1,010,025 $ 2,967,816 $ 19,345,264 (1) The classification of fund investments was revised from Level 3 to "Fair values based on NAV practical expedient" in order to align the disclosure with the valuation methodology used by the Company. In addition, the classification of certain investments in corporate loans was revised from Level 3 to Level 2 to reflect the appropriate fair value hierarchy level for investments with quoted prices, and one investment was reclassified from corporate loans to fund investments. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. These revisions are not considered to be material to previously issued financial statements. (2) A certain investment previously disclosed as equity method and excluded from the fair value table is now included and presented as a Level 3 investment in order to align the disclosure with the valuation methodology used by the Company. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. This revision is not considered to be material to previously issued financial statements. Accordingly, no changes were made to the prior period Consolidated Balance Sheet or Consolidated Statements of Operations. Other invested assets included in the fair value tables above at December 31, 2022 and 2021, exclude investments that are accounted for using the equity method of accounting (see Note 4(f) for further details). At December 31, 2022 and 2021, the carrying value of accrued investment income approximated fair value due to its short-term nature. Disclosures about the fair value of financial instruments that the Company does not measure at fair value exclude insurance contracts and certain other financial instruments. At December 31, 2022 and 2021, the fair values of financial instrument assets recorded in the Consolidated Balance Sheets not described above approximate their carrying values. The reconciliations of the beginning and ending balances for financial instruments measured at fair value using Level 3 inputs for the years ended December 31, 2022 and 2021, were as follows (in thousands of U.S. dollars): For the year ended December 31, 2022 Balance at (Losses) gains Purchases Settlements and (1) Net Balance Change in Fixed maturities U.S. states, territories and municipalities $ 95,181 $ (13,862) $ — $ (32,572) $ — $ 48,747 $ (14,108) Asset-backed securities 16,764 — — (834) — 15,930 — Fixed maturities $ 111,945 $ (13,862) $ — $ (33,406) $ — $ 64,677 $ (14,108) Short-term investments $ — $ — $ 6,907 $ — $ — $ 6,907 $ — Equities Energy $ 2,368 $ (854) $ — $ — $ — $ 1,514 $ (854) Consumer non-cyclical 10,081 — — — — 10,081 — Real estate 2,097 (283) — — — 1,814 (283) Consumer cyclical 1,394 (1,366) — — — 28 (1,366) Finance 128 (8) — — — 120 (8) Industrials 220 13 — (157) — 76 (53) Diversified 7,468 (223) 2,759 (337) — 9,667 (344) Equities $ 23,756 $ (2,721) $ 2,759 $ (494) $ — $ 23,300 $ (2,908) Other invested assets Derivatives, net $ 7,796 $ 1,929 $ 5,631 $ (8) $ — $ 15,348 $ 996 Corporate loans 287,527 1,443 34,543 (42,589) 6,354 287,278 2,166 Notes and loan receivables and notes securitization 6,575 (594) — (2,815) — 3,166 2,301 Fund investments 11,739 92 30,286 (5,843) — 36,274 322 Real estate company investment 560,687 (69,085) — — — 491,602 (69,085) Other invested assets $ 874,324 $ (66,215) $ 70,460 $ (51,255) $ 6,354 $ 833,668 $ (63,300) Total $ 1,010,025 $ (82,798) $ 80,126 $ (85,155) $ 6,354 $ 928,552 $ (80,316) (1) Included sales of Fixed maturities and Other invested assets of $32 million and $36 million, respectively. Sales of Fixed maturities were comprised of U.S. states, territories and municipalities. Sales of Other invested assets included sales of corporate loans of $33 million and sales of notes and loan receivables and notes securitization of $3 million. For the year ended December 31, 2021 Balance at (Losses) gains Purchases Settlements and sales (1) Net Balance Change in Fixed maturities U.S. states, territories and municipalities $ 120,477 $ (7,330) $ — $ (17,966) $ — $ 95,181 $ (8,818) Asset-backed securities 17,528 — — (764) — 16,764 — Corporate 16,530 165 — (16,695) — — — Fixed maturities $ 154,535 $ (7,165) $ — $ (35,425) $ — $ 111,945 $ (8,818) Equities Energy $ 34,448 $ 54,509 $ 6 $ (86,595) $ — $ 2,368 $ 1,326 Consumer non-cyclical 6,886 7,557 — — (4,362) 10,081 4,522 Insurance 4,000 — — (4,000) — — — Real estate 2,338 (241) — — — 2,097 (241) Consumer cyclical 475 (916) 1,835 — — 1,394 (916) Finance 138 (10) — — — 128 (10) Industrials 39 245 309 (334) (39) 220 99 Diversified 3,098 1,901 2,469 — — 7,468 1,901 Equities (2) $ 51,422 $ 63,045 $ 4,619 $ (90,929) $ (4,401) $ 23,756 $ 6,681 Other invested assets Derivatives, net $ (862) $ 5,718 $ 3,059 $ (119) $ — $ 7,796 $ 4,018 Corporate loans (2) 374,556 (9,883) 78,673 (151,543) (4,276) 287,527 (6,844) Notes and loan receivables and notes securitization 7,121 (71) 21 (496) — 6,575 (6,895) Fund investments (2) 32,810 (149) 392 (21,314) — 11,739 (149) Real estate company investment (2) 494,010 66,677 — — — 560,687 66,677 Other invested assets $ 907,635 $ 62,292 $ 82,145 $ (173,472) $ (4,276) $ 874,324 $ 56,807 Total $ 1,113,592 $ 118,172 $ 86,764 $ (299,826) $ (8,677) $ 1,010,025 $ 54,670 (1) Included sales of Fixed maturities, Equities and Other invested assets of $17 million, $91 million and $119 million, respectively. Sales of Fixed maturities were comprised of U.S. states, territories and municipalities. Sales of Equities included sales of $87 million in energy and $4 million in insurance. Sales of Other invested assets included sales of corporate loans. (2) The Level 3 reconciliation for the year ended December 31, 2021 has been recast to reflect the reclassification of certain investments within the fair value table as discussed above. During the year ended December 31, 2022, five corporate loans valued at $15 million were transferred from Level 2 to Level 3 due to the unavailability of quoted prices for similar securities in active markets, and five corporate loans valued at $9 million were transferred from Level 3 to Level 2 due to the availability of quoted prices for similar securities in active markets. During the year ended December 31, 2021, two equity securities valued at $4 million were transferred from Level 3 to Level 1 due to the availability of quoted prices in active markets, four corporate loans valued at $7 million were transferred from Level 3 to Level 2 due to the availability of quoted prices for similar securities in active markets, and one corporate loan valued at $3 million was transferred from Level 2 to Level 3 due to the unavailability of quoted prices for similar securities in active markets. The significant unobservable inputs used in the valuation of financial instruments measured at fair value using Level 3 inputs at December 31, 2022 and 2021 were as follows (fair value in thousands of U.S. dollars): December 31, 2022 Fair value Valuation techniques Unobservable inputs Range (Weighted average (1) ) Fixed maturities U.S. states, territories and municipalities $ 48,747 Discounted cash flow Credit spreads 2.7% – 3.6% (3.4%) Short-term investments 6,907 Discounted cash flow Credit spreads 2.5% (2.5%) Other invested assets Insurance-linked securities – longevity swaps 6,657 Discounted cash flow Credit spreads 5.7% (5.7%) Fund investments 6,008 Discounted cash flow Effective yield 0.6% (0.6%) Note securitization 188 Discounted cash flow Credit spreads 2.5% (2.5%) Real estate company investment 491,602 Income capitalization Estimated rental value (per sq ft) $84 – $90 ($87) Net initial yield 2.2% – 4.6% (3.9%) Reversionary yield 4.6% – 5.3% (4.9%) Comparable method Sale value (per sq ft) $1,617 – $5,459 ($4,836) December 31, 2021 Fair value Valuation techniques Unobservable inputs Range (Weighted average (1) ) Fixed maturities U.S. states, territories and municipalities $ 95,181 Discounted cash flow Credit spreads 2.5% – 254.5%, (14.3%) Other invested assets Total return swaps, net (926) Discounted cash flow Credit spreads 2.4% – 41.3%, (36.5%) Insurance-linked securities – longevity swaps 5,663 Discounted cash flow Credit spreads 1.7% (1.7%) Notes and loans receivables 1,791 Discounted cash flow Credit spreads 17.5% (17.5%) Gross revenue/fair value 1.1 (1.1) Note securitization 403 Discounted cash flow Credit spreads 2.5% (2.5%) Fund investments 8,832 Discounted cash flow Effective yield 3.5% (3.5%) Real estate company investment 560,687 Income capitalization Estimated rental value (per sq ft) $92 - $100 ($96) Net initial yield 2.2% - 4.5% (3.9%) Reversionary yield 4.4% - 4.9% (4.7%) Comparable method Sale value (per sq ft) $1,763 - $5,916 ($5,222) (1) Unobservable inputs were weighted by the relative fair value of the instruments. The tables above do not include financial instruments that are measured using unobservable inputs (Level 3) where the unobservable inputs were obtained from external sources and used without adjustment. These financial instruments include asset-backed securities (included in Fixed maturities); equities (included within Equities), certain notes and loans receivables and certain fund investments (included within Other invested assets), certain privately placed corporate loans (included within Other invested assets) and certain derivatives. Changes in the fair value of the Company’s financial instruments subject to the fair value option during the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Fixed maturities and short-term investments $ (1,807,048) $ (558,466) $ 219,946 Equities (505,072) 198,780 167,456 Other invested assets (136,580) 184,209 63,669 Total $ (2,448,700) $ (175,477) $ 451,071 All of the above changes in fair value are included in Net realized and unrealized investment (losses) gains in the Consolidated Statements of Operations. The change in the fair value of Other invested assets subject to the fair value option does not include certain derivatives. The following methods and assumptions were used by the Company in estimating the fair value of each class of financial instrument recorded in the Consolidated Balance Sheets. There have been no material changes in the Company’s valuation techniques during the periods presented. Fixed maturities • U.S. government and government sponsored enterprises —consists primarily of bonds issued by the U.S. Treasury and debt securities issued by government sponsored enterprises and federally owned or established corporations. These securities are generally priced by independent pricing services. The independent pricing services may use actual transaction prices for securities that have been actively traded. For securities that have not been actively traded, each pricing source has its own proprietary method to determine the fair value, which may incorporate option adjusted spreads (OAS), interest rate data and market news. The Company generally classifies these securities in Level 2. • U.S. states, territories and municipalities —consists primarily of bonds issued by U.S. states, territories and municipalities and the Federal Home Loan Mortgage Corporation. Certain of the bonds that are issued by municipal housing authorities and the Federal Home Loan Mortgage Corporation are not actively traded and are priced based on internal models using unobservable inputs (credit spreads). Accordingly, the Company classifies these securities in Level 3. A significant increase (decrease) in credit spreads in isolation could result in a significantly lower (higher) fair value measurement. The remaining securities are generally priced by independent pricing services using the techniques described for U.S. government and government sponsored enterprises above. The Company generally classifies these securities in Level 2. • Non-U.S. sovereign government, supranational and government related —consists primarily of bonds issued by non-U.S. national governments and their agencies, non-U.S. regional governments and supranational organizations. These securities are generally priced by independent pricing services using the techniques described for U.S. government and government sponsored enterprises above. The Company generally classifies these securities in Level 2. • Corporate —consists primarily of bonds issued by U.S. and foreign corporations covering a variety of industries and issuing countries. Corporate securities also include real estate investment trusts, catastrophe bonds, longevity and mortality bonds and government guaranteed corporate debt. These securities are generally priced by independent pricing services and brokers. The pricing provider incorporates information including credit spreads, interest rate data and market news into the valuation of each security. The Company generally classifies these securities in Level 2. When a corporate security is inactively traded or the valuation model uses unobservable inputs, the Company classifies the security in Level 3. • Asset-backed securities —consists of special purpose financing securities. With the exception of special purpose financing, these asset-backed securities are generally priced by independent pricing services and brokers. The pricing provider applies dealer quotes and other available trade information, prepayment speeds, yield curves and credit spreads to the valuation. The Company generally classifies these securities in Level 2. Special purpose financing securities are generally inactively traded and are priced based on valuation models using unobservable inputs (credit spreads). The Company generally classifies these securities in Level 3. A significant increase (decrease) in credit spreads in isolation could result in a significantly lower (higher) fair value measurement. • Residential mortgage-backed securities —primarily consists of bonds issued by the Government National Mortgage Association, the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, as well as private, non-agency issuers. These residential mortgage-backed securities are generally priced by independent pricing services and brokers. When current market trades are not available, the pricing provider or the Company will employ proprietary models with observable inputs including other trade information, prepayment speeds, yield curves and credit spreads. The Company generally classifies these securities in Level 2. In general, the methods employed by the independent pricing services to determine the fair value of the securities that have not been actively traded primarily involve the use of “matrix pricing” in which the independent pricing source applies the credit spread for a comparable security that has traded recently to the current yield curve to determine a reasonable fair value. The Company generally uses one pricing source per security and uses a pricing service ranking to consistently select the most appropriate pricing service in instances where it receives multiple quotes on the same security. When fair values are unavailable from these independent pricing sources, quotes are obtained directly from broker-dealers who are active in the corresponding markets. Most of the Company’s fixed maturities are priced from the pricing services or dealer quotes. The Company will typically not make adjustments to prices received from pricing services or dealer quotes; however, in instances where the quoted external price for a security uses significant unobservable inputs, the Company will classify that security as Level 3. The methods used to develop and substantiate the unobservable inputs used are based on the Company’s valuation policy and are dependent upon the facts and circumstances surrounding the individual investments which are generally transaction specific. The Company’s inactively traded fixed maturities are classified as Level 3. For all fixed maturity investments, the bid price is used for estimating fair value. Short-term investments Short-term investments are valued in a manner similar to the Company’s fixed maturity investments and are generally classified in Level 2 or 3 depending on the inputs used in the valuation of the asset. Equities Equity securities include U.S. and foreign common and preferred stocks, real estate investment trusts and certain fund investments. Publicly traded equities are generally classified in Level 1 as the Company uses prices received from independent pricing sources based on quoted prices in active markets. Equities classified as Level 2 are preferred equities. Equities classified as Level 3 are generally inactively traded common stocks. For these investments, the Company utilizes prices from third-party sources without adjustment. Fund investments are valued using net asset valuations as a practical expedient as discussed in further detail below. Other invested assets The Company’s foreign exchange forward contracts, interest rate swaps, TBAs and certain privately placed corporate loans are generally classified as Level 2 within the fair value hierarchy and are priced by independent pricing services. Included in the Company’s Level 3 classification, in general, are certain derivatives, including weather derivative insurance-linked securities and total return swaps; certain privately placed corporate loans; notes and loans receivable and note securitizations; certain fund investments; and a real estate company investment. For Level 3 instruments, the Company will generally (i) receive a price based on a manager’s or trustee’s valuation for the asset; (ii) develop an internal discounted cash flow model to measure fair value; (iii) use market return information, adjusted if necessary and weighted using management’s judgment, from comparable selected publicly traded equity funds in a similar region and of a similar size, or (iv) receive the valuation information and techniques used by real estate company investments. Where the Company receives prices from the manager or trustee, these prices are based on the manager’s or trustee’s estimate of fair value for the assets and are generally audited on an annual basis. Where the Company develops its own discounted cash flow models, the inputs will be specific to the asset in question, based on appropriate historical information, adjusted as necessary, and using appropriate discount rates. When the Company utilizes significant unobservable inputs including market return information, information is weighted using managements' judgement, obtained from comparable selected publicly traded companies in the same industry, in a similar region and of similar size and effective yields. Significant increases (decreases) in these inputs in isolation could result in a significantly higher (lower) fair value measurement for an asset. When the Company uses the valuation information and techniques used by real estate company investments, it independently evaluates the valuation techniques being utilized by the entity to ensure techniques are consistent with U.S. GAAP. Valuation techniques include the income capitalization technique or the comparable method and are based on the properties' highest and best use, with typical market based assumptions, such as estimated rental values, net initial yield, reversionary yield and sales values. A significant increase (decrease) in estimated rental values, reversionary yield and/or sales values could result in a significantly higher (lower) fair value measurement for an asset, while a significant increase (decrease) in net initial yield could result in a significantly lower (higher) fair value measurement for an asset. Significant unobservable inputs used in the fair value measurement of Other invested assets classified as Level 3 also include credit spreads and gross revenue to fair value ratios. Significant increases (decreases) in any of these inputs in isolation could result in a significantly lower (higher) fair value measurement. Fund investments included in Other invested assets are generally valued using net asset valuations as a practical expedient as discussed in further detail below. As part of the Company’s modeling to determine the fair value of an investment, other than for those measured using net asset valuations as a practical expedient, the Company also uses credit risk as an input to models, however, the majority of the Company’s counterparties are investment grade rated institutions and the failure of any one counterparty would not have a significant impact on the Company’s consolidated financial statements. Measuring the Fair Value of Investments Using Net Asset Valuations as the Practical Expedient The table below reflects the Company's portfolio of investments measured using net asset valuations as the practical expedient (in thousands of US dollars): At December 31, 2022 December 31, 2021 Carrying Value (1) Remaining Unfunded Commitment Carrying Value (1) Remaining Unfunded Commitment Redemption Frequency Redemption Notice Period Public equity funds $ 629,125 $ — $ 1,461,620 $ — See below See below Private equity funds 389,736 150,458 499,289 195,871 See below See below Private credit funds 404,065 67,815 294,760 184,590 See below See below Multi-strategy funds 689,004 147,409 712,147 114,880 See below See below Total fund investments $ 2,111,930 $ 365,682 $ 2,967,816 $ 495,341 (1) The table above only reflects the Company's investments valued at fair value based on the NAV practical expedient, which includes fund investments of $840 million included in Equities and $1,272 million included in Other invested assets at December 31, 2022 and fund investments of $1,621 million included in Equities and $1,347 million included in Other invested assets at December 31, 2021. Investment Strategies and redemption terms and conditions of the various funds included in the above table are as follows: Public Equity Funds — The Company's investments in public equity funds include long/short funds and also funds invested in geographically diverse regions such as Asia, seeking higher risk-adjusted returns, that primarily invest in public equities. The Company generally has the right to redeem these funds during a quarterly redemption period with 30 - 60 days' prior notice, some of which are subject to redemption thresholds and redemption fees. During 2022, the Company agreed it would not sell certain investments with a carrying value of $422 million at December 31, 2022 for a three year period. Private Equity Funds — The Company's investments in private equity funds include limited partnerships or similar interests that invest in private equity assets. The Company generally has no right to redeem its interest in any of these private equity funds in advance of dissolution of the applicable limited partnerships. Instead, distributions are received by the Company in connection with the exit from the underlying private equity investments of the fund. It is estimated that the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership. Private Credit Funds — The Company's investments in private credit funds include funds and limited partnerships or similar interests that invest in private credit instruments, including senior secured bank loan funds, secondaries, and mezzanine investments. The Company generally has no right to redeem its interest in any of these private credit funds in advance of dissolution of the applicable limited partnerships. Instead, distributions are received by the Company in connection with the liquidation or maturity of the underlying private credit assets of the fund. It is estimated that the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership. Multi-Strategy Funds — The Company's investments in multi-strategy funds include limited partnerships or similar interests that invest across diverse asset classes, including equities, bonds, credit markets, and real estate. For one multi-strategy fund with a carrying value of $314 million and $384 million at December 31, 2022 and 2021, respectively, the Company does have quarterly redemption rights subject to a 60 day notice period, gate policy and 36 month lock-up period which ends in 2024. The Company generally has no right to redeem its interest in any of the remaining multi-strategy limited partnership funds in advance of dissolution. Instead, distributions are received by the Company in connection with the liquidation or maturity of the underlying assets of the fund. It is estimated the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership. The fair values of these public equity, private equity, private credit and multi-strategy funds are estimated using net asset valuations as advised by external fund managers or third party administrators. NAV's are based on the manager's or administrator's valuation of the underlying assets of the fund in accordance with the fund's governing documents and in accordance with U.S. GAAP. For NAV fund valuations, valuation statements are typically released on a reporting lag and accordingly, the Company estimates the value of these funds using the most recent fund valuations as adjusted for c

Investments

Investments	12 Months Ended
	Dec. 31, 2022
Investments [Abstract]
Investments	Investments (a) Net Realized and Unrealized Investment (Losses) Gains The components of the net realized and unrealized investment (losses) gains for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Net realized investment gains on fixed maturities and short-term investments $ 859 $ 19,893 $ 24,828 Net realized investment gains on equities 461,041 78,501 21,538 Net realized investment gains (losses) on other invested assets 9,781 103,011 (30,436) Net realized investment gains $ 471,681 $ 201,405 $ 15,930 Change in net unrealized investment (losses) gains on fixed maturities and short-term investments $ (1,807,048) $ (558,466) $ 219,946 Change in net unrealized investment (losses) gains on equities (505,072) 198,780 167,456 Change in net unrealized investment (losses) gains on other invested assets (123,694) 196,926 58,452 Net other realized and unrealized investment losses (2,672) (848) (1,346) Change in net unrealized investment (losses) gains $ (2,438,486) $ (163,608) $ 444,508 Impairment loss on investments in real estate $ (2,209) $ — $ (6,119) Net realized and unrealized investment (losses) gains $ (1,969,014) $ 37,797 $ 454,319 (b) Net Investment Income The components of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Fixed maturities $ 310,152 $ 301,391 $ 290,259 Short-term investments and cash and cash equivalents 17,477 4,860 12,000 Other invested assets 99,375 90,442 89,129 Equities 11,118 12,686 3,918 Funds held and other (1) 10,801 17,871 16,559 Investment expenses (50,575) (50,781) (51,197) Net investment income $ 398,348 $ 376,469 $ 360,668 (1) The Company generally earns investment income on funds held by reinsured companies based upon a predetermined interest rate, either fixed contractually at the inception of the contract or based upon a recognized index. Interest rates ranged from 0.1% to 10.9%, 0.1% to 7.3% and 0.1% to 6.5% for the years ended December 31, 2022, 2021 and 2020, respectively. (c) Pledged and Restricted Assets At December 31, 2022 and 2021, approximately $138 million and $105 million, respectively, of cash and cash equivalents and approximately $5,258 million and $5,483 million, respectively, of securities were deposited, pledged or held in escrow accounts in favor of ceding companies and other counterparties or government authorities to comply with reinsurance contract provisions and insurance laws. (d) Receivable for Securities Sold and Payable for Securities Purchased At December 31, 2022 and 2021, receivables for securities sold of $52 million and $45 million, respectively, were recorded within Other assets. At December 31, 2022 and 2021, payables for securities purchased of $149 million and $202 million, respectively, were recorded within Accounts payable, accrued expenses, and other in the Consolidated Balance Sheets. (e) Variable Interest Entities The Company holds variable interests in VIEs including certain limited liability companies or partnerships, trusts, fixed maturity investments and asset-backed securities. The holdings in these VIEs are reported within Fixed maturities and Other invested assets in the Company’s Consolidated Balance Sheets. The Company’s involvement in these entities is, for the most part, passive in nature. The Company’s maximum exposure to loss with respect to these investments is limited to the amounts invested in and advanced to the VIEs and any unfunded commitments (see Note 15(c)). (f) Other Invested Assets At December 31, 2022 and 2021, the Company had carrying values of $1,856 million and $1,862 million respectively, of investments that were either accounted for under the equity method of accounting or would have been accounted for under the equity method if the Company had not chosen to apply the fair value option. At December 31, 2022 and 2021, the Company held a 36% shareholding in the privately held United Kingdom real estate investment and development group, Almacantar Group Limited (Almacantar). The total carrying value of this investment was $492 million and $561 million, at December 31, 2022 and 2021, respectively. This investment is accounted for under the fair value option and included within Other invested assets in the Consolidated Balance Sheets.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The Company’s objectives for holding or issuing derivatives are as follows: Foreign Exchange Forward Contracts —The Company utilizes foreign exchange forward contracts as part of its overall currency risk management and investment strategies. Insurance-linked Securities —The Company enters into various derivatives for which the underlying risks reference parametric weather risks, pandemic outbreaks and mortality, in addition to longevity total return swaps for which the underlying risks reference longevity risks. Total Return and Interest Rate Swaps —The Company enters into total return swaps referencing certain investments in Other invested assets. The Company enters into interest rate swaps to mitigate the interest rate risk on certain of the total return swaps and certain fixed maturity investments. To-Be-Announced Mortgage-Backed Securities (TBAs), Options and Warrants —The Company utilizes TBAs, options and warrants as part of its overall investment strategy and to enhance investment performance. There were no derivatives designated as hedges for the years ended December 31, 2022 and 2021. The net fair values of derivatives included in Other invested assets within the Company’s Consolidated Balance Sheets and the related net notional exposures at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): Asset Liability Net derivatives December 31, 2022 Fair value Net notional Derivatives not designated as hedges Foreign exchange forward contracts $ 13,705 $ (17,336) $ (3,631) $ 4,277,894 Insurance-linked securities (1) 6,657 — 6,657 16,937 Interest rate swaps (2) 258 (153) 105 — TBAs 578 — 578 — Options and warrants 8,691 — 8,691 8,815 Total derivatives not designated as hedges $ 29,889 $ (17,489) $ 12,400 Asset Liability Net derivatives December 31, 2021 Fair value Net notional Derivatives not designated as hedges Foreign exchange forward contracts $ 8,841 $ (6,657) $ 2,184 $ 3,092,396 Insurance-linked securities (1) 5,663 — 5,663 15,200 Total return swaps 153 (1,079) (926) 31,519 Interest rate swaps (2) — (10,489) (10,489) — Other 3,059 — 3,059 — Total derivatives not designated as hedges $ 17,716 $ (18,225) $ (509) (1) Insurance-linked securities include longevity swaps for which the notional amounts are not reflective of the overall potential exposure of the swaps. The net notional exposure above includes the Company's best estimate of the present value of future expected claims. (2) The Company enters into interest rate swaps to mitigate notional exposures on certain total return swaps and certain fixed maturities. The net notional exposure for interest rate swaps above relates to fixed maturities. The gains and losses in the Consolidated Statements of Operations for derivatives not designated as hedges for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Foreign exchange forward contracts $ (34,902) $ (16,788) $ (32,611) Total included in Net foreign exchange losses $ (34,902) $ (16,788) $ (32,611) Insurance-linked securities $ 2,049 $ 4,807 $ (2,341) Total return swaps 934 1,430 (845) Interest rate swaps 10,594 7,020 (5,131) TBAs (23) (56) (510) Other — (298) 1,376 Total included in Net realized and unrealized investment gains (losses) $ 13,554 $ 12,903 $ (7,451) Total derivatives not designated as hedges $ (21,348) $ (3,885) $ (40,062) Offsetting of Derivatives The gross and net fair values of derivatives that are subject to offsetting in the Consolidated Balance Sheets at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): Gross Net amounts of Gross amounts not offset December 31, 2022 Gross amounts recognized (1) Financial Cash collateral Net amount Total derivative assets $ 29,889 $ — $ 29,889 $ (258) $ (37,262) $ (7,631) Total derivative liabilities $ (17,489) $ — $ (17,489) $ 258 $ 15,978 $ (1,253) December 31, 2021 Total derivative assets $ 17,716 $ — $ 17,716 $ — $ (34,764) $ (17,048) Total derivative liabilities $ (18,225) $ — $ (18,225) $ — $ 1,671 $ (16,554) (1) Amounts include all derivative instruments, irrespective of whether there is a legally enforceable master netting arrangement in place.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets	Goodwill and Intangible Assets The Company’s goodwill related to the acquisitions of PartnerRe SA, Winterthur Re, Paris Re and Presidio and intangible assets related to the acquisitions of Paris Re, Presidio, Aurigen and Claims Analytics at December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): Goodwill Definite- Indefinite- Total Balance at December 31, 2019 $ 456,380 $ 107,983 $ 9,555 $ 117,538 Foreign currency translation — 119 — 119 Intangible assets amortization n/a (9,988) n/a (9,988) Balance at December 31, 2020 $ 456,380 $ 98,114 $ 9,555 $ 107,669 Foreign currency translation — 10 — 10 Intangible assets amortization n/a (8,861) n/a (8,861) Balance at December 31, 2021 $ 456,380 $ 89,263 $ 9,555 $ 98,818 Foreign currency translation — (137) — (137) Intangible assets amortization n/a (8,912) n/a (8,912) Balance at December 31, 2022 $ 456,380 $ 80,214 $ 9,555 $ 89,769 n/a: Not applicable The gross carrying value and accumulated amortization of intangible assets included in the Consolidated Balance Sheets at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Gross carrying Accumulated Net carrying value Gross carrying Accumulated Net carrying value Definite-lived intangible assets: Renewal rights $ 48,163 $ (43,032) $ 5,131 $ 48,163 $ (40,786) $ 7,377 Customer relationships 67,611 (56,850) 10,761 67,748 (52,661) 15,087 Life VOBA 75,583 (11,261) 64,322 75,583 (8,784) 66,799 Total definite-lived intangible assets $ 191,357 $ (111,143) $ 80,214 $ 191,494 $ (102,231) $ 89,263 Indefinite-lived intangible assets: Insurance licenses 9,555 n/a 9,555 9,555 n/a 9,555 Total intangible assets $ 200,912 $ (111,143) $ 89,769 $ 201,049 $ (102,231) $ 98,818 n/a: Not applicable Definite-lived intangible assets are amortized over a period of 10-13 years for renewal rights and customer relationships, and 100 years for life VOBA. The allocation of goodwill to the Company’s segments at December 31, 2022 and 2021 was as follows (in thousands of U.S. dollars): 2022 2021 P&C segment $ 242,376 $ 242,376 Specialty segment 196,047 196,047 Life and Health segment 17,957 17,957 Total $ 456,380 $ 456,380 The estimated future amortization expense related to the Company’s definite-lived intangible assets is as follows (in thousands of U.S. dollars): Year VOBA Other definite- Total definite- 2023 $ 2,272 $ 5,641 $ 7,913 2024 2,296 4,960 7,256 2025 2,070 4,367 6,437 2026 1,892 402 2,294 2027 2,238 402 2,640 Thereafter 53,554 120 53,674 Total $ 64,322 $ 15,892 $ 80,214

Non-life and Life and Health Re

Non-life and Life and Health Reserves	12 Months Ended
	Dec. 31, 2022
Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense [Abstract]
Non-life and Life and Health Reserves	Non-life and Life and Health Reserves (a) Non-life reserves Non-life reserves are categorized into three types of reserves: case reserves, ACRs and IBNR reserves. Case reserves represent unpaid losses reported by the Company’s cedants and recorded by the Company. ACRs are established for particular circumstances where, on the basis of individual loss reports, the Company estimates that the particular loss or collection of losses covered by a treaty may be greater than those advised by the cedant. IBNR reserves represent a provision for claims that have been incurred but not yet reported to the Company, as well as future loss development on losses already reported, in excess of the case reserves and ACRs. See also Note 2(b). The Company’s gross liability for non-life reserves at December 31, 2022 and 2021 was as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Case reserves $ 5,110,575 $ 4,881,892 ACRs 159,821 140,464 IBNR reserves 7,455,235 7,025,436 Non-life reserves $ 12,725,631 $ 12,047,792 The reconciliation of the beginning and ending gross and net liability for non-life reserves for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Gross liability at beginning of year $ 12,047,792 $ 11,395,321 $ 10,363,383 Reinsurance recoverable at beginning of year 1,532,666 782,330 754,795 Net liability at beginning of year 10,515,126 10,612,991 9,608,588 Net incurred losses related to: Current year 3,533,087 3,637,671 3,945,248 Prior years (219,853) (194,426) 71,456 3,313,234 3,443,245 4,016,704 Net paid losses related to: Current year (419,633) (437,938) (459,718) Prior years (2,238,503) (2,535,057) (2,772,886) (2,658,136) (2,972,995) (3,232,604) Retroactive reinsurance recoverable adjustment (35,695) (357,864) — Effects of foreign exchange rate changes and other (260,709) (210,251) 220,303 Net liability at end of year 10,873,820 10,515,126 10,612,991 Reinsurance recoverable at end of year 1,851,811 1,532,666 782,330 Gross liability at end of year $ 12,725,631 $ 12,047,792 $ 11,395,321 Prior Years' Reserve Development For the year ended December 31, 2022, the Company reported net favorable loss development for prior accident years resulting from favorable loss emergence in both the P&C and Specialty segments and a reduction in unallocated loss adjustment expenses. The favorable loss emergence within the P&C segment was across multiple accident years, mainly driven by the motor, catastrophe, and casualty business. The favorable loss emergence within the Specialty segment was across multiple accident years, predominantly from the financial risks, engineering, marine, and property business, which was partially offset by adverse loss emergence in the aviation business. For the year ended December 31, 2021, the Company reported net favorable loss development for prior accident years resulting from favorable loss emergence in both the P&C and Specialty segments. The favorable loss emergence within the Specialty segment was across multiple accident years, predominantly from financial risks lines. The favorable loss emergence within the P&C segment was primarily from a refinement of loss estimates for certain large catastrophic events from accident years 2017 - 2019. For the year ended December 31, 2020, the Company reported net unfavorable loss development for prior accident years resulting from adverse loss emergence in the Specialty segment, which was partially offset by favorable loss emergence in the P&C segment. The adverse loss emergence within the Specialty segment was across multiple accident years, predominantly from property, engineering, multiline and aviation business. The favorable loss emergence within the P&C segment was primarily from accident years 2015 and prior, mainly driven by the European casualty, motor and property business, which was partially offset by adverse loss emergence in the U.S. and Asia property business. Retroactive Reinsurance Recoverable During the second quarter of 2021, the Company entered into a loss portfolio transfer and adverse development cover agreement related to prior underwriting years on the Company's U.S. casualty and auto business within the P&C segment. Premium paid for the loss portfolio transfer and adverse development cover agreement, resulted in a cash transfer for the premium at inception of the agreement, and a reinsurance recoverable of $394 million at December 31, 2022 and $358 million at December 31, 2021. At December 31, 2022 and 2021, as a result of adverse prior years reserve development ceded under this agreement, a deferred gain of $47 million and $20 million, respectively, was recorded in Accounts payable, accrued expense and other in the Consolidated Balance Sheets. This transaction is presented retrospectively in the net loss and loss expenses incurred development table for the Casualty business in Section (c) below. Reinsurance recoveries under this transaction are attributed to calendar year and accident year based on the underlying distribution of losses subject to the agreement. In the fourth quarter of 2019, the Company entered into a loss portfolio transfer agreement transferring 100% of liabilities, including profit commissions, related to its wholesale managing general agent portfolio. As a result of the transaction, the Company recorded a reinsurance recoverable of $81 million and a related deferred gain of $14 million. In the fourth quarter of 2020, the Company completed a business transfer to extinguish the remaining $70 million of non-life reserves and derecognized the $70 million of related reinsurance recoverables. As a result, during 2020, the $14 million deferred gain was recognized within Losses and loss expenses in the Consolidated Statement of Operations. At settlement, $64 million of invested assets were transferred, and there was a corresponding decrease in Other reinsurance balances payable. Asbestos and Environmental Claims The Company’s net non-life reserves at December 31, 2022 and 2021 included $42 million and $44 million, respectively, related to asbestos and environmental claims. The gross liability for such claims at December 31, 2022 and 2021 was $49 million and $52 million, respectively. Ultimate loss estimates for such claims cannot be estimated using traditional reserving techniques and there are significant uncertainties in estimating the Company’s potential losses for these claims. In view of the legal and tort environment that affect the development of such claims, the uncertainties inherent in estimating asbestos and environmental claims are not likely to be resolved in the near future. There can be no assurance that the reserves established by the Company will not be adversely affected by development of other latent exposures, and further, there can be no assurance that the reserves established by the Company will be adequate. The Company does, however, actively evaluate potential exposure to asbestos and environmental claims and establishes additional reserves as appropriate. The Company believes that it has made a reasonable provision for these exposures and is unaware of any specific issues that would materially affect its unpaid losses and loss expense reserves related to this exposure. Non-life reserving methods The reserving methods commonly employed by the Company are summarized as follows: Chain Ladder (CL) Development Methods (Reported or Paid) These methods use the underlying assumption that losses reported (paid) for each underwriting year at a particular development stage follow a stable pattern. The CL development method assumes that on average, every underwriting year will display the same percentage of ultimate liabilities reported by the Company’s cedants at 24 months after the inception of the underwriting year. The percentages reported (paid) are established for each development stage after examining historical averages from the loss development data. These are sometimes supplemented by external benchmark information. Ultimate liabilities are estimated by multiplying the actual reported (paid) losses by the reciprocal of the assumed reported (paid) percentage. Reserves are then calculated by subtracting paid claims from the estimated ultimate liabilities. Expected Loss Ratio (ELR) Method This method estimates ultimate losses for an underwriting year by applying an estimated loss ratio to the earned premium for that underwriting year. Although the method is insensitive to actual reported or paid losses, it can often be useful at the early stages of development when very few losses have been reported or paid, and the principal sources of information available to the Company consist of information obtained during pricing and qualitative information supplied by the cedant. However, the lack of sensitivity to reported or paid losses means that the method is usually inappropriate at later stages of development. Bornhuetter-Ferguson (B-F) Methods (Reported or Paid) These methods aim to address the variability at early stages of development and incorporates external information such as pricing. The B-F methods are more sensitive to reported and paid losses than the ELR method, and can be seen as a blend of the ELR and CL development methods. Unreported (unpaid) claims are calculated using an expected reporting (payment) pattern and an externally determined estimate of ultimate liabilities (usually determined by multiplying an a priori loss ratio with estimates of premium volume). The accuracy of the a priori loss ratio is a critical assumption in this method. Usually a priori loss ratios are initially determined on the basis of pricing information, but may also be adjusted to reflect other information that subsequently emerges about underlying loss experience. Loss Event Specific Method The ultimate losses estimated under this method are derived from estimates of specific events based on reported claims, client and broker discussions, review of potential exposures, market loss estimates, modeled analysis and other event specific criteria. Method Weights In determining the loss reserves, the Company often relies on a blend of the results from two or more methods (e.g., weighted averages). The judgment as to which of the above method(s) is most appropriate for a particular underwriting year and reserving cell could change over time as new information emerges regarding underlying loss activity and other data issues. Furthermore, as each line is typically composed of several reserving cells, it is likely that the reserves for the line will be dependent on several reserving methods. This is because reserves for a line are the result of aggregating the reserves for each constituent reserving cell and that a different method could be selected for each reserving cell. The principal reserving methods used for each of the Specialty segment and P&C segment were ELR, Reported/Paid B-F, and Reported/Paid CL, with the exception of catastrophe risks within the P&C segment where the principal reserving methods used were ELR based on exposure analysis and loss event specific methods. (b) Life and Health Reserves The reconciliation of the beginning and ending gross and net liability for life and health reserves for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Gross liability at beginning of period $ 2,638,086 $ 2,704,229 $ 2,417,044 Reinsurance recoverable at beginning of period 21,000 35,662 16,183 Net liability at beginning of period $ 2,617,086 $ 2,668,567 $ 2,400,861 Net incurred losses (1) 1,434,169 1,440,739 1,318,196 Net losses paid (1,390,848) (1,413,316) (1,230,383) Effects of foreign exchange rate changes and other (181,789) (78,904) 179,893 Net liability at end of period $ 2,478,618 $ 2,617,086 $ 2,668,567 Reinsurance recoverable at end of period 31,675 21,000 35,662 Gross liability at end of period $ 2,510,293 $ 2,638,086 $ 2,704,229 (1) During 2021 and 2020, certain life and health treaties were recaptured, resulting in total gains upon recapture of $15 million and $28 million respectively, recorded as a reduction to net incurred losses. Net incurred losses includes unfavorable prior years' reserve development of $46 million for the year ended December 31, 2022, favorable prior years' reserve development of $5 million for the year ended December 31, 2021, and unfavorable prior years' reserve development of $52 million for the year ended December 31, 2020, which was driven by the Company's disability business. The Company used interest rate assumptions to estimate its liabilities for policy benefits for life and annuity contracts which ranged from 0% to 11% at December 31, 2022, 2021 and 2020. Life and health reserving methods The reserving methods commonly employed by the Company are summarized as follows: Mortality The reserves for the short-term mortality/morbidity business consist of case reserves calculated at the treaty level based upon cedant information. IBNR is calculated at the reserving segment level using either the ELR method or CL development method described above for Non-life business. The reserves for the traditional and limited payment long-duration contracts are established based upon accepted actuarial valuation methods which require us to make certain assumptions regarding future claims and policy benefits and includes a provision for adverse deviation. The provision for adverse deviation contemplates reasonable deviations from the best estimate assumptions for the key risk elements relevant to the product being evaluated, including mortality, disability, critical illness, expenses, and discount rates. The assumptions are locked in at contract inception and are subject to annual loss recognition testing (LRT). LRT occurs at the product group level, based on the manner of acquiring, servicing and measuring profitability of the reinsurance contracts. The LRT framework incorporates deferred acquisition cost (DAC) recoverability testing and involves determining an LRT reserve by re-measuring the policy benefit liabilities using current best estimate actuarial assumptions and current discount rates without any provisions for adverse deviation. If the aggregate LRT reserve is higher than the carrying amount of future policy benefit liabilities, net of DAC and VOBA, for a particular product grouping then a loss recognition event occurs. The DAC and VOBA asset balances for the given product grouping are first reduced, and if the balances are fully written off, the reserves will be increased, such that the current best estimate assumptions become the new locked-in basis. The reserves for the guaranteed minimum death benefit (GMDB) reinsurance business are established similar to provisions for universal life contracts. Key actuarial assumptions for this business are mortality, lapses, interest rates, expected returns on cash and bonds and stock market performance. For the latter parameter, a stochastic option pricing approach is used and the benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios. The assumptions of investment performance and volatility are consistent with expected future experience of the respective underlying funds available for policyholder investment options. Recorded reserves for GMDB reflect management’s best estimate based upon actuarial indications. Longevity Reserves for the annuity portfolio of reinsurance contracts within the longevity book are established using the reserving methodology discussed above for long-term traditional mortality. (c) Losses and Loss Expenses Losses and loss expenses in the Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020 were comprised as follows (in thousands of U.S. dollars): 2022 2021 2020 Non-life $ 3,313,234 $ 3,443,245 $ 4,016,704 Life and Health 1,434,169 1,440,739 1,318,196 Losses and loss expenses $ 4,747,403 $ 4,883,984 $ 5,334,900 Non-life net incurred and paid losses and loss expense development The net incurred and paid losses and loss expenses development by accident year for each of the years ended December 31, 2013 through 2022, and the total of IBNR plus expected development on reported claims included within the net incurred claims amounts, as at each of the years ended December 31, 2013 through 2022, are presented in the tables below (in thousands of U.S. dollars). The tables below reflect losses incurred and paid losses translated to U.S. dollars at the exchange rate as of the balance sheet date whereas the Losses and loss expenses in the Consolidated Statement of Operations reflect losses incurred at the average exchange rate for the period. NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - NON-LIFE For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 2,664,745 $ 2,722,788 $ 2,400,977 $ 3,277,749 $ 2,787,608 $ 2,313,004 $ 2,301,835 $ 2,276,767 $ 2,262,098 $ 2,242,254 $ 23,890 2014 2,481,720 2,514,200 2,368,967 2,349,869 2,353,759 2,315,021 2,277,135 2,262,546 2,232,454 35,019 2015 2,502,854 2,611,184 2,527,784 2,550,830 2,520,182 2,475,960 2,451,141 2,432,324 89,338 2016 2,451,204 2,559,851 2,516,126 2,486,199 2,467,920 2,484,069 2,476,383 130,477 2017 2,549,737 2,801,179 2,698,916 2,651,730 2,663,904 2,658,571 179,473 2018 2,596,552 2,974,243 2,969,810 2,972,766 3,009,359 387,763 2019 2,931,280 3,519,556 3,510,991 3,523,443 681,501 2020 4,186,395 3,586,462 3,499,097 976,332 2021 2,880,141 2,829,876 1,580,019 2022 3,410,844 2,119,500 Total $ 28,314,605 $ 6,203,312 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - NON-LIFE For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 267,413 $ 1,237,315 $ 1,577,293 $ 1,771,134 $ 1,900,282 $ 1,997,543 $ 2,061,865 $ 2,097,390 $ 2,121,980 $ 2,146,574 2014 336,270 1,291,273 1,594,146 1,810,171 1,946,054 2,044,804 2,118,939 2,164,676 2,196,720 2015 306,562 1,159,655 1,564,173 1,798,537 1,959,722 2,067,935 2,142,234 2,198,481 2016 321,351 1,272,443 1,627,697 1,893,694 2,030,728 2,123,169 2,211,977 2017 394,394 1,421,140 1,804,959 2,072,838 2,195,236 2,314,529 2018 271,827 1,276,542 1,811,055 2,093,543 2,283,931 2019 462,939 1,438,793 1,961,928 2,341,116 2020 480,122 1,277,034 1,805,063 2021 373,191 1,088,143 2022 394,598 Total $ 18,981,132 Net reserves for accident years and exposures included in the triangles $ 9,333,473 All outstanding liabilities before accident year 2013, net of reinsurance 1,239,090 Total outstanding liabilities for unpaid claims $ 10,572,563 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - NON-LIFE (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Non-life 13% 33% 15% 10% 6% 4% 3% 2% 1% 1% NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - PROPERTY For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 622,984 $ 560,072 $ 519,883 $ 505,636 $ 500,527 $ 492,673 $ 490,699 $ 489,268 $ 487,571 $ 485,091 $ 421 2014 469,568 488,446 463,409 458,609 452,907 450,487 447,816 447,894 444,808 588 2015 537,193 565,816 537,792 528,106 524,147 519,568 525,203 523,475 1,175 2016 663,490 681,050 644,349 625,873 622,562 624,375 623,593 2,622 2017 971,607 1,022,186 952,613 923,025 915,166 910,105 3,934 2018 805,960 820,675 799,735 778,867 766,591 10,844 2019 703,097 782,453 720,079 711,928 45,376 2020 1,252,575 1,070,935 1,061,772 134,726 2021 919,517 918,629 202,188 2022 944,920 557,288 Total $ 7,390,912 $ 959,162 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - PROPERTY For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 90,086 $ 320,510 $ 419,541 $ 453,191 $ 469,346 $ 472,517 $ 477,180 $ 479,094 $ 479,023 $ 479,578 2014 95,013 323,309 395,102 423,339 432,567 438,152 442,581 444,798 445,375 2015 85,015 330,876 435,539 469,036 481,879 489,195 498,557 501,524 2016 132,914 446,804 538,988 579,381 595,159 604,980 609,257 2017 214,026 694,240 805,627 853,945 862,942 870,638 2018 81,830 494,608 628,458 666,919 687,439 2019 78,527 426,566 545,163 586,587 2020 115,165 515,030 681,851 2021 121,453 491,546 2022 103,876 Total $ 5,457,671 Net reserves for accident years and exposures included in the triangles $ 1,933,241 All outstanding liabilities before accident year 2013, net of reinsurance 122,792 Total outstanding liabilities for unpaid claims $ 2,056,033 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - PROPERTY (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Property 15% 47% 16% 6% 2% 1% 1% —% —% —% NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - CASUALTY For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 747,448 $ 853,023 $ 757,402 $ 734,732 $ 732,716 $ 726,420 $ 714,114 $ 695,346 $ 691,195 $ 678,905 $ 19,235 2014 804,571 848,698 814,622 810,349 826,000 791,768 766,415 753,383 739,605 28,354 2015 699,327 783,275 761,091 803,497 770,242 751,652 726,451 714,608 76,827 2016 670,767 756,954 767,366 747,814 740,047 750,268 747,402 103,979 2017 621,095 743,114 720,966 709,881 716,862 720,732 136,389 2018 767,559 905,491 895,978 903,353 920,169 258,229 2019 999,955 1,226,210 1,272,980 1,273,687 519,757 2020 1,344,430 1,115,751 1,094,890 624,521 2021 1,013,896 967,726 920,590 2022 1,495,131 1,043,559 Total $ 9,352,855 $ 3,731,440 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - CASUALTY For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 49,468 $ 152,575 $ 260,249 $ 339,320 $ 410,241 $ 470,029 $ 510,855 $ 533,983 $ 558,218 $ 578,496 2014 69,119 189,458 292,152 387,182 470,964 536,883 594,035 631,367 654,893 2015 73,252 184,520 303,213 398,790 505,067 577,907 627,964 667,748 2016 28,304 140,081 244,560 369,651 455,982 520,069 586,050 2017 55,617 157,792 246,615 334,296 411,806 488,164 2018 59,105 201,190 323,510 425,887 532,717 2019 100,639 274,821 430,192 580,304 2020 112,281 176,740 304,592 2021 80,434 225,846 2022 120,660 Total $ 4,739,470 Net reserves for accident years and exposures included in the triangles $ 4,613,385 All outstanding liabilities before accident year 2013, net of reinsurance 1,023,715 Total outstanding liabilities for unpaid claims $ 5,637,100 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - CASUALTY (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Casualty 8% 14% 13% 13% 12% 9% 7% 5% 3% 3% NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - SPECIALTY For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 1,294,313 $ 1,309,693 $ 1,123,692 $ 2,037,381 $ 1,554,365 $ 1,093,911 $ 1,097,022 $ 1,092,153 $ 1,083,332 $ 1,078,258 $ 4,234 2014 1,207,581 1,177,056 1,090,936 1,080,911 1,074,852 1,072,766 1,062,904 1,061,269 1,048,041 6,077 2015 1,266,334 1,262,093 1,228,901 1,219,227 1,225,793 1,204,740 1,199,487 1,194,241 11,336 2016 1,116,947 1,121,847 1,104,411 1,112,512 1,105,311 1,109,426 1,105,388 23,876 2017 957,035 1,035,879 1,025,337 1,018,824 1,031,876 1,027,734 39,150 2018 1,023,033 1,248,077 1,274,097 1,290,546 1,322,599 118,690 2019 1,228,228 1,510,893 1,517,932 1,537,828 116,368 2020 1,589,390 1,399,776 1,342,435 217,085 2021 946,728 943,521 457,241 2022 970,793 518,653 Total $ 11,570,838 $ 1,512,710 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - SPECIALTY For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 127,859 $ 764,230 $ 897,503 $ 978,623 $ 1,020,695 $ 1,054,997 $ 1,073,830 $ 1,084,313 $ 1,084,739 $ 1,088,500 2014 172,138 778,506 906,892 999,650 1,042,523 1,069,769 1,082,323 1,088,511 1,096,452 2015 148,295 644,259 825,421 930,711 972,776 1,000,833 1,015,713 1,029,209 2016 160,133 685,558 844,149 944,662 979,587 998,120 1,016,670 2017 124,751 569,108 752,717 884,597 920,488 955,727 2018 130,892 580,744 859,087 1,000,737 1,063,775 2019 283,773 737,406 986,573 1,174,225 2020 252,676 585,264 818,620 2021 171,304 370,751 2022 170,062 Total $ 8,783,991 Net reserves for accident years and exposures included in the triangles $ 2,786,847 All outstanding liabilities before accident year 2013, net of reinsurance 92,583 Total outstanding liabilities for unpaid claims $ 2,879,430 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - SPECIALTY (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Specialty 15% 39% 16% 10% 4% 3% 1% 1% —% —% The Company is predominantly a reinsurer of primary insurers and does not have access to claim frequency information held by our cedants due to the majority of the Company’s business being written on a proportional basis. As such, the Company considers it impracticable to disclose information on the frequency of claims. The reconciliation of the net incurred and paid claims development information above to the Non-life reserves in the Consolidated Balance Sheet at December 31, 2022 was as follows (in thousands of U.S. dollars): December 31, 2022 Total outstanding liability for unpaid claims Property $ 2,056,033 Casualty 5,637,100 Specialty 2,879,430 Total outstanding liabilities for unpaid claims $ 10,572,563 Unallocated loss expenses $ 119,274 U.S. health net reserves (1) 168,146 Other 13,837 Total other liabilities $ 301,257 Net liability at end of year $ 10,873,820 Reinsurance recoverable on unpaid claims Property $ 922,141 Casualty 585,737 Specialty 343,933 Reinsurance recoverable at end of year $ 1,851,811 Gross liability at end of year $ 12,725,631 (1) U.S. health business is not meaningful to include in the development tables as the estimated average duration of the health reserves is less than one year and substantially all claims are expected to be paid within two years, based on historical payout patterns.

Reinsurance

Reinsurance	12 Months Ended
	Dec. 31, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	Reinsurance (a) Reinsurance Recoverable on Paid and Unpaid Losses The Company uses retrocessional agreements to reduce its exposure to risk of loss on reinsurance assumed. These agreements provide for recovery from retrocessionaires of a portion of losses and loss expenses. The Company remains liable to its cedants to the extent that the retrocessionaires do not meet their obligations under these agreements, and therefore the Company evaluates the financial condition of its reinsurers and monitors concentration of credit risk on an ongoing basis. The Company actively manages its reinsurance exposures by generally selecting either collateralized retrocessionaires or counterparties that have a credit rating of A- or higher. The Company established Lorenz Re Ltd. (“Lorenz Re”), a special purpose insurer registered as a segregated accounts company in Bermuda, as part of its third party capital platform to provide third party investors with access to portfolios of risk in the global reinsurance markets. Lorenz Re operates by providing fully collateralized reinsurance capacity to certain of the Company's operating subsidiaries in respect of multiple lines of business. Lorenz Re raises capital primarily from third party investors seeking exposure to the global reinsurance markets by issuing non-voting redeemable preferred shares in its individual segregated accounts. The proceeds from issuance of these preferred shares are deposited into trust accounts collateralizing varying portfolios of potential reinsurance recoverables, which have established investment guidelines that generally require assets to be held as either cash and cash equivalents or in U.S. government issued securities of high credit quality. For the years ended December 31, 2022, 2021 and 2020, the Company ceded premium written to Lorenz Re’s segregated cells of $664 million, $634 million and $81 million, respectively, and recorded a Reinsurance recoverable on paid and unpaid losses from the segregated cells of $921 million and $592 million as at December 31, 2022 and 2021, respectively. The Company adopted updated accounting guidance on the recognition of credit losses effective January 1, 2020. In assessing an allowance for reinsurance recoverable balances, the Company considers historical information, financial strength and credit ratings of reinsurers, collateralization amounts and the remaining expected life of reinsurance recoverable balances to determine the appropriateness of the allowance. Historically, the Company has not experienced material credit losses from retrocessional agreements. In assessing future default for reinsurance recoverable balances, the Company evaluates the valuation allowance under the probability of default and loss given default method and utilizes counterparty credit ratings from major rating agencies, as well as assesses the current market conditions and reasonable and supportable forecasts for the likelihood of default. At December 31, 2022 and 2021, the Company's allowance for credit losses on its reinsurance recoverable balance was $3 million. (b) Ceded Reinsurance Net premiums written, net premiums earned and losses and loss expenses are reported net of reinsurance in the Company’s Consolidated Statements of Operations. Assumed, ceded and net amounts for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): Premiums Premiums Losses and Loss 2022 Non-life $ 7,015,422 $ 6,696,769 $ 4,024,931 Life and Health 1,673,857 1,674,091 1,476,353 Assumed $ 8,689,279 $ 8,370,860 $ 5,501,284 Non-life $ 1,116,672 $ 1,085,317 $ 711,697 Life and Health 28,412 28,426 42,184 Ceded $ 1,145,084 $ 1,113,743 $ 753,881 Non-life $ 5,898,750 $ 5,611,452 $ 3,313,234 Life and Health 1,645,445 1,645,665 1,434,169 Net $ 7,544,195 $ 7,257,117 $ 4,747,403 Premiums Premiums Losses and Loss 2021 Non-life $ 6,557,055 $ 6,274,418 $ 4,212,465 Life and Health 1,646,870 1,651,485 1,454,065 Assumed $ 8,203,925 $ 7,925,903 $ 5,666,530 Non-life $ 1,046,227 $ 944,862 $ 769,220 Life and Health 23,680 24,519 13,326 Ceded $ 1,069,907 $ 969,381 $ 782,546 Non-life $ 5,510,828 $ 5,329,556 $ 3,443,245 Life and Health 1,623,190 1,626,966 1,440,739 Net $ 7,134,018 $ 6,956,522 $ 4,883,984 Premiums Premiums Losses and Loss 2020 Non-life $ 5,376,703 $ 5,571,201 $ 4,358,975 Life and Health 1,499,222 1,505,819 1,344,117 Assumed $ 6,875,925 $ 7,077,020 $ 5,703,092 Non-life $ 550,784 $ 516,672 $ 342,271 Life and Health 24,283 23,522 25,921 Ceded $ 575,067 $ 540,194 $ 368,192 Non-life $ 4,825,919 $ 5,054,529 $ 4,016,704 Life and Health 1,474,939 1,482,297 1,318,196 Net $ 6,300,858 $ 6,536,826 $ 5,334,900

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt The debt outstanding and the carrying value recorded in the Consolidated Balance Sheets at December 31, 2022 and 2021 was comprised as follows (in thousands): December 31, 2022 December 31, 2021 Commitment Carrying Value Fair Value Carrying Value Fair Value Senior notes due 2029 $ 500,000 $ 497,073 $ 462,521 $ 496,620 $ 561,099 Senior notes due 2026 € 750,000 794,368 721,807 843,950 882,126 Junior subordinated notes due 2050 $ 500,000 494,638 428,250 494,445 526,522 Capital efficient notes due 2066 $ 61,924 61,924 54,247 62,484 55,248 Debt $ 1,848,003 $ 1,666,825 $ 1,897,499 $ 2,024,995 Senior notes due 2029 In June 2019, PartnerRe Finance B LLC, an indirect wholly-owned financing subsidiary of the Company, issued $500 million aggregate principal amount of 3.700% senior notes at a price of 99.783% of the principal amount. The net proceeds of the issuance, after consideration of the offering discount and underwriting expenses and commissions, totaled $496 million. These senior notes may be redeemed at the option of the issuer, in whole or in part, at any time, with early redemption requiring the payment of a make-whole premium. Commencing on January 2, 2020, interest on these notes is payable semi-annually at an annual fixed rate of 3.700%. Unless previously redeemed, the notes mature on July 2, 2029. These senior notes are ranked as senior unsecured obligations of PartnerRe Finance B LLC and PartnerRe Ltd. has fully and unconditionally guaranteed all obligations of PartnerRe Finance B LLC related to these senior notes. PartnerRe Ltd.’s obligations under this guarantee are senior and unsecured and rank equally with all other senior unsecured indebtedness. Senior notes due 2026 In September 2016, PartnerRe Ireland Finance DAC, an indirect wholly-owned financing subsidiary of the Company, issued €750 million aggregate principal amount of 1.250% senior notes at a price of 99.144% of the principal amount, which are listed in the main securities market of the Irish Stock Exchange. Interest is payable annually commencing on September 15, 2017. These senior notes may be redeemed at the option of the issuer, in whole or in part, at any time. Unless previously redeemed, the notes mature on September 15, 2026. These senior notes are ranked as senior unsecured obligations of PartnerRe Ireland Finance DAC. PartnerRe Ltd. has fully and unconditionally guaranteed all obligations of PartnerRe Ireland Finance DAC under these senior notes. PartnerRe Ltd.’s obligations under this guarantee are senior and unsecured and rank equally with all other senior unsecured indebtedness. Junior subordinated notes due 2050 In September 2020, PartnerRe Finance B LLC issued $500 million aggregate principal amount of 4.500% fixed-rate reset junior subordinated notes at par. The net proceeds of the issuance, after consideration of the underwriting expenses, commissions and other expenses, totaled $494 million. Commencing on April 1, 2021, interest on these notes is payable semi-annually at an annual fixed rate of 4.500% until the first reset date on October 1, 2030. From the first reset date, and resetting every five years thereafter, the notes will bear interest at an annual rate equal to the five-year treasury rate plus 3.815%. These junior subordinated notes may be redeemed at the option of the issuer, in whole or in part, at any time, with early redemption outside of a par call period requiring the payment of a make-whole premium. Par call periods occur between April 1 and October 1 in each year in which the interest rate resets. Early redemption prior to October 1, 2025 is subject to the Bermuda Monetary Authority's approval. Unless previously redeemed, the notes mature on October 1, 2050. These notes are ranked as unsecured junior subordinated obligations, and will rank junior in right of payment to all outstanding and future senior indebtedness of PartnerRe Finance B LLC. PartnerRe Ltd. has fully and unconditionally guaranteed all obligations of PartnerRe Finance B LLC related to these junior subordinated notes. PartnerRe Ltd.’s obligations under this guarantee are unsecured junior subordinated obligations and rank junior in right of payment to all its outstanding and future senior indebtedness, and equally in right of payment with all outstanding and future unsecured indebtedness that is by its terms equal in right of payment to the junior subordinated notes. Capital efficient notes due 2066 In November 2006, PartnerRe Finance II Inc., an indirect wholly-owned financing subsidiary of the Company, issued Fixed-to-Floating Rate Junior Subordinated Capital Efficient Notes (CENts) with a principal amount of $250 million. In March 2009, $187 million of the principal amount was extinguished, with an additional $900 thousand of the principal amount extinguished in June 2019 and $560 thousand in December 2022. As a result, the remaining aggregate principal amount of the CENts as at December 31,

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity Authorized Shares At December 31, 2022 and 2021, the total authorized share capital (common and preferred) of the Company was $200 million. Common Shares At December 31, 2021, 100 million authorized and issued Class A common shares of $0.00000001 par value each were owned by EXOR Nederland N.V. On July 12, 2022, Covéa Coopérations S.A. completed the acquisition of all Class A common shares of PartnerRe Ltd. from EXOR Nederland N.V., and at December 31, 2022, 100 million authorized and issued Class A common shares of $0.00000001 par value each were owned by Covéa Coopérations S.A. See Note 13 for discussion of Class B and C common shares. Redeemable Preferred Shares On March 15, 2021, the Company issued 8,000,000 4.875% Series J fixed rate non-cumulative redeemable preferred shares at a par value of $1.00 per share and a redemption price of $200 million. The Company incurred issuance costs directly attributable to the new preferred shares of $6 million. The Series J preferred shares will remain outstanding into perpetuity, unless and until the Company decides to redeem them. The shares are not callable by the Company until March 15, 2026. On and after March 15, 2026, the Series J Preferred Shares will be redeemable at the Company’s option, in whole or from time to time in part, at a redemption price equal to $25 per Series J Preferred Share, plus declared and unpaid dividends. Dividends on the Series J preferred shares are non-cumulative and are payable quarterly in arrears. In the event of liquidation of the Company, the Series J preferred shares rank senior to the common shares, and the holders of the preferred shares would receive a distribution of $25 per share plus any declared but unpaid dividends. The Series J preferred shares were the only preferred shares issued and outstanding at December 31, 2022 and 2021. On May 3, 2021, the Company redeemed all outstanding Series G, Series H and Series I preferred shares at $25 per share for an aggregate liquidation value of $637 million. In addition, unpaid preferred dividends accrued to the redemption date totaling $7 million were paid. In connection with the redemption, the Company recognized a loss of $21 million related to the deferred issuance costs paid upon issuance which were included in Additional paid-in capital related to the Series G, H and I preferred shares. There was no additional gain or loss on redemption to recognize as the redemption price and the initial consideration received on the issue of preferred shares were both $25 per share. The loss of $21 million was recognized as a deemed preferred dividend in retained earnings and in determining the Net income available to common shareholder. On October 22, 2020, the Company redeemed 2,679,426 Series F preferred shares at $25 per share for an aggregate liquidation value of $67 million. In addition, unpaid preferred dividends accrued to the redemption date totaling $1 million were paid. In connection with the redemption, the Company recognized a loss of $2 million related to the deferred issuance costs paid upon issuance which were included in Additional paid-in capital related to the Series F preferred shares. There was no additional gain or loss on redemption to recognize as the redemption price and the initial consideration received on the issue of preferred shares were both $25 per share. The loss of $2 million was recognized as a deemed preferred dividend in retained earnings and in determining the Net income attributable to common shareholder.

Dividend Restrictions and Statu

Dividend Restrictions and Statutory Requirements	12 Months Ended
	Dec. 31, 2022
Disclosure - Dividend Restrictions and Statutory Requirements [Abstract]
Dividend Restrictions and Statutory Requirements	Dividend Restrictions and Statutory Requirements The Company’s ability to pay common and preferred shareholders’ dividends and its corporate expenses is dependent mainly on cash dividends from PartnerRe Bermuda, PartnerRe Europe, PartnerRe U.S., PartnerRe Asia and PartnerRe Canada (collectively, the reinsurance subsidiaries), which are the Company’s most significant subsidiaries. The payment of such dividends by the reinsurance subsidiaries to the Company is limited under Bermuda, Irish, Canadian and Singapore laws and certain statutes of various U.S. states in which PartnerRe U.S. is domiciled. The restrictions are generally based on net income and/or certain levels of surplus as determined in accordance with the relevant statutory accounting practices. On December 16, 2021, Exor signed a definitive agreement with Covéa Coopérations S.A., under which Covéa Coopérations S.A agreed to purchase all of the common shares of PartnerRe Ltd. from Exor. Consummation of this transaction occurred on July 12, 2022. The Company has not paid any dividends since July 12, 2022. At December 31, 2022, given the Company complied with its Bermuda solvency requirements, there were no other restrictions on the Company’s ability to pay common and preferred shareholders’ dividends from its retained earnings, except for the reinsurance subsidiaries’ dividend restrictions described below. The reinsurance subsidiaries are required to file annual statements with insurance regulatory authorities prepared on an accounting basis prescribed or permitted by such authorities (statutory basis), maintain minimum levels of solvency and liquidity and comply with risk-based capital requirements and licensing rules. At December 31, 2022, the reinsurance subsidiaries’ solvency, liquidity and risk-based capital amounts were in excess of the minimum levels required. The typical adjustments to insurance statutory basis amounts to convert to U.S. GAAP include the elimination of certain statutory reserves, deferral of certain acquisition costs, recognition of goodwill, intangible assets and deferred income taxes that are limited on a statutory basis, valuation of bonds at fair value, the deferral of gains on retroactive reinsurance on non-life business and presentation of ceded reinsurance balances gross of assumed balances. PartnerRe Bermuda may declare dividends subject to it continuing to meet its minimum solvency and minimum liquidity ratios, which are to hold statutory capital and surplus equal to or exceeding the Target Capital Level, which is equivalent to 120% of the Enhanced Capital Requirement (ECR) and to maintain a minimum general business liquidity ratio equal to the value of its relevant assets at not less than 75% of the amount of its relevant liabilities. The ECR is calculated with reference to the Bermuda Solvency Capital Requirement model, which is a risk-based capital model. During 2023, the maximum dividend that PartnerRe Bermuda can pay without prior regulatory approval is approximately $789 million. The reporting deadline for the annual submission is April 30, 2023. PartnerRe Europe is subject to the Solvency II European Directive (Solvency II Regulations). The Solvency II Regulations relate to the solvency standards applicable to insurers and reinsurers and lay down, at the level of PartnerRe Europe, the minimum amounts of financial resources required in order to cover the risks to which it is exposed and the principles that should guide its overall risk management and reporting. PartnerRe Europe may declare dividends subject to it continuing to meet its Solvency II requirements, which are to hold available capital, calculated on a Solvency II balance sheet basis, in excess of the solvency capital requirement (SCR). The maximum dividend is limited to “profits available for distribution”, which consist of accumulated realized profits less accumulated realized losses. The reporting deadline for the annual Solvency II submission is April 8, 2023. PartnerRe U.S. may declare dividends subject to it continuing to meet its minimum solvency and capital requirements and is generally limited to paying dividends from earned surplus. In connection with the acquisition by Covéa, it was agreed that PartnerRe US would not take action to declare or distribute any dividend for the two year period from July 12, 2022 to July 12, 2024 without the prior approval of the New York State Department of Financial Services. The maximum dividend that can be declared and paid without prior approval is limited, to the lesser of adjusted net investment income or 10% of its total statutory capital and surplus as of the most recently filed annual statement. The reporting deadline for the annual filing is March 1, 2023. PartnerRe Asia may declare dividends from unappropriated profits subject to meeting the capital requirements, as laid out by the Monetary Authority of Singapore. As a licensed reinsurer, PartnerRe Asia is required to maintain minimum capital of SGD25 million. In addition, PartnerRe Asia is required to establish and maintain separate insurance funds for each class of business that it writes, for both Singapore and offshore policies. The solvency requirement in respect of each insurance fund shall at all times be not less than the total risk requirement of the fund (determined by reference to three components being insurance risks, asset portfolio risks and asset concentration risks) and above 120% of the total risk requirement on a Company basis. The declaration of a dividend by PartnerRe Asia is subject to conditions and requirements being met as specified under the Companies Act and the Insurance Act and its associated regulations. The filing date for the annual submission is March 31, 2023. PartnerRe Canada may declare dividends subject to it continuing to meet its capital requirements and maintaining adequate and appropriate forms of liquidity in addition to complying with related regulations. Dividends and capital distributions are subject to regulations under the Insurance Companies Act (Canada) and the requirements of the Office of the Superintendent of Financial Institutions (OSFI). The reporting deadline for the annual filing is March 1, 2023. The statutory financial statements and returns of the Company’s reinsurance subsidiaries as at, and for the year ended, December 31, 2022 are due to be submitted to the relevant regulatory authorities later in 2023, with different filing dates in each jurisdiction. In certain jurisdictions, the statutory financial statements and returns are subject to the review and final approval of the relevant regulatory authorities. As a result, the comparative figures in the tables below reflect final figures submitted to regulatory authorities for 2021 and 2020. The statutory net income (loss) of PartnerRe Bermuda, PartnerRe Europe, PartnerRe U.S., PartnerRe Asia and PartnerRe Canada for the years ended December 31, 2022, 2021 and 2020 was as follows (in millions of U.S. dollars): 2022 2021 2020 PartnerRe Bermuda $ (139) $ 900 $ (52) PartnerRe Europe $ (329) $ 28 $ 237 PartnerRe U.S. $ 242 $ 68 $ 28 PartnerRe Asia $ (31) $ (6) $ (2) PartnerRe Canada $ (14) $ (12) $ 13 The required and actual statutory capital and surplus of PartnerRe Bermuda, PartnerRe Europe, PartnerRe U.S., PartnerRe Asia and PartnerRe Canada at December 31, 2022 and 2021 was as follows (in millions of U.S. dollars): PartnerRe Bermuda (1) PartnerRe Europe PartnerRe U.S. PartnerRe Asia PartnerRe Canada 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Required statutory capital and surplus $ 2,725 $ 2,846 $ 1,537 $ 1,873 $ 1,356 $ 1,244 $ 47 $ 50 $ 1,144 $ 999 Actual statutory capital and surplus $ 5,816 $ 6,004 $ 2,672 $ 2,744 $ 1,928 $ 1,369 $ 215 $ 249 $ 1,392 $ 1,240 (1) Required statutory capital and surplus is calculated at the Target Capital Level In addition to the required statutory capital and surplus requirements for the reinsurance subsidiaries in the table above, the Company is required to assess its solvency capital needs both at a Group and subsidiary level. The Company’s capital requirements determine the amount of capital available to be declared as dividends to its shareholders. As Group Supervisor, the Bermuda Monetary Authority is tasked with assessing the financial condition of the Group and coordinates the dissemination of information to other relevant authorities for the purpose of assisting in their regulatory functions and the enforcement of regulatory action against the Company or any of its subsidiaries, including the power to impose restrictions on the ability of the relevant subsidiaries to declare dividends to the Company, and the ability of the Company to pay dividends to shareholders. In addition, the Company is required to maintain the Group ECR imposed by the BMA under Bermuda law. The Company is currently completing the 2022 group BSCR, which must be filed with the BMA on or before May 31, 2023, and at this time, we expect we will exceed the ECR.

Taxation

Taxation	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Taxation	Taxation The Company and its Bermuda domiciled subsidiaries are not subject to Bermuda income or capital gains tax under current Bermuda law. In the event that there is a change in current law such that taxes on income or capital gains are imposed, the Company and its Bermuda domiciled subsidiaries would be exempt from such tax until March 2035 pursuant to the Bermuda Exempted Undertakings Tax Protection Act of 1966. The Company has subsidiaries and branches that operate in various other jurisdictions around the world that are subject to tax in the jurisdictions in which they operate. The significant jurisdictions in which the Company’s subsidiaries and branches are subject to tax are Canada, France, Hong Kong, Ireland, Singapore, Switzerland and the U.S. Income tax returns are open for examination for the tax years 2013-2022 in the U.S., 2017-2022 in Hong Kong and Canada, 2018-2022 in Singapore, France and Ireland, and 2021-2022 in Switzerland. As a global organization, the Company may be subject to a variety of transfer pricing or permanent establishment challenges by taxing authorities in various jurisdictions. While management believes that adequate provision has been made in the Consolidated Financial Statements for any potential assessments that may result from tax examinations for all open tax years, the completion of tax examinations for open years may result in changes to the amounts recognized in the Consolidated Financial Statements. Income tax expense (benefit) for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Current income tax expense (benefit) U.S. $ 93,906 $ 31,216 $ (97,155) Non U.S. 20,622 18,293 44,764 Total current income tax expense (benefit) $ 114,528 $ 49,509 $ (52,391) Deferred income tax (benefit) expense U.S. $ (14,428) $ (9,404) $ 60,932 Non U.S. (70,699) (1,687) (25,560) Total deferred income tax (benefit) expense $ (85,127) $ (11,091) $ 35,372 Unrecognized tax expense (benefit) U.S. $ — $ — $ — Non U.S. 1,933 (199) 3,928 Total unrecognized tax expense (benefit) $ 1,933 $ (199) $ 3,928 Total income tax expense (benefit) U.S. $ 79,478 $ 21,812 $ (36,223) Non U.S. (48,144) 16,407 23,132 Total income tax expense (benefit) $ 31,334 $ 38,219 $ (13,091) (Loss) income before taxes attributable to the Company’s domestic and foreign operations and a reconciliation of the actual income tax rate to the amount computed by applying the effective tax rate of 0% under Bermuda (the Company’s domicile) law to (loss) income before taxes was as follows for the years ended December 31, 2022, 2021 and 2020 (in thousands of U.S. dollars): 2022 2021 2020 Domestic (Bermuda) $ (205,731) $ 636,043 $ 3,894 Foreign (852,964) 125,580 237,204 (Loss) income before taxes $ (1,058,695) $ 761,623 $ 241,098 Reconciliation of effective tax rate (% of (loss) income before taxes) Expected tax rate 0.0 % 0.0 % 0.0 % Foreign taxes at local expected tax rates 14.2 5.7 15.5 Impact of foreign exchange gains or losses (0.3) (0.1) (8.1) Unrecognized tax (expense) benefit (0.2) — 1.6 Tax-exempt income and expenses not deductible 0.1 (0.4) (1.4) Foreign branch tax 3.5 0.1 (3.3) Valuation allowance (17.6) 0.6 3.4 Other (2.7) (0.9) (13.1) Actual tax rate (3.0) % 5.0 % (5.4) % On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The Company did not make use of any direct support measures. It was only the Company’s U.S. subsidiaries that benefited from the CARES Act through the passage of modified tax loss carry-back rules that allow losses to be carried back to years with a higher tax rate. As a result, the Company’s U.S. subsidiaries realized a tax benefit of $35 million (or a reduction of 14.4 points on the effective tax rate) for the year ended December 31, 2020, which is included in Other in the table above. The components of net tax assets and liabilities at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Net tax assets $ 164,384 $ 154,472 Net tax liabilities (29,154) (90,974) Net tax assets $ 135,230 $ 63,498 December 31, 2022 December 31, 2021 Net current tax assets $ 108,836 $ 117,872 Net deferred tax assets (liabilities) 37,103 (45,098) Net unrecognized tax benefit (10,709) (9,276) Net tax assets $ 135,230 $ 63,498 Deferred tax assets and liabilities reflect the tax impact of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. Significant components of the net deferred tax assets and liabilities at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Deferred tax assets Discounting of loss reserves and adjustment to life policy reserves $ 18,049 $ 18,340 Foreign tax credit carryforwards 211,023 180,510 Tax loss carryforwards 123,597 106,555 Unearned premiums 46,029 36,421 Statutory basis funds held — 58,899 Unrealized depreciation and timing differences on foreign exchange revaluations — 3,838 Unrealized depreciation and timing differences on investments 170,720 — Other deferred tax assets 37,423 47,034 $ 606,841 $ 451,597 Valuation allowance (399,329) (211,798) Deferred tax assets $ 207,512 $ 239,799 Deferred tax liabilities Deferred acquisition costs $ 92,459 $ 75,924 Goodwill and other intangibles 55,882 56,870 Statutory basis reserves — 114,240 Equalization reserves 8,235 7,192 Unrealized appreciation and timing differences on investments — 4,877 Other deferred tax liabilities 13,833 25,794 Deferred tax liabilities $ 170,409 $ 284,897 Net deferred tax assets (liabilities) $ 37,103 $ (45,098) Realization of deferred tax assets is dependent on generating sufficient taxable income in future periods. Although realization is not assured, management believes that it is more likely than not that the deferred tax assets will be realized. The valuation allowance recorded at December 31, 2022 relates to a foreign tax credit carryforward of $211 million in Ireland, a net unrealized investment loss position in the United States generating a deferred tax asset of $148 million, and net deferred tax assets of $22 million in the United States, $11 million in the United Kingdom and $7 million in Canada. The valuation allowance recorded at December 31, 2021 related to a foreign tax credit carryforward of $181 million in Ireland, and net deferred tax assets of $13 million in the United States, $12 million in the United Kingdom and $6 million in Canada, At December 31, 2022, the deferred tax assets included $70 million in aggregate tax loss carryforwards (after valuation allowance) including: $26 million in Switzerland, $20 million in Singapore, $10 million in the United States, $9 million in Ireland, $2 million in both the United Kingdom and Hong Kong, and $1 million in Canada. At December 31, 2021, the deferred tax assets included $76 million in aggregate tax loss carryforwards (after valuation allowance) including: $44 million in the United States, $19 million in Singapore, $6 million in Switzerland, $5 million in Canada and $2 million in Hong Kong. The loss carryforwards at both December 31, 2022 and December 31, 2021 can be carried forward for an unlimited period of time except Canada which is limited to twenty years and Switzerland which is limited to seven years. The total amount of unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Balance at January 1 $ 9,276 $ 10,273 $ 5,689 Changes in tax positions taken during a prior year 1,933 (199) 3,870 Impact of the change in foreign currency exchange rates (500) (798) 714 Balance at December 31 $ 10,709 $ 9,276 $ 10,273 For the years ended December 31, 2022, 2021 and 2020, there were no new uncertain tax positions taken. For the years ended December 31, 2022, 2021 and 2020, there were no unrecognized tax benefits that, if recognized, would create a temporary difference between the reported amount of an item in the Company’s Consolidated Balance Sheets and its tax basis. The Company recognizes interest and penalties as Income tax expense (benefit) in the Consolidated Statements of Operations. At December 31, 2022, there are no unrecognized tax benefit positions that are reasonably expected to reverse within twelve months.

Share-Based Incentives

Share-Based Incentives	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Incentives	Share-Based Incentives The Company is authorized to issue Class C common shares (Class C shares) and restricted share units to certain executives and directors of the Company. Prior to the adoption of the new Class C shares and related restricted share unit plan in 2021, the Company was authorized to issue restricted Class B common shares (Class B shares) which ranked pari passu with Class C shares in all respects. Class C Shares and Restricted Share Unit Plan During 2021, the Company designated a new class of voting Class C shares and also adopted a related restricted share unit plan and French sub-plan (collectively the “RSU Plan”). The RSU Plan provides for the award of restricted share units to certain executives of the Company (each a “Participant”). Grants under the RSU plan are split evenly between restricted share units and performance share units (collectively referred to as RSUs) which are adjusted for personal performance (range of 75% to 125% of target) and Company performance (range of 50% to 150% of target), respectively, after one year following the date of grant. RSUs are generally granted on March 1 of a given year, and the target number of RSUs initially granted is determined based on a long-term incentive (“LTI”) target award amount divided by the latest U.S. GAAP book value (or common shareholder’s equity) per share published as of December 31. The RSUs are granted at $nil consideration and cliff vest after a three year vesting period from the date of grant, in accordance with the terms set out in the RSU Agreement and the RSU Plan provided to the Participant. An acceleration of the vesting period will occur under certain circumstances, including death or permanent disability of the Participant or change of control for the Company. Notwithstanding these provisions, the Company's Board of Directors has authority to accelerate the vesting period at its own discretion. The RSUs are eligible for imputed dividends which are subject to the same forfeiture provisions as the related RSUs. RSUs do not entitle the holder to any voting rights for the Company. RSUs are settled in unrestricted Class C shares following the vesting date. Class C shares can also be purchased by or granted to certain executives or non-executive directors of the Company, provided requisite approvals have been granted, at the discretion of the Company's Board of Directors. Purchases of Class C shares are based on the latest U.S. GAAP book value as of the applicable valuation date. Unrestricted Class C shares can be sold back to the Company at a redemption price based on the Company’s U.S. GAAP book value per share as of the applicable valuation date, at the discretion of the Company as further defined in the RSU Agreement and RSU Plan. The RSU Plan requires that the Participant can only sell Class C shares back to the Company provided that the Participant holds cumulative Class C shares and RSUs in the amount of a minimum of two times their gross annual LTI target value, unless otherwise agreed (the “Minimum Holding Requirement”). Class B Shares During 2017, the Company designated a class of voting Class B shares. Prior to the approval of the new Class C shares and related RSU Plan in 2021, Class B shares could either be purchased by or granted to certain executives or non-executive directors of the Company at the discretion of the Company in line with the provisions set out in the Class B Certificate of Designation, or any sub-plan or addendum thereto. Effective 2021, the Company no longer grants Class B shares or authorizes new purchases of Class B shares. Prior to 2021, grants of restricted Class B shares were made by the Company twice per year as of March 1 or September 1, and the number of shares granted was determined based on a LTI award amount divided by the latest U.S. GAAP book value (or common shareholder's equity) per share published as of the most recent valuation date, being either December 31 or June 30. The granted Class B shares in some instances were issued net of share equivalent to settle related withholding taxes. Restricted Class B shares were granted at $nil consideration and were restricted from sale for a period of up to three years from the date of grant. An acceleration of the restriction period could occur under certain circumstances, including death, permanent disability, retirement of the shareholder, or change of control for the Company. Notwithstanding these provisions, the Company's Board of Directors had authority to accelerate the restriction period at its own discretion. Purchases of unrestricted Class B shares were based on the latest U.S. GAAP book value as of the applicable valuation date. All Class B shares were extinguished in 2022 and there were no longer any Class B shares issued or outstanding as at December 31, 2022. Summary of Activity Restricted Class B shares, Class C shares and RSUs granted are recognized at fair value over the requisite service period. The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period. In July 2022, Covéa completed the acquisition of PartnerRe Ltd. from Exor. Upon the change of control, all Class B shares, Class C shares and RSUs vested and were repurchased by the Company, with the exception of Class C shares and RSUs issued in 2022. The repurchase price for all Class B shares, Class C shares and RSUs was based on a valuation utilizing the Covéa acquisition purchase price per share of the Company. The Company's total settlement amount paid upon change of control was $43 million, net of $3 million of tax withholding, which included $40 million paid for granted shares and RSUs and $3 million for certain shares that were previously purchased by executives and directors of the Company. Included in Accounts payable, accrued expense and other in the Consolidated Balance Sheets was a liability of $7 million for Class C Shares and RSUs at December 31, 2022, and a liability of $24 million for Class B shares, Class C shares and RSUs at December 31, 2021. The compensation expense related to Class B shares, Class C shares and RSUs for the years ended December 31, 2022, 2021, and 2020 was $29 million, $13 million and $11 million, respectively, included in Other expenses in the Company's Consolidated Statements of Operations. The 2022 expense included the impact of accelerated vesting of Class B shares, Class C shares and RSUs due to the change of control. As of December 31, 2022, there was $17 million of total unrecognized compensation cost related to RSUs, which will be recognized on a weighted average basis during the next 2.0 years. The following tables provide activity summaries of the Company's Class B shares, Class C shares, and RSUs outstanding: RSUs (1) Outstanding December 31, 2020 — Granted 263,214 Outstanding December 31, 2021 263,214 Forfeitures (2,964) Accelerated vesting and repurchase upon change of control (260,250) Granted 265,805 Outstanding December 31, 2022 265,805 (1) For RSUs, the number of grants in the table are shown at the maximum number that can be attained if the performance conditions are fully met for personal and Company performance. Forfeitures represent adjustments to grants falling below the maximum attainable as a result of not fully meeting the performance conditions. Restricted Class C shares Unrestricted Class C shares Total Class C shares Outstanding December 31, 2020 — — — Granted 7,373 — 7,373 Purchased — 2,072 2,072 Outstanding December 31, 2021 7,373 2,072 9,445 Accelerated vesting and repurchase upon change of control (7,373) (5,819) (13,192) Granted 7,666 3,747 11,413 Outstanding December 31, 2022 7,666 — 7,666 Restricted Class B shares Unrestricted Class B shares Total Class B shares Outstanding December 31, 2019 179,332 102,436 281,768 Granted 167,202 — 167,202 Purchased — 38,838 38,838 Repurchased (129,583) (83,561) (213,144) Expiration of restricted period (27,785) 27,785 — Outstanding December 31, 2020 189,166 85,498 274,664 Repurchased (29,048) (22,957) (52,005) Expiration of restricted period (20,298) 20,298 — Outstanding December 31, 2021 139,820 82,839 222,659 Expiration of restricted period (32,168) 32,168 — Accelerated vesting and repurchase upon change of control (107,652) (115,007) (222,659) Outstanding December 31, 2022 — — —

Retirement Benefit Arrangements

Retirement Benefit Arrangements	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Benefit Arrangements	Retirement Benefit Arrangements For employee retirement benefits, the Company maintains certain defined contribution plans and other active and frozen defined benefit plans. Defined Contribution Plans Contributions are made by the Company, and in some locations, these contributions are supplemented by the local plan participants. Contributions are based on a percentage of the participant’s base salary depending upon competitive local market practice and vesting provisions meeting legal compliance standards and market trends. The accumulated benefits for the majority of these plans vest immediately or over a period of up to four years. As required by law, certain retirement plans also provide for death and disability benefits and lump sum indemnities to employees upon retirement. The Company incurred expenses for these defined contribution arrangements of $13 million for the years ended December 31, 2022, 2021 and 2020, respectively, included within Other expenses in the Company's Consolidated Statements of Operations. Active Defined Benefit Plan The majority of the defined benefit obligation at December 31, 2022 relates to a hybrid plan accounted for as a defined benefit plan under U.S. GAAP for the Company’s Zurich office employees (the Zurich Plan). At December 31, 2022 and 2021, the funded status of the Zurich Plan was as follows (in thousands of U.S. dollars): 2022 2021 Underfunded pension obligation at beginning of year $ 32,636 $ 62,050 Change in pension obligation Service cost $ 8,746 $ 11,811 Interest cost 373 228 Plan participants’ contributions 3,792 4,048 Actuarial gain (37,992) (24,211) Benefits paid (4,576) (1,651) Foreign currency adjustments (3,736) (8,735) Settlements — (20,682) Change in pension obligation $ (33,393) $ (39,192) Change in fair value of plan assets Actual return on plan assets $ (14,936) $ 6,847 Employer contributions 7,658 8,035 Plan participants’ contributions 3,792 4,048 Benefits paid (4,576) (1,651) Foreign currency adjustments (2,233) (6,375) Settlements — (20,682) Change in fair value of plan assets $ (10,295) $ (9,778) Underfunded pension obligation at end of year $ 9,538 $ 32,636 Additional information: Projected benefit obligation at end of year (1) $ 169,527 $ 202,920 Fair value of plan assets at end of year $ 159,989 $ 170,284 Underfunded pension obligation at end of year $ 9,538 $ 32,636 Accumulated pension obligation at end of year (2) $ 167,560 $ 194,730 (1) Represents the actuarial present value of all benefits attributed to employee service rendered to December 31, measured using assumptions as to future compensation levels (2) Represents the actuarial present value of benefits (whether vested or non-vested) attributed to employee service rendered and compensation to December 31, with no assumption about future compensation levels At December 31, 2022 and 2021, the underfunded pension obligation of $10 million and $33 million, respectively, was included in Accounts payable, accrued expenses and other in the Consolidated Balance Sheets. The amounts included in Accumulated other comprehensive loss at December 31, 2022 and 2021 were cumulative gains of $6 million (net of $1 million of taxes) and cumulative losses of $7 million (net of $2 million of taxes), respectively. The net periodic benefit cost reported in Other expenses in the Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020 was $1 million, $8 million and $5 million, respectively. The projected benefit obligation decreased by $33 million during 2022, driven by an update of actuarial assumptions primarily to reflect an increase in discount rates during the year. This was offset by decreases to the fair value of plan assets of $10 million, due primarily to the actual return on plan assets during the year, partially offset by $8 million in employer contributions. In 2021, the decrease in the projected benefit obligation was driven primarily by an update of actuarial demographic assumptions to reflect recently released actuarial tables, a decrease in members and $21 million of settlements during the year. This was offset by decreases to the fair value of plan assets of $10 million, due primarily to $21 million of settlements during the year, partially offset by $8 million in employer contributions and the actual return on plan assets. The investment strategy for the plan is to achieve a consistent long-term return, which will provide sufficient funding for future pension obligations while limiting risk. The expected long-term rate of return on plan assets is based on the expected asset allocation and assumptions concerning long-term interest rates, inflation rates and risk premiums for equities above the risk-free rates of return. These assumptions take into consideration historical long-term rates of return for the relevant asset categories. The investment strategy is reviewed regularly. The Zurich Plan is a partially insured scheme participating in a single investment pool under the pension provider. As at December 31, 2022 and 2021, the coverage ratio was 101% and 115%, respectively, based on the performance of the assets. The fair value of the Zurich Plan’s assets, comprised of an investment pool of funds and including cash, at December 31, 2022 and 2021 was $160 million and $170 million, respectively. The partially insured funds comprise the accumulated pension plan contributions and investment returns thereon. These funds meet the definition of Level 2 inputs of the fair value hierarchy as defined in Note 3(a). The actual return on plan assets for the year ended December 31, 2022 was a loss of $15 million and gains of $7 million and $3 million for the years ended December 31, 2021 and 2020, respectively. The assumptions used to determine the Zurich Plan’s pension obligation and net periodic benefit cost for the years ended December 31, 2022, 2021 and 2020 were as follows: 2022 2021 2020 Pension Net periodic Pension Net periodic Pension Net periodic Discount rate 2.20 % 0.20 % 0.20 % 0.10 % 0.10 % 0.25 % Interest crediting rate 2.20 % 1.00 % 1.00 % 1.00 % 1.00 % 1.00 % Expected long-term return on plan assets — 4.25 % — 3.50 % — 3.50 % Rate of compensation increase 2.25 % 2.00 % 2.00 % 2.00 % 2.00 % 2.00 % At December 31, 2022, estimated employer contributions to be paid in 2023 related to the Zurich Plan were $8 million and future benefit payments were estimated to be paid as follows (in thousands of U.S. dollars): Year Amount 2023 $ 11,377 2024 $ 9,696 2025 $ 10,739 2026 $ 12,454 2027 $ 11,111 2028 to 2032 $ 52,119

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Concentration of Credit Risk Fixed maturities The Company’s investment portfolio is managed following prudent standards of diversification and a prudent investment philosophy. The Company is not exposed to any significant credit concentration risk on its investments, except for debt securities issued by the U.S. government and government sponsored enterprises and other highly rated non-U.S. sovereign governments’ securities. At December 31, 2022 and 2021, other than the U.S. government and U.S. government sponsored enterprises, the Company’s fixed maturity investment portfolio did not contain exposure to any non-U.S. sovereign government or any other issuer that accounted for more than 10% of the Company’s shareholders’ equity. The Company keeps cash and cash equivalents in several banks and ensures that there are no significant concentrations of credit risk in any one bank. Derivatives The Company’s investment strategy allows for the use of derivative instruments, subject to strict limitations. Derivative instruments may be used to replicate investment positions and for the purpose of managing overall currency risk, market exposures and portfolio duration, for hedging certain investments, or for enhancing investment performance that would be allowed under the Company’s investment policy if implemented in other ways. The Company is exposed to credit risk in the event of non-performance by the counterparties to the Company’s derivative contracts. However, the Company diversifies the counterparties to its derivative contracts to reduce credit risk, and because the counterparties to these contracts are high credit quality international banks, the Company does not anticipate non-performance. These contracts are generally of short duration and settle on a net basis. The difference between the contract amounts and the related market value represents the Company’s maximum credit exposure. Underwriting operations The Company is also exposed to credit risk in its underwriting operations, most notably in the credit/surety line. Loss experience in these lines of business is cyclical and is affected by the state of the general economic environment. The Company provides its clients in these lines of business with reinsurance protection against credit deterioration, defaults or other types of financial non-performance of or by the underlying credits that are the subject of the reinsurance provided and, accordingly, the Company is exposed to the credit risk of those credits. The Company mitigates the risks associated with these credit-sensitive lines of business through the use of risk management techniques such as risk diversification, careful monitoring of risk aggregations and accumulations and, at times, through the use of retrocessional reinsurance protection and the purchase of credit default, total return and interest rate swaps. The Company has exposure to credit risk as it relates to its business written through brokers, if any of the Company’s brokers is unable to fulfill their contractual obligations with respect to payments to the Company. In addition, in some jurisdictions, if the broker fails to make payments to the insured under the Company’s policy, the Company might remain liable to the insured for the deficiency. The Company’s exposure to such credit risk is somewhat mitigated in certain jurisdictions by contractual terms. The Company has exposure to credit risk related to reinsurance balances receivable, reinsurance recoverable on paid and unpaid losses, funds held by reinsured companies and deposit assets. The credit risk exposure related to these balances is mitigated by several factors, including but not limited to, credit checks performed as part of the underwriting process, monitoring of aged receivable balances and, in certain cases, the contractual right to offset amounts payable by the Company to the counterparty against amounts due to the Company from the counterparty. The Company adopted updated accounting guidance on the recognition of credit losses effective January 1, 2020. In assessing future default for reinsurance balances receivable, the Company evaluates the valuation allowance under the loss rate method and utilizes historic loss activity, adjusted for its assessment of current market conditions and reasonable and supportable forecasts on loss rates. At December 31, 2022 and 2021, the Company's allowance for credit losses for its reinsurance balances receivable was $12 million and $10 million, respectively. In assessing an allowance for funds held by reinsured companies and deposit assets, the Company considers historical information and the financial strength and credit ratings of counterparties to determine the appropriateness of the allowance. In assessing future default for these balances, the Company evaluates the valuation allowance under the probability of default and loss given default method and utilizes counterparty credit ratings from major rating agencies, as well as assessing the current market conditions and reasonable and supportable forecasts for the likelihood of default. At December 31, 2022 and 2021, the Company's allowance for credit losses was $4 million for funds held by reinsured companies and $1 million for deposit assets, respectively. See Note 8 for discussion of credit risk related to reinsurance recoverable on paid and unpaid losses. (b) Lease Arrangements The Company leases office space under operating leases expiring in various years through 2038. At the lease commencement, the Company determines the classification of each lease as either a finance lease or an operating lease. The Company currently only has leases classified as operating and the lease expense is recognized on a straight-line basis over the lease term. Operating lease right-of-use assets and operating lease liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Variable lease payments are excluded from these lease payments to the extent they are not based on consumer price index or a market index and are recognized in the period in which the obligation for those payments is incurred. Many of the Company's lease terms include options to extend or terminate the lease at the discretion of the Company, and are reflected in the lease measurement only if the Company is reasonably certain of exercising those options. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company has lease agreements with lease and non-lease components, such as common-area maintenance costs. The Company has elected the practical expedient to account for lease components together with non-lease components as a single lease component for all real estate leases. As most leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The following table summarizes the balances related to the Company's total lease expense and provides supplemental other information related to operating leases for the year ended December 31, 2022 and 2021 (in thousands of U.S. dollars): 2022 2021 Operating lease costs $ 12,437 $ 14,928 Variable lease costs 1,292 904 Sublease income — (368) Total lease costs $ 13,729 $ 15,464 Other information: Operating lease right-of-use assets (1) $ 71,174 $ 75,010 Operating lease liabilities (2) $ 79,925 $ 85,462 Operating lease right-of-use assets obtained in exchange for lease obligations, non-cash $ 4,016 $ 26,553 Operating cash outflows from operating leases $ 13,545 $ 16,874 Weighted-average remaining lease term on operating leases (3) 7.8 Yrs 8.9 Yrs Weighted-average discount rate on operating leases (4) 2.3 % 2.4 % (1) Included in Other assets (2) Included in Accounts payable, accrued expenses and other (3) Weighted-average remaining lease term is calculated on the basis of the remaining lease term and the lease liability balance for each lease as of the reporting date (4) Weighted-average discount rate is calculated on the basis of the discount rate for the lease that was used to calculate the lease liability balance for each lease as of the reporting date and the remaining balance of the lease payments for each lease as of the reporting date The following table shows the contractual maturities of the Company's operating lease liabilities at December 31, 2022 (in thousands of U.S. dollars): Year Expected cash flows 2023 $ 13,671 2024 13,642 2025 12,303 2026 12,089 2027 10,953 2028 to 2038 24,005 Discount (6,738) Total discounted operating lease liabilities $ 79,925 The Company has additional lease commitments of $4 million related to a lease that will not commence until 2023, with a contractual lease term of 8 years. As this lease has not yet commenced, the related commitment is not included in the maturity table above or in the Consolidated Balance Sheets at December 31, 2022. (c) Other Agreements The Company has entered into maintenance agreements and service agreements that provide for business and information technology support and computer equipment. Future payments under these contracts amount to $28 million, with $17 million and $6 million to be paid during 2023 and 2024, respectively, and the remainder to be paid through 2029. The Company has entered into certain investments, including investments in VIEs (see Note 4(e)), with unfunded capital commitments. As of December 31, 2022, the Company expects to fund capital commitments totaling $447 million with $237 million, $132 million, $45 million, $20 million, and $13 million to be paid during 2023, 2024, 2025, 2026 and 2027, respectively. In exchange for a fee, the Company has committed to provide statutory reserve support to a third party by funding loans if certain events occur. At December 31, 2022, the Company does not believe that it will be required to provide any funding under this commitment, as the occurrence of the defined events is considered remote. (d) Legal Proceedings Litigation The Company’s reinsurance subsidiaries, and the insurance and reinsurance industry in general, are subject to litigation and arbitration in the normal course of their business operations. In addition to claims litigation and disputes, the Company and its subsidiaries may be subject to lawsuits and regulatory actions in the normal course of business that do not arise from or directly relate to claims on reinsurance contracts. While the outcome of any such litigation cannot be predicted with certainty, the Company will dispute all allegations against the Company and/or its subsidiaries that management believes are without merit. In March 2019, a cedant (“the Cedant”) brought a motion for a declaratory judgment against the Company seeking a declaration that the Cedant had properly exercised its right, pursuant to an agreement between the parties, to recapture certain portfolios of life reinsurance contracts that the Cedant had retroceded to the Company. In February 2021, the Company reached a settlement with the Cedant.

Credit Agreements

Credit Agreements	12 Months Ended
	Dec. 31, 2022
Line of Credit Facility [Abstract]
Credit Agreements	Credit Agreements In the normal course of its operations, the Company enters into agreements with financial institutions to obtain unsecured and secured letter of credit facilities. At December 31, 2022, the total amount of such credit facilities available to the Company was approximately $752 million, with the significant facilities as follows: • $400 million combined credit facility, with the first $100 million being unsecured and any further utilization secured. This credit facility matures each year on November 14, and automatically extends for a further year, unless canceled by either counterparty. • $250 million secured credit facility, that matures each year on March 24 and automatically extends for a further year unless canceled by either counterparty. • $100 million secured credit facility, that matures each year on December 21, and automatically extends for a further year unless canceled by either counterparty. Under the terms of certain reinsurance agreements, irrevocable letters of credit were issued for a total of $102 million on an unsecured basis and $479 million on a secured basis at December 31, 2022 in respect of losses and unearned premium reserves. The committed secured credit facilities maintained by the Company are used for the issuance of letters of credit which must be fully secured with either cash, government bonds and/or investment grade bonds. The agreements include default covenants, which could require the Company to fully secure the outstanding letters of credit to the extent that the facility is not already fully secured and/or result in the Company not being allowed to issue any new letters of credit. At December 31, 2022, no conditions of default existed under these facilities.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions (a) Transactions with EXOR Prior to the acquisition of the Company's common shares by Covéa, EXOR was a related party to PartnerRe. The following transactions occurred during EXOR's ownership of the Company. During 2022 and 2021, the Company declared and paid to EXOR Nederland N.V. common share dividends totaling $178 million and $107 million, respectively. In the normal course of its investment operations, the Company bought or held securities of companies affiliated with the Company, including the following: • In 2021, the Company invested in two Exor managed funds. At December 31, 2022 and 2021, the carrying value of these investments totaled $396 million and $468 million, respectively. Net unrealized losses related to these funds of $72 million were recorded in the Consolidated Statements of Operations for the year ended December 31, 2022 (including $34 million pre-acquisition), compared to net unrealized gains of $115 million for the year ended December 31, 2021. These investments are recorded at fair value and included within Other invested assets in the Consolidated Balance Sheets. • In 2018, the Company entered into an agreement with Exor to invest in a newly formed limited partnership, Exor Seeds L.P. At December 31, 2021, the carrying value of the Company's investment in the limited partnership was $51 million, and was accounted for using the equity method and was included within Other invested assets in the Consolidated Balance Sheets. During 2021, the Company sold its interest in Exor Seeds L.P. to Exor S.A. at a transaction price of $51 million. • In 2017, the Company invested $500 million in two Exor managed public equity funds. At December 31, 2022 and 2021, the carrying value of these investments totaled $422 million and $1,154 million, respectively. These investments are recorded at fair value and are included within Equities in the Consolidated Balance Sheets. In conjunction with the Covéa acquisition in 2022, the Company sold a portion of these funds to EXOR for total consideration of $772 million, resulting in a realized gain of $450 million, the majority of which was included in unrealized gains in prior periods. Net realized and unrealized investment gains related to these funds of $40 million (including $24 million of losses pre-acquisition), $115 million and $91 million were recorded in the Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020, respectively. During the years ended December 31, 2022, 2021 and 2020, the Company was a party to various agreements with Exor whereby Exor provides services in exchange for fees as follows: • advisory services related to certain real estate investments where the Company paid approximately $265 thousand, $433 thousand and $310 thousand for services rendered in 2022, 2021 and 2020, respectively. • investment advisory services and use of certain office space, where the Company paid $175 thousand and $259 thousand related to services provided in 2021 and 2020, respectively. This agreement was terminated in 2021. • certain advisory services for a fee of $184 thousand for 2022, $350 thousand for 2021 and $500 thousand in 2020. This agreement terminated in 2022 in conjunction with the Covéa acquisition. • consulting services related to certain investments such as alternative fixed income, real estate, public equity and private equity funds as well as co-invest opportunities. The related consulting service agreement was effective April 1, 2021 and the Company paid $3.9 million and $2.6 million related to services provided in 2022 and 2021, respectively. This agreement will terminate effective March 31, 2023. Following the acquisition of the Company's common shared by Covéa, EXOR is no longer a related party to PartnerRe. The transactions discussed above were entered into at arm's-length. (b) Transactions with Covéa Following the acquisition, the Covéa Group meets the definition of a related party. In this context, the Covéa Group covers Covéa SGAM (Société de Groupe d’Assurance Mutuelle), its eight affiliated mutual companies, Covéa Coopérations S.A., their subsidiaries and affiliates included in their consolidated financial statements. In the normal course of its underwriting activities, the Company entered into assumed reinsurance agreements with certain affiliates of Covéa Group. Included in the Consolidated Balance Sheets at December 31, 2022 were the following balances related to the Covéa Group (in thousands of U.S. dollars): 2022 Reinsurance balances receivable $ 3,169 Non-life reserves $ 95,013 Life and health reserves $ 1,175 Unearned premiums $ 571 Upon close of the Covéa acquisition, Covéa sold its interest in the Company's third-party capital vehicles. The transactions between related parties discussed above were entered into at arm's-length. (c) Other

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information The Company monitors the performance of its operations in three segments: Property and Casualty (P&C), Specialty and Life and Health. The business in the P&C and Specialty segments is collectively referred to as Non-life business. P&C, Specialty and Life and Health each separately represent markets that are reasonably homogeneous in terms of client types, buying patterns, underlying risk patterns and approach to risk management. The P&C segment is comprised of property and casualty business underwritten, including property catastrophe, facultative and U.S. health risks. The Specialty segment is comprised of specialty business underwritten, including treaty and facultative contracts. The Life and Health segment is comprised of mortality, morbidity, longevity and financial reinsurance solutions businesses. Management measures results for the P&C and Specialty segments on the basis of the loss ratio, acquisition ratio, technical ratio, other expense ratio and combined ratio (all defined below). Management measures results for the Life and Health segment on the basis of the allocated underwriting result, which includes underwriting result and net investment income allocated to life business. The segment results for the years ended December 31, 2022, 2021 and 2020 are presented below (in millions of U.S. dollars, except ratios). Segment Information For the year ended December 31, 2022 P&C Specialty Total Life Corporate Total Gross premiums written $ 5,025 $ 1,990 $ 7,015 $ 1,674 $ — $ 8,689 Net premiums written $ 4,234 $ 1,665 $ 5,899 $ 1,645 $ — $ 7,544 (Increase) decrease in unearned premiums (293) 5 (288) 1 — (287) Net premiums earned $ 3,941 $ 1,670 $ 5,611 $ 1,646 $ — $ 7,257 Losses and loss expenses (2,410) (903) (3,313) (1,434) — (4,747) Acquisition costs (995) (435) (1,430) (111) — (1,541) Technical result $ 536 $ 332 $ 868 $ 101 $ — $ 969 Other income — — — 39 1 40 Other expenses (84) (35) (119) (93) (203) (415) Underwriting result $ 452 $ 297 $ 749 $ 47 n/a $ 594 Net investment income 74 324 398 Allocated underwriting result $ 121 n/a n/a Net realized and unrealized investment losses (1,969) (1,969) Interest expense (55) (55) Amortization of intangible assets (9) (9) Net foreign exchange losses (29) (29) Income tax expense (31) (31) Interest in earnings of equity method investments 11 11 Net loss n/a $ (1,090) Loss ratio (1) 61.2 % 54.1 % 59.0 % Acquisition ratio (2) 25.2 26.0 25.5 Technical ratio (3) 86.4 % 80.1 % 84.5 % Other expense ratio (4) 2.1 2.1 2.1 Combined ratio (5) 88.5 % 82.2 % 86.6 % (1) Loss ratio is obtained by dividing losses and loss expenses by net premiums earned. (2) Acquisition ratio is obtained by dividing acquisition costs by net premiums earned. (3) Technical ratio is defined as the sum of the loss ratio and the acquisition ratio. (4) Other expense ratio is obtained by dividing other expenses by net premiums earned. (5) Combined ratio is defined as the sum of the technical ratio and the other expense ratio. Segment Information For the year ended December 31, 2021 P&C Specialty Total Life Corporate Total Gross premiums written $ 4,541 $ 2,016 $ 6,557 $ 1,647 $ — $ 8,204 Net premiums written $ 3,722 $ 1,789 $ 5,511 $ 1,623 $ — $ 7,134 (Increase) decrease in unearned premiums (194) 13 (181) 4 — (177) Net premiums earned $ 3,528 $ 1,802 $ 5,330 $ 1,627 $ — $ 6,957 Losses and loss expenses (2,391) (1,052) (3,443) (1,441) — (4,884) Acquisition costs (864) (415) (1,279) (108) — (1,387) Technical result $ 273 $ 335 $ 608 $ 78 $ — $ 686 Other income — — — 26 3 29 Other expenses (71) (30) (101) (88) (210) (399) Underwriting result $ 202 $ 305 $ 507 $ 16 n/a $ 316 Net investment income 81 295 376 Allocated underwriting result $ 97 n/a n/a Net realized and unrealized investment gains 38 38 Interest expense (56) (56) Amortization of intangible assets (9) (9) Net foreign exchange losses (31) (31) Income tax expense (38) (38) Interest in earnings of equity method investments 127 127 Net income n/a $ 723 Loss ratio 67.8 % 58.4 % 64.6 % Acquisition ratio 24.5 23.0 24.0 Technical ratio 92.3 % 81.4 % 88.6 % Other expense ratio 2.0 1.7 1.9 Combined ratio 94.3 % 83.1 % 90.5 % Segment Information For the year ended December 31, 2020 P&C Specialty Total Life Corporate Total Gross premiums written $ 3,442 $ 1,935 $ 5,377 $ 1,499 $ — $ 6,876 Net premiums written $ 3,044 $ 1,782 $ 4,826 $ 1,475 $ — $ 6,301 Decrease in unearned premiums 119 110 229 7 — 236 Net premiums earned $ 3,163 $ 1,892 $ 5,055 $ 1,482 $ — $ 6,537 Losses and loss expenses (2,389) (1,628) (4,017) (1,318) — (5,335) Acquisition costs (784) (470) (1,254) (102) — (1,356) Technical result $ (10) $ (206) $ (216) $ 62 $ — $ (154) Other (loss) income (1) — (1) 13 1 13 Other expenses (61) (26) (87) (73) (196) (356) Underwriting result $ (72) $ (232) $ (304) $ 2 n/a $ (497) Net investment income 68 293 361 Allocated underwriting result $ 70 n/a n/a Net realized and unrealized investment gains 454 454 Interest expense (39) (39) Amortization of intangible assets (10) (10) Net foreign exchange losses (52) (52) Income tax benefit 13 13 Interest in earnings of equity method investments 24 24 Net income n/a $ 254 Loss ratio 75.5 % 86.0 % 79.5 % Acquisition ratio 24.8 24.8 24.8 Technical ratio 100.3 % 110.8 % 104.3 % Other expense ratio 1.9 1.4 1.7 Combined ratio 102.2 % 112.2 % 106.0 % The following table provides the geographic distribution of gross premiums written by region for the years ended December 31, 2022, 2021 and 2020 (in millions of U.S. dollars, except percentages): 2022 2021 2020 North America $ 5,040 58 % $ 4,649 57 % $ 3,794 55 % Europe 2,592 30 2,410 29 1,921 28 Asia, Australia and New Zealand 720 8 814 10 806 12 Latin America and the Caribbean 223 3 189 2 220 3 Middle East, Africa, Russia and the Commonwealth of Independent States (CIS) 114 1 142 2 135 2 Total $ 8,689 100 % $ 8,204 100 % $ 6,876 100 % The following table provides the gross premiums written by segment and line of business for the years ended December 31, 2022, 2021 and 2020 (in millions of U.S. dollars, except percentages): 2022 2021 2020 P&C Casualty $ 2,777 $ 2,145 $ 1,430 Catastrophe 933 924 545 Property 764 809 641 U.S. health 355 351 379 Multiline and other 119 183 289 Motor 77 129 158 Total P&C $ 5,025 $ 4,541 $ 3,442 Specialty Financial risks $ 634 $ 510 $ 568 Aviation and space 362 416 219 Energy 346 314 192 Property 240 277 173 Marine 223 174 142 Agriculture 101 205 468 Multiline and other 45 20 152 Engineering 39 100 17 Casualty — — 4 Total Specialty $ 1,990 $ 2,016 $ 1,935 Life and Health $ 1,674 $ 1,647 $ 1,499 Total $ 8,689 $ 8,204 $ 6,876 The Company produces its business both through brokers and through direct relationships with insurance company clients. None of the Company’s cedants individually accounted for more than 5% of total gross premiums written during each of the years ended December 31, 2022, 2021 and 2020. The Company has two brokers that individually accounted for 10% or more of its gross premiums written during the years ended December 31, 2022, 2021 and 2020, as follows: 2022 2021 2020 Marsh & McLennan Companies, Inc 30 % 28 % 30 % Aon PLC 26 % 24 % 21 % The following table summarizes the percentage of gross premiums written through these two brokers by segment for the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 P&C 67 % 63 % 64 % Specialty 70 % 66 % 64 % Life and Health 6 % 6 % 6 %

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn February 16, 2023, the Company's Board of Directors declared a dividend for the period December 15, 2022 – March 14, 2023 of $0.3046875 per share on the Company’s 4.875% Fixed Rate Non-Cumulative Redeemable Preferred Shares, Series J. The dividend is payable on March 15, 2023 to shareholders of record on February 28, 2023.

SCHEDULE I - Consolidated Summa

SCHEDULE I - Consolidated Summary of Investments Other Than Investments in Related Parties	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Consolidated Summary of Investments Other Than Investments in Related Parties	PartnerRe Ltd. Consolidated Summary of Investments Other Than Investments in Related Parties at December 31, 2022 (Expressed in thousands of U.S. dollars) Type of investment Cost (1) Fair Value Amount at which shown in Fixed maturities U.S. government and government sponsored enterprises $ 2,106,556 $ 1,797,934 $ 1,797,934 U.S. states, territories and municipalities 58,707 58,873 58,873 Non-U.S. sovereign government, supranational and government related 1,834,025 1,654,532 1,654,532 Corporate bonds 6,477,064 5,759,149 5,759,149 Asset-backed securities 28,550 28,364 28,364 Residential mortgage-backed securities 4,420,417 3,723,062 3,723,062 Fixed maturities $ 14,925,319 $ 13,021,914 $ 13,021,914 Equities Common stocks Banks, trust and insurance companies $ 88,584 $ 61,873 $ 61,873 Industrial, miscellaneous and all other 487,726 854,431 854,431 Nonredeemable preferred stocks 9,797 13,582 13,582 Equities $ 586,107 $ 929,886 $ 929,886 Short-term investments $ 536,139 $ 523,510 $ 523,510 Other invested assets (2) $ 3,117,861 $ 3,355,106 Investments in real estate (3) $ — $ 57,984 Total $ 17,593,171 $ 17,888,400 (1) Original cost of fixed maturities reduced by repayments and adjusted for amortization of premiums or accrual of discounts. Original cost of equity securities. (2) Other invested assets shown in the Consolidated Balance Sheets in Item 18 also includes the Company’s investments accounted for using the equity method of accounting of $237 million. (3) Investments in real estate are carried at original cost less any impairments.

SCHEDULE II - Condensed Financi

SCHEDULE II - Condensed Financial Information of Registrant	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Disclosure [Abstract]
Condensed Financial Information of Parent Company Only	SCHEDULE II PartnerRe Ltd. Condensed Financial Information of Registrant Condensed Balance Sheets—Parent Company Only (Expressed in thousands of U.S. dollars, except parenthetical share and per share data) December 31, 2022 December 31, 2021 Assets Fixed maturities, at fair value (amortized cost: 2022, $90,171; 2021, $85,811) $ 73,642 $ 85,111 Cash and cash equivalents 3,814 1,988 Investments in subsidiaries 8,640,997 9,757,268 Intercompany loans and balances receivable 18,546 24,834 Other 21,042 19,906 Total assets $ 8,758,041 $ 9,889,107 Liabilities Intercompany loans and balances payable (1) $ 2,423,951 $ 2,297,350 Accounts payable, accrued expenses and other 45,740 47,771 Total liabilities 2,469,691 2,345,121 Shareholders’ Equity Common shares (par value $0.00000001; issued and outstanding: 100,000,000 shares) — — Preferred shares (par value $1.00; issued and outstanding: 8,000,000 shares; aggregate liquidation value: $200,000) 8,000 8,000 Additional paid-in capital 1,929,934 1,929,934 Accumulated other comprehensive loss (7,669) (29,706) Retained earnings 4,358,085 5,635,758 Total shareholders’ equity 6,288,350 7,543,986 Total liabilities and shareholders’ equity $ 8,758,041 $ 9,889,107 (1) The parent has fully and unconditionally guaranteed all obligations of PartnerRe Finance B LLC and PartnerRe Finance Ireland DAC, a direct 100% owned subsidiary of the parent, related to the issuance of the 3.700% senior notes and 1.250% senior notes, respectively. The parent’s obligations under these guarantees are senior and unsecured and rank equally with all other senior unsecured indebtedness of the parent. The parent has also fully and unconditionally guaranteed all obligations of PartnerRe Finance II Inc. and PartnerRe Finance B LLC, both indirect 100% owned finance subsidiaries of the parent, related to the remaining $62 million aggregate principal amount of Fixed-to-Floating Rate junior subordinated CENts, with an annual rate of 3-month LIBOR plus a margin equal to 2.325%, and $500 million aggregate principal amount of 4.500% Fixed-Rate Reset junior subordinated notes, respectively. The parent’s obligations under these guarantees are unsecured junior subordinated obligations and rank junior in right of payment to all of the parent's outstanding and future senior indebtedness, and equally in right of payment with all outstanding and future unsecured indebtedness that is by its terms equal in right of payment to the junior subordinated notes. SCHEDULE II PartnerRe Ltd. Condensed Financial Information of Registrant - Continued Condensed Statements of Operations and Comprehensive (Loss) Income —Parent Company Only (Expressed in thousands of U.S. dollars) For the year ended December 31, 2022 December 31, 2021 December 31, 2020 Revenues Net investment income $ 1,851 $ 2,496 $ 2,094 Net realized and unrealized investment (losses) gains (15,406) (16,730) 641 Other income 106 148 113 Total revenues (13,449) (14,086) 2,848 Expenses Other expenses 73,046 55,996 53,458 Interest expense on intercompany loans 33,408 35,204 17,188 Net foreign exchange (gains) losses (65,165) (79,696) 82,986 Total expenses 41,289 11,504 153,632 Loss before equity in net (loss) income of subsidiaries (54,738) (25,590) (150,784) Equity in net (loss) income of subsidiaries (1,035,291) 748,994 404,973 Net (loss) income (1,090,029) 723,404 254,189 Preferred dividends 9,750 22,693 45,990 Loss on redemption of preferred shares — 21,234 2,341 Net (loss) income available to common shareholder $ (1,099,779) $ 679,477 $ 205,858 Comprehensive (loss) income Net (loss) income $ (1,090,029) $ 723,404 $ 254,189 Other comprehensive income (loss) 22,037 66,299 (20,080) Comprehensive (loss) income $ (1,067,992) $ 789,703 $ 234,109 SCHEDULE II PartnerRe Ltd. Condensed Financial Information of Registrant - Continued Condensed Statements of Cash Flows—Parent Company Only (Expressed in thousands of U.S. dollars) For the year ended December 31, 2022 December 31, 2021 December 31, 2020 Cash flows from operating activities Net (loss) income $ (1,090,029) $ 723,404 $ 254,189 Adjustments to reconcile net income to net cash used in operating activities: Equity in net loss (income) of subsidiaries 1,035,291 (748,994) (404,973) Other, net 41,810 (51,783) 87,789 Net cash used in operating activities (12,928) (77,373) (62,995) Cash flows from investing activities Advances to/from subsidiaries, net (1) 22,213 100,426 73,738 Net issue of intercompany loans receivable and payable (1) (2) — — 458,489 Sales and redemptions of fixed maturities 11,290 481,015 32,230 Sales and redemptions of short-term investments 5,173 — 43,899 Purchases of fixed maturities (15,984) (62,239) (496,139) Purchases of short-term investments (5,173) — (39,913) Other, net (3,341) (8,465) (3,987) Net cash provided by investing activities 14,178 510,737 68,317 Cash flows from financing activities (1) Issuance of preferred shares (3) — 193,887 — Redemption of preferred shares (3) — (637,241) — Net cash used in financing activities — (443,354) — Effect of foreign exchange rate changes on cash 576 1,958 186 Increase (decrease) in cash and cash equivalents 1,826 (8,032) 5,508 Cash and cash equivalents—beginning of year 1,988 10,020 4,512 Cash and cash equivalents—end of year $ 3,814 $ 1,988 $ 10,020 (1) The following non-cash transactions were excluded from the Condensed Statement of Cash Flows - Parent Company Only: a. During 2020, the parent recorded a non-cash exchange related to a reduction of intercompany loans and balances receivable of $204 million and a corresponding reduction of intercompany loans and balances payable of $204 million. b. During 2022, 2021 and 2020, dividends paid to common and preferred shareholders of $188 million, $129 million and $96 million, respectively, were paid by a Bermuda subsidiary on behalf of the parent, with a corresponding increase to intercompany balances payable. During 2020, the redemption of Series F preferred shares of $67 million in 2020 was also paid by a Bermuda subsidiary on behalf of the parent, with a corresponding increase to intercompany balances payable. c. During 2021, the parent recorded a non-cash dividend received from a subsidiary of $350 million, with a corresponding change to intercompany balances payable. During 2020, the parent recorded a non-cash capital contribution to a subsidiary of $25 million, with a corresponding change to the intercompany balances payable. d. During 2022, the parent recorded a non-cash exchange of certain intercompany balances payable for an intercompany loan payable of $744 million. e. During 2022, the parent recorded non-cash dividends received from subsidiaries of $630 million, non-cash capital contributions to subsidiaries of $527 million and a corresponding decrease in intercompany balances payable of $103 million. (2) During 2020, the Company recorded a $458 million loan payable maturing in 2030 with a direct Bermuda subsidiary in exchange for shares of an indirectly owned subsidiary, which were subsequently transferred to another subsidiary in exchange for cash. The cash proceeds were primarily invested in fixed maturities and used during 2021 to redeem the Series G, H and I preferred shares. (3) During 2021, the parent issued 8 million 4.875% Series J fixed rate non-cumulative redeemable preferred shares at a par value of $1.00 per share and a redemption price of $200 million, and incurred preferred share issuance costs of $6 million. The parent also redeemed all outstanding Series G, H and I preferred shares at $25 per share for an aggregate liquidation value of $637 million during 2021.

SCHEDULE III - Supplementary In

SCHEDULE III - Supplementary Insurance Information	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Abstract]
Supplementary Insurance Information	PartnerRe Ltd. Supplementary Insurance Information As of and for the years ended December 31, 2022, 2021 and 2020 (Expressed in thousands of U.S. dollars) Deferred Policy Acquisition Costs Non-life Reserves Unearned Premiums Life and Health Reserves Premium Revenue Net Investment Income (1) Losses Incurred Acquisition Costs Other Expenses (2) Net Premiums Written 2022 Non-life $ 700,694 $ 12,725,631 $ 2,743,406 $ — $ 5,611,452 $ N/A $ 3,313,234 $ 1,430,121 $ 119,274 $ 5,898,750 Life and Health 312,156 — 1,965 2,510,293 1,645,665 73,656 1,434,169 110,560 92,919 1,645,445 Corporate and Other — — — — — 324,692 — — 202,683 — Total $ 1,012,850 $ 12,725,631 $ 2,745,371 $ 2,510,293 $ 7,257,117 $ 398,348 $ 4,747,403 $ 1,540,681 $ 414,876 $ 7,544,195 2021 Non-life $ 617,537 $ 12,047,792 $ 2,498,426 $ — $ 5,329,556 $ N/A $ 3,443,245 $ 1,279,039 $ 100,635 $ 5,510,828 Life and Health 303,242 — 2,735 2,638,086 1,626,966 81,226 1,440,739 107,793 88,069 1,623,190 Corporate and Other — — — — — 295,243 — — 209,838 — Total $ 920,779 $ 12,047,792 $ 2,501,161 $ 2,638,086 $ 6,956,522 $ 376,469 $ 4,883,984 $ 1,386,832 $ 398,542 $ 7,134,018 2020 Non-life $ 543,416 $ 11,395,321 $ 2,257,441 $ — $ 5,054,529 $ N/A $ 4,016,704 $ 1,254,067 $ 87,163 $ 4,825,919 Life and Health 276,555 — 7,773 2,704,229 1,482,297 68,259 1,318,196 102,051 73,105 1,474,939 Corporate and Other — — — — — 292,409 — — 195,379 — Total $ 819,971 $ 11,395,321 $ 2,265,214 $ 2,704,229 $ 6,536,826 $ 360,668 $ 5,334,900 $ 1,356,118 $ 355,647 $ 6,300,858 (1) Because the Company does not manage its assets by segment, net investment income is not allocated to the Non-life business of the reinsurance operations. However, because of the interest-sensitive nature of some of the Company’s Life products, net investment income is considered in management’s assessment of the profitability of the Life and Health segment.

SCHEDULE IV - Reinsurance

SCHEDULE IV - Reinsurance	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract]
Reinsurance	PartnerRe Ltd. Reinsurance For the years ended December 31, 2022, 2021 and 2020 (Expressed in thousands of U.S. dollars) Gross amount Ceded to other companies Assumed from other companies Net amount Percentage of amount assumed to net 2022 Life reinsurance in force (1) $ — $ 20,301,849 $ 529,438,861 $ 509,137,012 104 % Premiums earned Life $ — $ 28,426 $ 1,648,455 $ 1,620,029 102 % Accident and health — — 25,636 25,636 100 % P&C (2) 377,380 1,085,317 6,319,389 5,611,452 113 % Total premiums $ 377,380 $ 1,113,743 $ 7,993,480 $ 7,257,117 110 % 2021 Life reinsurance in force (1) $ — $ 19,383,794 $ 453,373,378 $ 433,989,584 104 % Premiums earned Life $ — $ 24,519 $ 1,620,130 $ 1,595,611 102 % Accident and health — — 31,355 31,355 100 % P&C (2) 318,058 944,862 5,956,360 5,329,556 112 % Total premiums $ 318,058 $ 969,381 $ 7,607,845 $ 6,956,522 109 % 2020 Life reinsurance in force (1) $ — $ 18,764,660 $ 398,443,383 $ 379,678,723 105 % Premiums earned Life $ — $ 23,522 $ 1,483,298 $ 1,459,776 102 % Accident and health — — 22,521 22,521 100 % P&C (2) 269,691 516,672 5,301,510 5,054,529 105 % Total premiums $ 269,691 $ 540,194 $ 6,807,329 $ 6,536,826 104 % (1) Life reinsurance in force excludes products that do not pass risk transfer. (2) P&C includes Specialty and U.S. health premiums.

SCHEDULE VI - Supplemental Info

SCHEDULE VI - Supplemental Information Concerning Property-Casualty Insurance Operations	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Abstract]
Supplemental Information Concerning Property-Casualty Insurance Operations	PartnerRe Ltd. Supplemental Information Concerning Property-Casualty Insurance Operations (1) For the years ended December 31, 2022, 2021 and 2020 (Expressed in thousands of U.S. dollars) Losses and Loss Expenses Incurred Related to Affiliation with Registrant Deferred Policy Acquisition Costs Liability for Unpaid Losses and Loss Expenses Unearned Premiums Premiums Earned Current year Prior year Acquisition Costs Paid Losses and Loss Expenses Premiums Written Consolidated subsidiaries 2022 $ 700,694 $ 12,725,631 $ 2,743,406 $ 5,611,452 $ 3,533,087 $ (219,853) $ 1,430,121 $ 2,658,136 $ 5,898,750 2021 $ 617,537 $ 12,047,792 $ 2,498,426 $ 5,329,556 $ 3,637,671 $ (194,426) $ 1,279,039 $ 2,972,995 $ 5,510,828 2020 $ 543,416 $ 11,395,321 $ 2,257,441 $ 5,054,529 $ 3,945,248 $ 71,456 $ 1,254,067 $ 3,232,604 $ 4,825,919 (1) Includes the Company's P&C and Specialty segments.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting	The Company’s Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated.
Use Of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. While management believes that the amounts included in the Consolidated Financial Statements reflect its best estimates and assumptions, actual results could differ from those estimates. The Company’s principal estimates include: • Non-life reserves; • Life and health reserves; • Reinsurance recoverable for unpaid losses; • Gross and net premiums written and net premiums earned; • Recoverability of deferred acquisition costs; • Recoverability of deferred tax assets; • Fair value measurements of financial instrument assets; and • Valuation of goodwill and intangible assets.
Premiums	Gross premiums written and earned are based upon reports received from ceding companies, supplemented by the Company’s own estimates of premiums written and earned for which ceding company reports have not been received. The determination of premium estimates requires a review of the Company’s experience with cedants, familiarity with each market, an understanding of the characteristics of each line of business and management’s assessment of the impact of various other factors on the volume of business written and ceded to the Company. Premium estimates are updated as new information is received from cedants and differences between such estimates and actual amounts are recorded in the period in which the estimates are changed or the actual amounts are determined. Net premiums written and earned are presented net of ceded premiums. Premiums related to non-life business are earned on a basis that is consistent with the risks covered under the terms of the reinsurance contracts, which is generally one to two years. Reinstatement premiums are recognized as written and earned at the time a loss event occurs, where coverage limits for the remaining life of the contract are reinstated under pre-defined contract terms. The accrual of reinstatement premiums is based on management’s estimate of losses and loss expenses associated with the loss event. Unearned premiums represent the portion of premiums written which is applicable to the unexpired risks under contracts in force. Premiums related to life and annuity business are recorded over the premium-paying period on the underlying policies. Premiums on contracts for which there is no significant mortality or critical illness risk are accounted for in a manner consistent with accounting for interest-bearing financial instruments and are not reported as revenues, but rather as direct deposits to the contract. Amounts assessed against annuity and universal life policyholders are recognized as revenue in the period assessed.
Losses and Loss Expenses	The reserves for non-life business include amounts determined from loss reports on individual treaties (case reserves), additional case reserves when the Company’s loss estimate is higher than reported by the cedants (ACRs) and amounts for losses incurred but not yet reported to the Company (IBNR). Such reserves are estimated by management based upon reports received from ceding companies, supplemented by the Company’s own actuarial estimates of reserves for which ceding company reports have not been received, and based on the Company’s own historical experience. To the extent that the Company’s own historical experience is inadequate for estimating reserves, such estimates may be determined based upon industry experience and management’s judgment. The estimates are regularly reviewed and the ultimate liability may be materially in excess of, or less than, the amounts provided. Any adjustments are reflected in the periods in which they are determined, which may affect the Company’s operating results in future periods.
Life Policy Benefits	The life and health reserves have been established based upon information reported by ceding companies, supplemented by the Company’s actuarial estimates, which for life include mortality, morbidity, critical illness, persistency and future investment income, with appropriate provision to reflect uncertainty. For traditional and limited payment long-duration contracts, the assumptions are locked in at contract inception and are subject to annual loss recognition testing. Future policy benefit reserves for annuity and universal life contracts are carried at their accumulated values. Reserves for policy claims and benefits include both mortality, morbidity and critical illness claims in the process of settlement, and claims that have been incurred but not yet reported.
Deferred Acquisition Costs	Acquisition costs, comprising primarily incremental brokerage fees, commissions and excise taxes, which vary directly with, and are related to, the successful acquisition of reinsurance contracts, are capitalized and charged to expense as the related premium is earned. All other acquisition related costs, including indirect costs, are expensed as incurred. Acquisition costs are shown net of commissions earned on ceded reinsurance. Acquisition costs related to individual life and annuity contracts are deferred and amortized over the premium-paying periods in proportion to anticipated premium income, allowing for lapses, terminations and anticipated investment income. Acquisition costs related to universal life and single premium annuity contracts for which there is no significant mortality or critical illness risk are deferred and amortized over the lives of the contracts as a percentage of the estimated gross profits expected to be realized on the contracts. The Company establishes a premium deficiency reserve to the extent the deferred acquisition costs are insufficient to cover the excess of expected losses and loss expenses, settlement costs and deferred acquisition costs over the related unearned premiums. Actual and anticipated losses and loss expenses, other costs, and investment income related to underlying premiums are considered in determining the recoverability of deferred acquisition costs for the Company’s short-duration contracts. Actual and anticipated loss experience, together with the present value of future gross premiums, the present value of future benefits, and settlement and maintenance costs are considered in determining the recoverability of deferred acquisition costs related to the Company’s life and annuity business.
Reinsurance	The Company purchases retrocessional contracts to reduce its exposure to risk of losses on reinsurance assumed. Ceded premiums, which represent the cost of retrocessional protection purchased by the Company, are expensed over the coverage period. Prepaid reinsurance premiums represent the portion of premiums ceded applicable to the unexpired term of policies in force. Reinsurance recoverable on paid and unpaid losses involves actuarial estimates consistent with those used to establish the associated liabilities for non-life and life and health reserves and are recorded net of a valuation allowance for estimated uncollectible recoveries. Retroactive reinsurance reimburses a ceding company for liabilities incurred as a result of past insurable events covered under contracts subject to the reinsurance. Premiums payable for retroactive reinsurance coverage meeting the conditions of reinsurance accounting are reported as reinsurance recoverables. To the extent that recorded liabilities on an underlying reinsurance contract exceed premiums payable for retroactive coverage, a deferred gain is recognized in Accounts payable, accrued expenses and other on the Company's Consolidated Balance Sheets and amortized over estimated remaining settlement period of the underlying contract. Any such amortization is included in Loss and loss expenses in the Consolidated Statements of Operations.
Funds Held by Reinsured Companies	The Company writes certain business on a funds held basis. Under such contractual arrangements, the cedant retains the premiums that would have otherwise been paid to the Company and the Company is credited with investment income on these funds. The Company generally earns investment income on the funds held balances based upon a predetermined interest rate, either fixed contractually at the inception of the contract or based upon a recognized index (e.g. LIBOR, SOFR). However, in certain circumstances, the Company may receive an investment return based upon either the result of a pool of assets held by the cedant, generally used to collateralize the funds held balance, or the investment return earned by the cedant on its entire investment portfolio. In these arrangements, investment returns are typically reflected in Net investment income in the Company’s Consolidated Statements of Operations. In these arrangements, the Company is exposed, to a limited extent, to the underlying credit risk of the pool of assets inasmuch as the underlying policies may have guaranteed minimum returns. In such cases, an embedded derivative exists and its fair value is recorded by the Company as an increase or decrease to the funds held balance.
Deposit Assets and Liabilities	In the normal course of its operations, the Company writes certain contracts that do not meet the risk transfer provisions of U.S. GAAP. While these contracts do not meet risk transfer provisions for accounting purposes, there is a remote possibility that the Company will suffer a loss. The Company accounts for these contracts using the deposit accounting method originally recording deposit assets or liabilities for an amount equivalent to the consideration paid or received, respectively. The difference between the consideration received and the estimated liability for unpaid losses is determined upon entering into the contract and, if a loss, recognized into income immediately, and if a gain, the gain is deferred and earned over the expected settlement period of the contract, with the unearned portion recorded as a component of deposit liabilities. Actuarial studies are used to estimate the liabilities under these contracts and the appropriate accretion rates to increase or decrease the liabilities over the term of the contracts. The change in the estimated liability for the period is recorded in Other income or loss in the Consolidated Statements of Operations. Under some of these contracts, cedants retain the assets on a funds-held basis. In those cases, the Company records those assets as deposit assets and records the related income in Net investment income in the Consolidated Statements of Operations. Also included in Deposit assets are receivables included as an element of certain life reinsurance agreements that do not meet risk transfer.
Investments	The Company elects the fair value option for Fixed maturities, Short-term investments and Equities with changes in fair value recorded in Net realized and unrealized investment gains or losses in the Consolidated Statements of Operations. Short-term investments comprise securities with a maturity greater than three months but less than one year from the date of purchase. Investments in real estate includes real estate that is directly held by the Company, which is recorded at cost less any write down for impairment, where applicable. Real estate assets held for investment are reviewed for impairment at least annually, or more frequently when events or changes in circumstances indicate the carrying value may not be recoverable and exceeds its estimated fair value. The Company recognizes Other invested assets at fair value, except for those that are accounted for using the equity method of accounting. Other invested assets consist of equity investments in non-publicly traded companies such as limited liability companies and limited partnerships (or similar structures); privately placed corporate loans, notes and loans receivable and notes securitization; and derivative financial instruments. Non-publicly traded entities in which the Company has significant influence, including an ownership of more than 20% and less than 50% of the voting rights, and limited partnerships (or similar structures) in which the Company has more than a minor interest (typically more than 3 to 5%), are accounted for using either the equity method or the fair value option. Where the equity method is used, the Company's share of profits or losses of the investee are recorded in Interest in earnings or losses of equity method investees in the Consolidated Statements of Operations. The Company has not elected the fair value option for these equity method investees as the carrying values already approximate fair value. Where the fair value option is elected, the investment is recognized in the Consolidated Balance Sheets at fair value with changes in fair value recorded in Net realized and unrealized investment gains or losses in the Consolidated Statements of Operations. See Note 2(n) below for significant accounting policy for derivatives. The Company defines fair value as the price received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company measures the fair value of financial instruments according to a fair value hierarchy that prioritizes the information used to measure fair value into three broad levels. The Company’s policy is to recognize transfers between the hierarchy levels at the beginning of the period. Refer to Note 3 for the valuation techniques used by the Company. The Company invests in various funds where the net asset value (NAV) is used as a basis for determining fair value. The Company applies the practical expedient relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of these fund investments based on that NAV per share, or its equivalent. Refer to Note 3 for the valuation methods and assumptions used by the Company. Net investment income includes interest and dividend income, amortization of premiums and discounts on fixed maturities and short-term investments, and is net of investment expenses and withholding taxes. Investment income is recognized when earned and accrued to the balance sheet date. Realized gains or losses on the disposal of investments are determined on a first-in, first-out basis. Investment purchases and sales are recorded on a trade-date basis.
Cash and Cash Equivalents	Cash equivalents are carried at fair value and include fixed income securities that, from the date of purchase, have a maturity of three months or less.
Business Combinations	The Company accounts for transactions in which it obtains control over one or more businesses using the acquisition method. The purchase price is allocated to identifiable assets and liabilities, including any intangible assets, based on their estimated fair value at the acquisition date. The estimates of fair values for assets and liabilities acquired are determined based on various market and income analyses and appraisals. Any excess of the purchase price over the fair value of net assets acquired is recorded as Goodwill in the Company’s Consolidated Balance Sheets, while any excess of the fair value of net assets acquired over the purchase price is recorded as a gain in the Consolidated Statements of Operations. All costs associated with an acquisition are expensed as incurred.
Goodwill	Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in a business combination. The Company assesses the appropriateness of its valuation of goodwill on an annual basis (as of December 31) or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. If, as a result of the assessment, the Company determines that the value of its goodwill is impaired, goodwill will be written down in the period in which the determination is made.
Intangible Assets	Intangible assets represent the fair value adjustments related to renewal rights, and customer relationships; value of life business acquired; and U.S. licenses arising from acquisitions. Definite-lived intangible assets are amortized over their useful lives and the Amortization of intangible assets is recorded in the Consolidated Statement of Operations. Indefinite-lived intangible assets are not subject to amortization. The carrying values of indefinite-lived intangible assets are reviewed for indicators of impairment on an annual basis (as of December 31) or more frequently if events or changes in circumstances indicate that impairment may exist. Impairment is recognized if the carrying values of the intangible assets are not recoverable from their undiscounted cash flows and is measured as the difference between the carrying value and the fair value.
Income Taxes	Certain subsidiaries and branches of the Company operate in jurisdictions where they are subject to taxation. Current and deferred income taxes are charged or credited to Net income or loss or, in certain cases, to Accumulated other comprehensive income or loss, based upon enacted tax laws and rates applicable in the relevant jurisdiction in the period in which the tax becomes accruable or realizable. Deferred income taxes are provided for all temporary differences between the bases of assets and liabilities used in the Consolidated Balance Sheets and those used in the various jurisdictional tax returns. When management’s assessment indicates that it is more likely than not that deferred tax assets will not be realized, a valuation allowance is recorded against the deferred tax assets. Where appropriate, the valuation allowance assessment considers tax planning strategies. The Company recognizes a tax benefit relating to uncertain tax positions only where the position is more likely than not to be sustained assuming examination by tax authorities. A liability is recognized for any tax benefit (along with any interest and penalty, if applicable) claimed in a tax return in excess of the amount recognized in the financial statements under U.S. GAAP. Any changes in amounts recognized are recorded in the period in which they are determined.
Foreign Exchange	In recording foreign currency transactions, revenue and expense items in a currency other than the functional currency are converted into the functional currency at the average rates of exchange for the period. Monetary assets and liabilities originating in currencies other than the functional currency are remeasured into the functional currency at the rates of exchange in effect at the balance sheet dates. The resulting foreign exchange transaction gains or losses are included in Net foreign exchange gains or losses in the Consolidated Statements of Operations. Non-monetary assets and liabilities denominated in foreign currency are not subsequently remeasured.The reporting currency of the Company is the U.S. dollar. The national currencies of the Company’s subsidiaries and branches are generally their functional currencies, except for the Company’s Bermuda subsidiaries, its branches in Switzerland and the United Kingdom and its Singapore subsidiary and branches, whose functional currency is the U.S. dollar. In translating the financial statements of those subsidiaries or branches whose functional currency is other than the U.S. dollar, assets and liabilities are converted into U.S. dollars using the rates of exchange in effect at the balance sheet dates, and revenues and expenses are converted using the average foreign exchange rates for the period. The effect of translation adjustments are reported in the Consolidated Balance Sheets as Currency translation adjustment, a separate component of Accumulated other comprehensive income or loss. The change in currency translation adjustment is reflected in Other comprehensive income or loss.
Derivatives	The Company’s investment strategy allows for the use of certain derivative instruments, subject to strict limitations. The Company may use derivative financial instruments such as foreign exchange forward contracts, foreign currency option contracts, futures contracts, to-be-announced mortgage-backed securities (TBAs), total return swaps, interest rate swaps, insurance-linked securities, and credit default swaps for the purpose of managing overall currency risk, market exposures and portfolio duration, for hedging certain investments, or for enhancing investment performance that would be allowed under the Company’s investment policy if implemented in other ways. On the date the Company enters into a derivative contract, management determines whether or not the derivative is to be used and designated as a hedge of an identified underlying risk exposure (a designated hedge). The Company’s derivative instruments are recorded in Other invested assets in the Consolidated Balance Sheets at fair value, with gains and losses associated with changes in fair value recognized in either Net realized and unrealized investment gains or losses or Net foreign exchange gains or losses in the Consolidated Statements of Operations, or in Other comprehensive income or loss, depending on the nature and designation of the derivative instrument (see also Note 5). The Company formally documents all relationships between designated hedging instruments and hedged items, as well as its risk management objectives and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the asset or liability that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally measures effectiveness of its designated hedging relationships both at the hedge inception and on an ongoing basis. The Company will discontinue hedge accounting prospectively if it is determined that the derivative is no longer effective in hedging the exposure to variability in expected future cash flows that is attributable to the risk it was meant to hedge; if the derivative instrument expires, is sold, or is otherwise terminated; or if the Company removes the designation of the hedge. To the extent that the Company discontinues hedge accounting because, based on management’s assessment, the derivative no longer qualifies as an effective hedge, or the Company otherwise de-designates the hedge, the derivative will continue to be carried in the Consolidated Balance Sheet at its fair value, with changes in its fair value recognized in in the Consolidated Statements of Operations, or in Other comprehensive income or loss, depending on the type of derivative held.
Pensions	The Company recognizes an asset or a liability in the Consolidated Balance Sheets for the funded status of its defined benefit plans that are overfunded or underfunded, respectively, measured as the difference between the fair value of plan assets and the pension obligation and recognizes changes in the funded status of defined benefit plans in the year in which the changes occur as a component of Accumulated other comprehensive income or loss, net of tax.
Variable Interest Entities	The Company is involved in the normal course of business with variable interest entities (VIEs). An assessment is performed as of the date the Company becomes initially involved in the VIE followed by a reassessment upon certain events related to its involvement in the VIE. The Company consolidates a VIE when it is the primary beneficiary having a controlling financial interest as a result of having the power to direct the activities that most significantly impact the economic performance of the VIE and the obligation to absorb losses, or right to receive benefits, that could potentially be significant to the VIE.
Segment Reporting	The Company monitors the performance of its operations in three segments: Property & Casualty (P&C), Specialty and Life and Health. Segments represent markets that are reasonably homogeneous in terms of client types, buying patterns, underlying risk patterns or approach to risk management.Since the Company does not manage its assets by segment, neither assets nor net investment income are allocated to the P&C and Specialty segments. However, because of the interest-sensitive nature of some of the Company’s life products, allocated net investment income is considered in management’s assessment of the profitability of the Life and Health segment. The following items are not considered in evaluating the results of the P&C, Specialty and Life and Health segments: Net realized and unrealized investment gains or losses, Interest expense, Loss on redemption of debt, Amortization of intangible assets, Net foreign exchange gains or losses, Income tax expense or benefit and Interest in earnings and losses of equity method investments. These items are included in the Corporate and Other component, which is comprised of the Company’s investment and corporate activities, including other expenses.
Share-based Incentives	The Company is authorized to issue Class C common shares and restricted share units to certain executives and directors. Prior to the adoption of the new Class C common shares and related restricted share unit plan in 2021, the Company was authorized to issue restricted Class B common shares. The compensation cost for grants of Class B and C common shares and restricted share units is measured at fair value and expensed over the period for which the employee is required to provide services in exchange for the award, up to three years from the date of grant. The Company has elected to recognize forfeitures as they occur. Class B and C common shares and restricted share units are accounted for as liabilities and included in Accounts payable, accrued expenses and other on the Consolidated Balance Sheets.
Recent Accounting Pronouncements	Recently adopted In October 2020, the FASB issued updated guidance to clarify that callable debt securities should be reevaluated each reporting period to determine if the amortized cost exceeds the amount repayable by the issuer at the next earliest call date and, if so, the excess should be amortized to the next call date. This guidance is effective for fiscal years beginning after December 15, 2020, and the Company adopted this guidance effective January 1, 2021 on a prospective basis for existing or newly purchased callable debt securities. The adoption did not have a material impact on the Company's Consolidated Financial Statements. In March 2020, the U.S. Securities and Exchange Commission (the SEC) adopted amendments to the financial disclosure requirements related to certain debt securities, including registered debt securities issued by a wholly-owned, operating subsidiary that are fully and unconditionally guaranteed by the parent company. In October 2020, the FASB issued updated guidance to reflect the SEC's new disclosure requirements. This new guidance narrows the circumstances that require separate financial statements of subsidiary issuers and guarantors and streamlines the alternative disclosures required in lieu of those statements. The amended SEC rules became effective on January 4, 2021, and the Company adopted the new disclosure requirements at that time. As the guidance is disclosure-related only, it did not have a material impact on the Company's Consolidated Financial Statements. In January and April 2017, the FASB issued updated guidance on the accounting for goodwill impairment. This update removes the second step of the goodwill impairment test and requires entities to apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The guidance is effective for annual impairment tests in fiscal years beginning after December 15, 2019, and the Company adopted the guidance effective January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements. In August 2018, the FASB issued updated guidance to the disclosure requirements for fair value measurement as part of the disclosure framework project. The updated guidance allows for the removal and modification of certain disclosures to improve the effectiveness of disclosures in the notes to financial statements. This guidance is effective for fiscal years beginning after December 15, 2019, and the Company adopted this guidance effective January 1, 2020. As the guidance is disclosure-related only, it did not have a material impact on the Company's Consolidated Financial Statements. Refer to Note 3 for the relevant disclosures. In August 2018, the FASB issued updated guidance to improve the effectiveness of disclosures for defined benefit plans, as part of the disclosure framework project. The updated guidance allows for the removal and modification of certain disclosures to improve the effectiveness of disclosures in the notes to financial statements. This guidance is effective for fiscal years beginning after December 15, 2019, and the Company adopted the guidance effective January 1, 2020. As the guidance is disclosure-related only, it did not have a material impact on the Company's Consolidated Financial Statements. Refer to Note 14 for the relevant disclosures. In June 2016, the FASB issued updated guidance on the recognition of credit losses by replacing the incurred loss impairment methodology with new accounting models related to how credit losses on financial instruments are determined. The new guidance is applicable to financial assets measured at amortized cost such as loans, reinsurance receivables, trade receivables, debt securities, off-balance sheet credit exposures and other financial assets that have a contractual right to receive cash. The Company's investments, except for certain Other invested assets that are accounted for using the equity method of accounting and Investments in real estate, are measured at fair value through net income, and therefore those investments are not impacted by the adoption of this guidance. The guidance is effective for annual periods beginning after December 15, 2019. The Company adopted the guidance on January 1, 2020 and recorded an after-tax cumulative effect adjustment as a decrease to retained earnings of $14 million upon adoption. Refer to Notes 8(a) and 15(a) for further information regarding the impacts of adoption of this guidance. Not yet adopted Targeted Improvements to the Accounting for Long-duration Contracts In August 2018, the FASB issued updated guidance to improve financial reporting for insurance companies that issue long-duration contracts such as life insurance and annuities. The updated guidance changes how insurers account for long-duration contracts, including recognition, measurement, presentation and disclosure requirements. The objective of the new guidance is to improve, simplify, and enhance the financial reporting for long-duration contracts. These updates amend four key areas pertaining to the accounting and disclosures for long-duration insurance contracts: • Cash flow assumptions and liability for future policy benefits: The update requires cash flow assumptions used to measure the liability for future policy benefits to be reviewed at least annually and updated, if necessary, with the effect of changes in those assumptions remeasured retrospectively and reflected in current period Net income or loss. Assumptions no longer allow a provision for adverse deviation. Loss recognition testing is eliminated for traditional and limited-payment contracts. Upon adoption, there will be an adjustment to Retained earnings as a result of capping the net premium ratio at 100% and eliminating negative reserves on certain cohorts. The update also requires the discount rate used in measuring the liability to be an upper-medium grade fixed-income instrument yield, which is to be updated at each reporting date, with the impact to be recognized in Other comprehensive income or loss. • Market risk benefits: Market risk benefits are contracts or contract features that provide protection to policyholders from nominal capital market risk and expose the Company to other than nominal capital market risk. The update requires market risk benefits to be measured at fair value. Among the products included in this definition are guaranteed minimum death benefit (GMDB) products. The change in fair value of the market risk benefits is to be recognized in Net income or loss, excluding the portion attributable to changes in instrument-specific credit risk, which is recognized in Other comprehensive income or loss. • Deferred policy acquisition costs and other balances: The update simplifies the amortization for Deferred acquisition costs and other similar balances, requiring such balances to be amortized on a constant level basis over the expected term of the contracts. Deferred costs are required to be written off for unexpected contract terminations but are not subject to recoverability testing. • Disclosure requirements: The update also introduces disclosure requirements around the liability for future policy benefits, market risk benefits and deferred acquisition costs. These disclosures include, among many items, disaggregated rollforwards of these balances and information about, and any changes to significant inputs, judgments, assumptions and methods used in their measurement. Additional fair value disclosures are also required surrounding market risk benefits. Transitional disclosures will be required. This guidance is effective on January 1, 2023 Reference Rate Reform In March 2020, the FASB issued guidance which provides optional expedients and exceptions for applying U.S. GAAP to modification of contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. Along with the optional expedients, the amendments include a general principle that permits an entity to consider contract modifications due to reference reform to be an event that does not require contract re-measurement at the modification date or reassessment of a previous accounting determination. In 2022, the sunset date of this guidance was deferred to December 31, 2024, and the guidance may be elected over time as reference rate reform activities occur. The Company is currently evaluating the impact of adopting this guidance on its Consolidated Financial Statements and disclosures. Fair Value Measurement In June 2022, the FASB issued updated guidance to address diversity in practice by clarifying that a contractual sale restriction should not be considered in the measurement of the fair value of an equity security. It also requires entities with investments in equity securities subject to contractual sale restrictions to disclose certain qualitative and quantitative information about such securities. The guidance is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The update applies prospectively, with any adjustments resulting from adoption recognized in earnings on the date of adoption. The Company is currently evaluating the impact of adopting this guidance on its Consolidated Financial Statements and disclosures.

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Financial instruments measured at fair value and categorized between Levels 1, 2 and 3	At December 31, 2022 and 2021, the Company’s financial instruments measured at fair value were classified between Levels 1, 2 and 3 as follows (in thousands of U.S. dollars): December 31, 2022 Quoted prices in Significant Significant Fair value based on NAV as practical expedient Total Fixed maturities U.S. government and government sponsored enterprises $ — $ 1,797,934 $ — $ — $ 1,797,934 U.S. states, territories and municipalities — 10,126 48,747 — 58,873 Non-U.S. sovereign government, supranational and government related — 1,654,532 — — 1,654,532 Corporate bonds — 5,759,149 — — 5,759,149 Asset-backed securities — 12,434 15,930 — 28,364 Residential mortgage-backed securities — 3,723,062 — — 3,723,062 Fixed maturities $ — $ 12,957,237 $ 64,677 $ — $ 13,021,914 Short-term investments $ — $ 516,603 $ 6,907 $ — $ 523,510 Equities Real estate $ 61,754 $ — $ 1,814 $ — $ 63,568 Consumer non-cyclical — — 10,081 — 10,081 Diversified — — 9,667 — 9,667 Consumer cyclical 4,449 — 28 — 4,477 Energy 3 — 1,514 — 1,517 Finance — — 120 — 120 Industrials 20 — 76 — 96 Insurance — 42 — — 42 Fund investments — — — 840,318 840,318 Equities $ 66,226 $ 42 $ 23,300 $ 840,318 $ 929,886 Other invested assets Derivative assets Foreign exchange forward contracts $ — $ 13,705 $ — $ — $ 13,705 Interest rate swaps — 258 — — 258 Insurance-linked securities — — 6,657 — 6,657 Options and warrants — — 8,691 — 8,691 TBAs — 578 — — 578 Other Corporate loans (1) — 1,015,529 287,278 — 1,302,807 Notes and loans receivable and notes securitization — — 3,166 — 3,166 Real estate company investment — — 491,602 — 491,602 Fund investments — — 36,274 1,271,612 1,307,886 Derivative liabilities Foreign exchange forward contracts — (17,336) — — (17,336) Interest rate swaps — (153) — — (153) Other invested assets $ — $ 1,012,581 $ 833,668 $ 1,271,612 $ 3,117,861 Total $ 66,226 $ 14,486,463 $ 928,552 $ 2,111,930 $ 17,593,171 (1) Corporate loans includes a portfolio of third-party, individually managed privately issued corporate loans that are managed under an externally managed mandate with a fair value of $1.0 billion and $1.0 billion at December 31, 2022 and 2021, respectively. The mandate primarily invests in U.S. floating rate, first lien, senior secured broadly syndicated loans with a focus on facility sizes greater than $300 million. Corporate loans also includes $0.3 billion and $0.4 billion of other privately issued corporate loans at December 31, 2022 and 2021, respectively . December 31, 2021 Quoted prices in Significant Significant Fair value based on NAV practical expedient Total Fixed maturities U.S. government and government sponsored enterprises $ — $ 2,118,772 $ — $ — $ 2,118,772 U.S. states, territories and municipalities — 12,878 95,181 — 108,059 Non-U.S. sovereign government, supranational and government related — 2,181,127 — — 2,181,127 Corporate bonds — 5,441,908 — — 5,441,908 Asset-backed securities — — 16,764 — 16,764 Residential mortgage-backed securities — 4,204,644 — — 4,204,644 Fixed maturities $ — $ 13,959,329 $ 111,945 $ — $ 14,071,274 Short-term investments $ — $ 205,146 $ — $ — $ 205,146 Equities Real estate $ 97,854 $ — $ 2,097 $ — $ 99,951 Consumer non-cyclical 343 — 10,081 10,424 Consumer cyclical 7,341 — 1,394 — 8,735 Diversified 4 — 7,468 — 7,472 Energy 1,112 — 2,368 — 3,480 Industrials 137 — 220 — 357 Finance — — 128 — 128 Insurance — 18 — — 18 Fund investments (1) — — — 1,621,019 1,621,019 Equities $ 106,791 $ 18 $ 23,756 $ 1,621,019 $ 1,751,584 Other invested assets Derivative assets Foreign exchange forward contracts $ — $ 8,841 $ — $ — $ 8,841 Total return swaps — — 153 — 153 Insurance-linked securities — — 5,663 — 5,663 Other — — 3,059 — 3,059 Other Corporate loans (1) — 1,104,444 287,527 — 1,391,971 Notes and loans receivable and notes securitization — — 6,575 — 6,575 Real estate company investment (2) — — 560,687 — 560,687 Fund investments (1) — — 11,739 1,346,797 1,358,536 Derivative liabilities Foreign exchange forward contracts — (6,657) — — (6,657) Total return swaps — — (1,079) — (1,079) Interest rate swaps — (10,489) — — (10,489) Other invested assets $ — $ 1,096,139 $ 874,324 $ 1,346,797 $ 3,317,260 Total $ 106,791 $ 15,260,632 $ 1,010,025 $ 2,967,816 $ 19,345,264 (1) The classification of fund investments was revised from Level 3 to "Fair values based on NAV practical expedient" in order to align the disclosure with the valuation methodology used by the Company. In addition, the classification of certain investments in corporate loans was revised from Level 3 to Level 2 to reflect the appropriate fair value hierarchy level for investments with quoted prices, and one investment was reclassified from corporate loans to fund investments. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. These revisions are not considered to be material to previously issued financial statements. (2) A certain investment previously disclosed as equity method and excluded from the fair value table is now included and presented as a Level 3 investment in order to align the disclosure with the valuation methodology used by the Company. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. This revision is not considered to be material to previously issued financial statements. Accordingly, no changes were made to the prior period Consolidated Balance Sheet or Consolidated Statements of Operations.
Reconciliation of beginning and ending balances for all financial instruments measured at fair value using Level 3 inputs	The reconciliations of the beginning and ending balances for financial instruments measured at fair value using Level 3 inputs for the years ended December 31, 2022 and 2021, were as follows (in thousands of U.S. dollars): For the year ended December 31, 2022 Balance at (Losses) gains Purchases Settlements and (1) Net Balance Change in Fixed maturities U.S. states, territories and municipalities $ 95,181 $ (13,862) $ — $ (32,572) $ — $ 48,747 $ (14,108) Asset-backed securities 16,764 — — (834) — 15,930 — Fixed maturities $ 111,945 $ (13,862) $ — $ (33,406) $ — $ 64,677 $ (14,108) Short-term investments $ — $ — $ 6,907 $ — $ — $ 6,907 $ — Equities Energy $ 2,368 $ (854) $ — $ — $ — $ 1,514 $ (854) Consumer non-cyclical 10,081 — — — — 10,081 — Real estate 2,097 (283) — — — 1,814 (283) Consumer cyclical 1,394 (1,366) — — — 28 (1,366) Finance 128 (8) — — — 120 (8) Industrials 220 13 — (157) — 76 (53) Diversified 7,468 (223) 2,759 (337) — 9,667 (344) Equities $ 23,756 $ (2,721) $ 2,759 $ (494) $ — $ 23,300 $ (2,908) Other invested assets Derivatives, net $ 7,796 $ 1,929 $ 5,631 $ (8) $ — $ 15,348 $ 996 Corporate loans 287,527 1,443 34,543 (42,589) 6,354 287,278 2,166 Notes and loan receivables and notes securitization 6,575 (594) — (2,815) — 3,166 2,301 Fund investments 11,739 92 30,286 (5,843) — 36,274 322 Real estate company investment 560,687 (69,085) — — — 491,602 (69,085) Other invested assets $ 874,324 $ (66,215) $ 70,460 $ (51,255) $ 6,354 $ 833,668 $ (63,300) Total $ 1,010,025 $ (82,798) $ 80,126 $ (85,155) $ 6,354 $ 928,552 $ (80,316) (1) Included sales of Fixed maturities and Other invested assets of $32 million and $36 million, respectively. Sales of Fixed maturities were comprised of U.S. states, territories and municipalities. Sales of Other invested assets included sales of corporate loans of $33 million and sales of notes and loan receivables and notes securitization of $3 million. For the year ended December 31, 2021 Balance at (Losses) gains Purchases Settlements and sales (1) Net Balance Change in Fixed maturities U.S. states, territories and municipalities $ 120,477 $ (7,330) $ — $ (17,966) $ — $ 95,181 $ (8,818) Asset-backed securities 17,528 — — (764) — 16,764 — Corporate 16,530 165 — (16,695) — — — Fixed maturities $ 154,535 $ (7,165) $ — $ (35,425) $ — $ 111,945 $ (8,818) Equities Energy $ 34,448 $ 54,509 $ 6 $ (86,595) $ — $ 2,368 $ 1,326 Consumer non-cyclical 6,886 7,557 — — (4,362) 10,081 4,522 Insurance 4,000 — — (4,000) — — — Real estate 2,338 (241) — — — 2,097 (241) Consumer cyclical 475 (916) 1,835 — — 1,394 (916) Finance 138 (10) — — — 128 (10) Industrials 39 245 309 (334) (39) 220 99 Diversified 3,098 1,901 2,469 — — 7,468 1,901 Equities (2) $ 51,422 $ 63,045 $ 4,619 $ (90,929) $ (4,401) $ 23,756 $ 6,681 Other invested assets Derivatives, net $ (862) $ 5,718 $ 3,059 $ (119) $ — $ 7,796 $ 4,018 Corporate loans (2) 374,556 (9,883) 78,673 (151,543) (4,276) 287,527 (6,844) Notes and loan receivables and notes securitization 7,121 (71) 21 (496) — 6,575 (6,895) Fund investments (2) 32,810 (149) 392 (21,314) — 11,739 (149) Real estate company investment (2) 494,010 66,677 — — — 560,687 66,677 Other invested assets $ 907,635 $ 62,292 $ 82,145 $ (173,472) $ (4,276) $ 874,324 $ 56,807 Total $ 1,113,592 $ 118,172 $ 86,764 $ (299,826) $ (8,677) $ 1,010,025 $ 54,670 (1) Included sales of Fixed maturities, Equities and Other invested assets of $17 million, $91 million and $119 million, respectively. Sales of Fixed maturities were comprised of U.S. states, territories and municipalities. Sales of Equities included sales of $87 million in energy and $4 million in insurance. Sales of Other invested assets included sales of corporate loans. (2) The Level 3 reconciliation for the year ended December 31, 2021 has been recast to reflect the reclassification of certain investments within the fair value table as discussed above.
Summary of significant unobservable inputs used in the valuation of financial instruments	The significant unobservable inputs used in the valuation of financial instruments measured at fair value using Level 3 inputs at December 31, 2022 and 2021 were as follows (fair value in thousands of U.S. dollars): December 31, 2022 Fair value Valuation techniques Unobservable inputs Range (Weighted average (1) ) Fixed maturities U.S. states, territories and municipalities $ 48,747 Discounted cash flow Credit spreads 2.7% – 3.6% (3.4%) Short-term investments 6,907 Discounted cash flow Credit spreads 2.5% (2.5%) Other invested assets Insurance-linked securities – longevity swaps 6,657 Discounted cash flow Credit spreads 5.7% (5.7%) Fund investments 6,008 Discounted cash flow Effective yield 0.6% (0.6%) Note securitization 188 Discounted cash flow Credit spreads 2.5% (2.5%) Real estate company investment 491,602 Income capitalization Estimated rental value (per sq ft) $84 – $90 ($87) Net initial yield 2.2% – 4.6% (3.9%) Reversionary yield 4.6% – 5.3% (4.9%) Comparable method Sale value (per sq ft) $1,617 – $5,459 ($4,836) December 31, 2021 Fair value Valuation techniques Unobservable inputs Range (Weighted average (1) ) Fixed maturities U.S. states, territories and municipalities $ 95,181 Discounted cash flow Credit spreads 2.5% – 254.5%, (14.3%) Other invested assets Total return swaps, net (926) Discounted cash flow Credit spreads 2.4% – 41.3%, (36.5%) Insurance-linked securities – longevity swaps 5,663 Discounted cash flow Credit spreads 1.7% (1.7%) Notes and loans receivables 1,791 Discounted cash flow Credit spreads 17.5% (17.5%) Gross revenue/fair value 1.1 (1.1) Note securitization 403 Discounted cash flow Credit spreads 2.5% (2.5%) Fund investments 8,832 Discounted cash flow Effective yield 3.5% (3.5%) Real estate company investment 560,687 Income capitalization Estimated rental value (per sq ft) $92 - $100 ($96) Net initial yield 2.2% - 4.5% (3.9%) Reversionary yield 4.4% - 4.9% (4.7%) Comparable method Sale value (per sq ft) $1,763 - $5,916 ($5,222) (1) Unobservable inputs were weighted by the relative fair value of the instruments.
Change in fair value of financial instruments subject to fair value option	Changes in the fair value of the Company’s financial instruments subject to the fair value option during the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Fixed maturities and short-term investments $ (1,807,048) $ (558,466) $ 219,946 Equities (505,072) 198,780 167,456 Other invested assets (136,580) 184,209 63,669 Total $ (2,448,700) $ (175,477) $ 451,071
Details of portfolio of investments using NAV as a practical expedient	The table below reflects the Company's portfolio of investments measured using net asset valuations as the practical expedient (in thousands of US dollars): At December 31, 2022 December 31, 2021 Carrying Value (1) Remaining Unfunded Commitment Carrying Value (1) Remaining Unfunded Commitment Redemption Frequency Redemption Notice Period Public equity funds $ 629,125 $ — $ 1,461,620 $ — See below See below Private equity funds 389,736 150,458 499,289 195,871 See below See below Private credit funds 404,065 67,815 294,760 184,590 See below See below Multi-strategy funds 689,004 147,409 712,147 114,880 See below See below Total fund investments $ 2,111,930 $ 365,682 $ 2,967,816 $ 495,341 (1) The table above only reflects the Company's investments valued at fair value based on the NAV practical expedient, which includes fund investments of $840 million included in Equities and $1,272 million included in Other invested assets at December 31, 2022 and fund investments of $1,621 million included in Equities and $1,347 million included in Other invested assets at December 31, 2021.

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments [Abstract]
Net Realized and Unrealized Investment (Losses) Gains	The components of the net realized and unrealized investment (losses) gains for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Net realized investment gains on fixed maturities and short-term investments $ 859 $ 19,893 $ 24,828 Net realized investment gains on equities 461,041 78,501 21,538 Net realized investment gains (losses) on other invested assets 9,781 103,011 (30,436) Net realized investment gains $ 471,681 $ 201,405 $ 15,930 Change in net unrealized investment (losses) gains on fixed maturities and short-term investments $ (1,807,048) $ (558,466) $ 219,946 Change in net unrealized investment (losses) gains on equities (505,072) 198,780 167,456 Change in net unrealized investment (losses) gains on other invested assets (123,694) 196,926 58,452 Net other realized and unrealized investment losses (2,672) (848) (1,346) Change in net unrealized investment (losses) gains $ (2,438,486) $ (163,608) $ 444,508 Impairment loss on investments in real estate $ (2,209) $ — $ (6,119) Net realized and unrealized investment (losses) gains $ (1,969,014) $ 37,797 $ 454,319
Net investment income	The components of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Fixed maturities $ 310,152 $ 301,391 $ 290,259 Short-term investments and cash and cash equivalents 17,477 4,860 12,000 Other invested assets 99,375 90,442 89,129 Equities 11,118 12,686 3,918 Funds held and other (1) 10,801 17,871 16,559 Investment expenses (50,575) (50,781) (51,197) Net investment income $ 398,348 $ 376,469 $ 360,668 (1) The Company generally earns investment income on funds held by reinsured companies based upon a predetermined interest rate, either fixed contractually at the inception of the contract or based upon a recognized index. Interest rates ranged from 0.1% to 10.9%, 0.1% to 7.3% and 0.1% to 6.5% for the years ended December 31, 2022, 2021 and 2020, respectively.

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair values and notional values of derivatives	The net fair values of derivatives included in Other invested assets within the Company’s Consolidated Balance Sheets and the related net notional exposures at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): Asset Liability Net derivatives December 31, 2022 Fair value Net notional Derivatives not designated as hedges Foreign exchange forward contracts $ 13,705 $ (17,336) $ (3,631) $ 4,277,894 Insurance-linked securities (1) 6,657 — 6,657 16,937 Interest rate swaps (2) 258 (153) 105 — TBAs 578 — 578 — Options and warrants 8,691 — 8,691 8,815 Total derivatives not designated as hedges $ 29,889 $ (17,489) $ 12,400 Asset Liability Net derivatives December 31, 2021 Fair value Net notional Derivatives not designated as hedges Foreign exchange forward contracts $ 8,841 $ (6,657) $ 2,184 $ 3,092,396 Insurance-linked securities (1) 5,663 — 5,663 15,200 Total return swaps 153 (1,079) (926) 31,519 Interest rate swaps (2) — (10,489) (10,489) — Other 3,059 — 3,059 — Total derivatives not designated as hedges $ 17,716 $ (18,225) $ (509) (1) Insurance-linked securities include longevity swaps for which the notional amounts are not reflective of the overall potential exposure of the swaps. The net notional exposure above includes the Company's best estimate of the present value of future expected claims. (2) The Company enters into interest rate swaps to mitigate notional exposures on certain total return swaps and certain fixed maturities. The net notional exposure for interest rate swaps above relates to fixed maturities.
Gains and losses for derivatives not designated as hedges	The gains and losses in the Consolidated Statements of Operations for derivatives not designated as hedges for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): 2022 2021 2020 Foreign exchange forward contracts $ (34,902) $ (16,788) $ (32,611) Total included in Net foreign exchange losses $ (34,902) $ (16,788) $ (32,611) Insurance-linked securities $ 2,049 $ 4,807 $ (2,341) Total return swaps 934 1,430 (845) Interest rate swaps 10,594 7,020 (5,131) TBAs (23) (56) (510) Other — (298) 1,376 Total included in Net realized and unrealized investment gains (losses) $ 13,554 $ 12,903 $ (7,451) Total derivatives not designated as hedges $ (21,348) $ (3,885) $ (40,062)
Gross and net fair values of derivatives subject to offsetting	The gross and net fair values of derivatives that are subject to offsetting in the Consolidated Balance Sheets at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): Gross Net amounts of Gross amounts not offset December 31, 2022 Gross amounts recognized (1) Financial Cash collateral Net amount Total derivative assets $ 29,889 $ — $ 29,889 $ (258) $ (37,262) $ (7,631) Total derivative liabilities $ (17,489) $ — $ (17,489) $ 258 $ 15,978 $ (1,253) December 31, 2021 Total derivative assets $ 17,716 $ — $ 17,716 $ — $ (34,764) $ (17,048) Total derivative liabilities $ (18,225) $ — $ (18,225) $ — $ 1,671 $ (16,554) (1) Amounts include all derivative instruments, irrespective of whether there is a legally enforceable master netting arrangement in place.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	The Company’s goodwill related to the acquisitions of PartnerRe SA, Winterthur Re, Paris Re and Presidio and intangible assets related to the acquisitions of Paris Re, Presidio, Aurigen and Claims Analytics at December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): Goodwill Definite- Indefinite- Total Balance at December 31, 2019 $ 456,380 $ 107,983 $ 9,555 $ 117,538 Foreign currency translation — 119 — 119 Intangible assets amortization n/a (9,988) n/a (9,988) Balance at December 31, 2020 $ 456,380 $ 98,114 $ 9,555 $ 107,669 Foreign currency translation — 10 — 10 Intangible assets amortization n/a (8,861) n/a (8,861) Balance at December 31, 2021 $ 456,380 $ 89,263 $ 9,555 $ 98,818 Foreign currency translation — (137) — (137) Intangible assets amortization n/a (8,912) n/a (8,912) Balance at December 31, 2022 $ 456,380 $ 80,214 $ 9,555 $ 89,769 n/a: Not applicable
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The gross carrying value and accumulated amortization of intangible assets included in the Consolidated Balance Sheets at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Gross carrying Accumulated Net carrying value Gross carrying Accumulated Net carrying value Definite-lived intangible assets: Renewal rights $ 48,163 $ (43,032) $ 5,131 $ 48,163 $ (40,786) $ 7,377 Customer relationships 67,611 (56,850) 10,761 67,748 (52,661) 15,087 Life VOBA 75,583 (11,261) 64,322 75,583 (8,784) 66,799 Total definite-lived intangible assets $ 191,357 $ (111,143) $ 80,214 $ 191,494 $ (102,231) $ 89,263 Indefinite-lived intangible assets: Insurance licenses 9,555 n/a 9,555 9,555 n/a 9,555 Total intangible assets $ 200,912 $ (111,143) $ 89,769 $ 201,049 $ (102,231) $ 98,818 n/a: Not applicable
Allocation of goodwill by segment	The allocation of goodwill to the Company’s segments at December 31, 2022 and 2021 was as follows (in thousands of U.S. dollars): 2022 2021 P&C segment $ 242,376 $ 242,376 Specialty segment 196,047 196,047 Life and Health segment 17,957 17,957 Total $ 456,380 $ 456,380
Estimated future amortization expense	The estimated future amortization expense related to the Company’s definite-lived intangible assets is as follows (in thousands of U.S. dollars): Year VOBA Other definite- Total definite- 2023 $ 2,272 $ 5,641 $ 7,913 2024 2,296 4,960 7,256 2025 2,070 4,367 6,437 2026 1,892 402 2,294 2027 2,238 402 2,640 Thereafter 53,554 120 53,674 Total $ 64,322 $ 15,892 $ 80,214

Non-life and Life and Health _2

Non-life and Life and Health Reserves (Tables)	12 Months Ended
	Dec. 31, 2022
Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense [Abstract]
Components of non-life reserves	The Company’s gross liability for non-life reserves at December 31, 2022 and 2021 was as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Case reserves $ 5,110,575 $ 4,881,892 ACRs 159,821 140,464 IBNR reserves 7,455,235 7,025,436 Non-life reserves $ 12,725,631 $ 12,047,792
Reconciliation of the beginning and ending gross and net liability for non-life reserves	The reconciliation of the beginning and ending gross and net liability for non-life reserves for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Gross liability at beginning of year $ 12,047,792 $ 11,395,321 $ 10,363,383 Reinsurance recoverable at beginning of year 1,532,666 782,330 754,795 Net liability at beginning of year 10,515,126 10,612,991 9,608,588 Net incurred losses related to: Current year 3,533,087 3,637,671 3,945,248 Prior years (219,853) (194,426) 71,456 3,313,234 3,443,245 4,016,704 Net paid losses related to: Current year (419,633) (437,938) (459,718) Prior years (2,238,503) (2,535,057) (2,772,886) (2,658,136) (2,972,995) (3,232,604) Retroactive reinsurance recoverable adjustment (35,695) (357,864) — Effects of foreign exchange rate changes and other (260,709) (210,251) 220,303 Net liability at end of year 10,873,820 10,515,126 10,612,991 Reinsurance recoverable at end of year 1,851,811 1,532,666 782,330 Gross liability at end of year $ 12,725,631 $ 12,047,792 $ 11,395,321
Reconciliation of the beginning and ending gross and net liability for life and health reserves	The reconciliation of the beginning and ending gross and net liability for life and health reserves for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Gross liability at beginning of period $ 2,638,086 $ 2,704,229 $ 2,417,044 Reinsurance recoverable at beginning of period 21,000 35,662 16,183 Net liability at beginning of period $ 2,617,086 $ 2,668,567 $ 2,400,861 Net incurred losses (1) 1,434,169 1,440,739 1,318,196 Net losses paid (1,390,848) (1,413,316) (1,230,383) Effects of foreign exchange rate changes and other (181,789) (78,904) 179,893 Net liability at end of period $ 2,478,618 $ 2,617,086 $ 2,668,567 Reinsurance recoverable at end of period 31,675 21,000 35,662 Gross liability at end of period $ 2,510,293 $ 2,638,086 $ 2,704,229 (1) During 2021 and 2020, certain life and health treaties were recaptured, resulting in total gains upon recapture of $15 million and $28 million respectively, recorded as a reduction to net incurred losses.
Components of losses and loss expenses by segment	Losses and loss expenses in the Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020 were comprised as follows (in thousands of U.S. dollars): 2022 2021 2020 Non-life $ 3,313,234 $ 3,443,245 $ 4,016,704 Life and Health 1,434,169 1,440,739 1,318,196 Losses and loss expenses $ 4,747,403 $ 4,883,984 $ 5,334,900
Incurred and paid claims development and average annual percentage payout of incurred claims by age, net of reinsurance	The tables below reflect losses incurred and paid losses translated to U.S. dollars at the exchange rate as of the balance sheet date whereas the Losses and loss expenses in the Consolidated Statement of Operations reflect losses incurred at the average exchange rate for the period. NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - NON-LIFE For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 2,664,745 $ 2,722,788 $ 2,400,977 $ 3,277,749 $ 2,787,608 $ 2,313,004 $ 2,301,835 $ 2,276,767 $ 2,262,098 $ 2,242,254 $ 23,890 2014 2,481,720 2,514,200 2,368,967 2,349,869 2,353,759 2,315,021 2,277,135 2,262,546 2,232,454 35,019 2015 2,502,854 2,611,184 2,527,784 2,550,830 2,520,182 2,475,960 2,451,141 2,432,324 89,338 2016 2,451,204 2,559,851 2,516,126 2,486,199 2,467,920 2,484,069 2,476,383 130,477 2017 2,549,737 2,801,179 2,698,916 2,651,730 2,663,904 2,658,571 179,473 2018 2,596,552 2,974,243 2,969,810 2,972,766 3,009,359 387,763 2019 2,931,280 3,519,556 3,510,991 3,523,443 681,501 2020 4,186,395 3,586,462 3,499,097 976,332 2021 2,880,141 2,829,876 1,580,019 2022 3,410,844 2,119,500 Total $ 28,314,605 $ 6,203,312 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - NON-LIFE For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 267,413 $ 1,237,315 $ 1,577,293 $ 1,771,134 $ 1,900,282 $ 1,997,543 $ 2,061,865 $ 2,097,390 $ 2,121,980 $ 2,146,574 2014 336,270 1,291,273 1,594,146 1,810,171 1,946,054 2,044,804 2,118,939 2,164,676 2,196,720 2015 306,562 1,159,655 1,564,173 1,798,537 1,959,722 2,067,935 2,142,234 2,198,481 2016 321,351 1,272,443 1,627,697 1,893,694 2,030,728 2,123,169 2,211,977 2017 394,394 1,421,140 1,804,959 2,072,838 2,195,236 2,314,529 2018 271,827 1,276,542 1,811,055 2,093,543 2,283,931 2019 462,939 1,438,793 1,961,928 2,341,116 2020 480,122 1,277,034 1,805,063 2021 373,191 1,088,143 2022 394,598 Total $ 18,981,132 Net reserves for accident years and exposures included in the triangles $ 9,333,473 All outstanding liabilities before accident year 2013, net of reinsurance 1,239,090 Total outstanding liabilities for unpaid claims $ 10,572,563 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - NON-LIFE (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Non-life 13% 33% 15% 10% 6% 4% 3% 2% 1% 1% NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - PROPERTY For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 622,984 $ 560,072 $ 519,883 $ 505,636 $ 500,527 $ 492,673 $ 490,699 $ 489,268 $ 487,571 $ 485,091 $ 421 2014 469,568 488,446 463,409 458,609 452,907 450,487 447,816 447,894 444,808 588 2015 537,193 565,816 537,792 528,106 524,147 519,568 525,203 523,475 1,175 2016 663,490 681,050 644,349 625,873 622,562 624,375 623,593 2,622 2017 971,607 1,022,186 952,613 923,025 915,166 910,105 3,934 2018 805,960 820,675 799,735 778,867 766,591 10,844 2019 703,097 782,453 720,079 711,928 45,376 2020 1,252,575 1,070,935 1,061,772 134,726 2021 919,517 918,629 202,188 2022 944,920 557,288 Total $ 7,390,912 $ 959,162 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - PROPERTY For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 90,086 $ 320,510 $ 419,541 $ 453,191 $ 469,346 $ 472,517 $ 477,180 $ 479,094 $ 479,023 $ 479,578 2014 95,013 323,309 395,102 423,339 432,567 438,152 442,581 444,798 445,375 2015 85,015 330,876 435,539 469,036 481,879 489,195 498,557 501,524 2016 132,914 446,804 538,988 579,381 595,159 604,980 609,257 2017 214,026 694,240 805,627 853,945 862,942 870,638 2018 81,830 494,608 628,458 666,919 687,439 2019 78,527 426,566 545,163 586,587 2020 115,165 515,030 681,851 2021 121,453 491,546 2022 103,876 Total $ 5,457,671 Net reserves for accident years and exposures included in the triangles $ 1,933,241 All outstanding liabilities before accident year 2013, net of reinsurance 122,792 Total outstanding liabilities for unpaid claims $ 2,056,033 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - PROPERTY (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Property 15% 47% 16% 6% 2% 1% 1% —% —% —% NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - CASUALTY For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 747,448 $ 853,023 $ 757,402 $ 734,732 $ 732,716 $ 726,420 $ 714,114 $ 695,346 $ 691,195 $ 678,905 $ 19,235 2014 804,571 848,698 814,622 810,349 826,000 791,768 766,415 753,383 739,605 28,354 2015 699,327 783,275 761,091 803,497 770,242 751,652 726,451 714,608 76,827 2016 670,767 756,954 767,366 747,814 740,047 750,268 747,402 103,979 2017 621,095 743,114 720,966 709,881 716,862 720,732 136,389 2018 767,559 905,491 895,978 903,353 920,169 258,229 2019 999,955 1,226,210 1,272,980 1,273,687 519,757 2020 1,344,430 1,115,751 1,094,890 624,521 2021 1,013,896 967,726 920,590 2022 1,495,131 1,043,559 Total $ 9,352,855 $ 3,731,440 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - CASUALTY For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 49,468 $ 152,575 $ 260,249 $ 339,320 $ 410,241 $ 470,029 $ 510,855 $ 533,983 $ 558,218 $ 578,496 2014 69,119 189,458 292,152 387,182 470,964 536,883 594,035 631,367 654,893 2015 73,252 184,520 303,213 398,790 505,067 577,907 627,964 667,748 2016 28,304 140,081 244,560 369,651 455,982 520,069 586,050 2017 55,617 157,792 246,615 334,296 411,806 488,164 2018 59,105 201,190 323,510 425,887 532,717 2019 100,639 274,821 430,192 580,304 2020 112,281 176,740 304,592 2021 80,434 225,846 2022 120,660 Total $ 4,739,470 Net reserves for accident years and exposures included in the triangles $ 4,613,385 All outstanding liabilities before accident year 2013, net of reinsurance 1,023,715 Total outstanding liabilities for unpaid claims $ 5,637,100 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - CASUALTY (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Casualty 8% 14% 13% 13% 12% 9% 7% 5% 3% 3% NET INCURRED LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - SPECIALTY For the year ended December 31, December 31, 2022 Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total of IBNR plus expected development on reported claims (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 1,294,313 $ 1,309,693 $ 1,123,692 $ 2,037,381 $ 1,554,365 $ 1,093,911 $ 1,097,022 $ 1,092,153 $ 1,083,332 $ 1,078,258 $ 4,234 2014 1,207,581 1,177,056 1,090,936 1,080,911 1,074,852 1,072,766 1,062,904 1,061,269 1,048,041 6,077 2015 1,266,334 1,262,093 1,228,901 1,219,227 1,225,793 1,204,740 1,199,487 1,194,241 11,336 2016 1,116,947 1,121,847 1,104,411 1,112,512 1,105,311 1,109,426 1,105,388 23,876 2017 957,035 1,035,879 1,025,337 1,018,824 1,031,876 1,027,734 39,150 2018 1,023,033 1,248,077 1,274,097 1,290,546 1,322,599 118,690 2019 1,228,228 1,510,893 1,517,932 1,537,828 116,368 2020 1,589,390 1,399,776 1,342,435 217,085 2021 946,728 943,521 457,241 2022 970,793 518,653 Total $ 11,570,838 $ 1,512,710 NET PAID LOSSES AND LOSS EXPENSES DEVELOPMENT TABLE - SPECIALTY For the year ended December 31, Accident year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2013 $ 127,859 $ 764,230 $ 897,503 $ 978,623 $ 1,020,695 $ 1,054,997 $ 1,073,830 $ 1,084,313 $ 1,084,739 $ 1,088,500 2014 172,138 778,506 906,892 999,650 1,042,523 1,069,769 1,082,323 1,088,511 1,096,452 2015 148,295 644,259 825,421 930,711 972,776 1,000,833 1,015,713 1,029,209 2016 160,133 685,558 844,149 944,662 979,587 998,120 1,016,670 2017 124,751 569,108 752,717 884,597 920,488 955,727 2018 130,892 580,744 859,087 1,000,737 1,063,775 2019 283,773 737,406 986,573 1,174,225 2020 252,676 585,264 818,620 2021 171,304 370,751 2022 170,062 Total $ 8,783,991 Net reserves for accident years and exposures included in the triangles $ 2,786,847 All outstanding liabilities before accident year 2013, net of reinsurance 92,583 Total outstanding liabilities for unpaid claims $ 2,879,430 AVERAGE ANNUAL PERCENTAGE PAYOUT OF INCURRED CLAIMS BY AGE, NET OF REINSURANCE - SPECIALTY (unaudited) Years 1 2 3 4 5 6 7 8 9 10 Specialty 15% 39% 16% 10% 4% 3% 1% 1% —% —%
Reconciliation of net incurred and paid claims development to Non-life reserves	The reconciliation of the net incurred and paid claims development information above to the Non-life reserves in the Consolidated Balance Sheet at December 31, 2022 was as follows (in thousands of U.S. dollars): December 31, 2022 Total outstanding liability for unpaid claims Property $ 2,056,033 Casualty 5,637,100 Specialty 2,879,430 Total outstanding liabilities for unpaid claims $ 10,572,563 Unallocated loss expenses $ 119,274 U.S. health net reserves (1) 168,146 Other 13,837 Total other liabilities $ 301,257 Net liability at end of year $ 10,873,820 Reinsurance recoverable on unpaid claims Property $ 922,141 Casualty 585,737 Specialty 343,933 Reinsurance recoverable at end of year $ 1,851,811 Gross liability at end of year $ 12,725,631 (1) U.S. health business is not meaningful to include in the development tables as the estimated average duration of the health reserves is less than one year and substantially all claims are expected to be paid within two years, based on historical payout patterns.

Reinsurance (Tables)

Reinsurance (Tables)	12 Months Ended
	Dec. 31, 2022
Reinsurance Disclosures [Abstract]
Ceded reinsurance	Assumed, ceded and net amounts for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands of U.S. dollars): Premiums Premiums Losses and Loss 2022 Non-life $ 7,015,422 $ 6,696,769 $ 4,024,931 Life and Health 1,673,857 1,674,091 1,476,353 Assumed $ 8,689,279 $ 8,370,860 $ 5,501,284 Non-life $ 1,116,672 $ 1,085,317 $ 711,697 Life and Health 28,412 28,426 42,184 Ceded $ 1,145,084 $ 1,113,743 $ 753,881 Non-life $ 5,898,750 $ 5,611,452 $ 3,313,234 Life and Health 1,645,445 1,645,665 1,434,169 Net $ 7,544,195 $ 7,257,117 $ 4,747,403 Premiums Premiums Losses and Loss 2021 Non-life $ 6,557,055 $ 6,274,418 $ 4,212,465 Life and Health 1,646,870 1,651,485 1,454,065 Assumed $ 8,203,925 $ 7,925,903 $ 5,666,530 Non-life $ 1,046,227 $ 944,862 $ 769,220 Life and Health 23,680 24,519 13,326 Ceded $ 1,069,907 $ 969,381 $ 782,546 Non-life $ 5,510,828 $ 5,329,556 $ 3,443,245 Life and Health 1,623,190 1,626,966 1,440,739 Net $ 7,134,018 $ 6,956,522 $ 4,883,984 Premiums Premiums Losses and Loss 2020 Non-life $ 5,376,703 $ 5,571,201 $ 4,358,975 Life and Health 1,499,222 1,505,819 1,344,117 Assumed $ 6,875,925 $ 7,077,020 $ 5,703,092 Non-life $ 550,784 $ 516,672 $ 342,271 Life and Health 24,283 23,522 25,921 Ceded $ 575,067 $ 540,194 $ 368,192 Non-life $ 4,825,919 $ 5,054,529 $ 4,016,704 Life and Health 1,474,939 1,482,297 1,318,196 Net $ 6,300,858 $ 6,536,826 $ 5,334,900

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Summary of debt outstanding	The debt outstanding and the carrying value recorded in the Consolidated Balance Sheets at December 31, 2022 and 2021 was comprised as follows (in thousands): December 31, 2022 December 31, 2021 Commitment Carrying Value Fair Value Carrying Value Fair Value Senior notes due 2029 $ 500,000 $ 497,073 $ 462,521 $ 496,620 $ 561,099 Senior notes due 2026 € 750,000 794,368 721,807 843,950 882,126 Junior subordinated notes due 2050 $ 500,000 494,638 428,250 494,445 526,522 Capital efficient notes due 2066 $ 61,924 61,924 54,247 62,484 55,248 Debt $ 1,848,003 $ 1,666,825 $ 1,897,499 $ 2,024,995

Dividend Restrictions and Sta_2

Dividend Restrictions and Statutory Requirements (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure - Dividend Restrictions and Statutory Requirements [Abstract]
Statutory measurements	The statutory net income (loss) of PartnerRe Bermuda, PartnerRe Europe, PartnerRe U.S., PartnerRe Asia and PartnerRe Canada for the years ended December 31, 2022, 2021 and 2020 was as follows (in millions of U.S. dollars): 2022 2021 2020 PartnerRe Bermuda $ (139) $ 900 $ (52) PartnerRe Europe $ (329) $ 28 $ 237 PartnerRe U.S. $ 242 $ 68 $ 28 PartnerRe Asia $ (31) $ (6) $ (2) PartnerRe Canada $ (14) $ (12) $ 13 The required and actual statutory capital and surplus of PartnerRe Bermuda, PartnerRe Europe, PartnerRe U.S., PartnerRe Asia and PartnerRe Canada at December 31, 2022 and 2021 was as follows (in millions of U.S. dollars): PartnerRe Bermuda (1) PartnerRe Europe PartnerRe U.S. PartnerRe Asia PartnerRe Canada 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Required statutory capital and surplus $ 2,725 $ 2,846 $ 1,537 $ 1,873 $ 1,356 $ 1,244 $ 47 $ 50 $ 1,144 $ 999 Actual statutory capital and surplus $ 5,816 $ 6,004 $ 2,672 $ 2,744 $ 1,928 $ 1,369 $ 215 $ 249 $ 1,392 $ 1,240 (1) Required statutory capital and surplus is calculated at the Target Capital Level

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Components of income tax expense	Income tax expense (benefit) for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Current income tax expense (benefit) U.S. $ 93,906 $ 31,216 $ (97,155) Non U.S. 20,622 18,293 44,764 Total current income tax expense (benefit) $ 114,528 $ 49,509 $ (52,391) Deferred income tax (benefit) expense U.S. $ (14,428) $ (9,404) $ 60,932 Non U.S. (70,699) (1,687) (25,560) Total deferred income tax (benefit) expense $ (85,127) $ (11,091) $ 35,372 Unrecognized tax expense (benefit) U.S. $ — $ — $ — Non U.S. 1,933 (199) 3,928 Total unrecognized tax expense (benefit) $ 1,933 $ (199) $ 3,928 Total income tax expense (benefit) U.S. $ 79,478 $ 21,812 $ (36,223) Non U.S. (48,144) 16,407 23,132 Total income tax expense (benefit) $ 31,334 $ 38,219 $ (13,091)
Income before taxes attributable to domestic and foreign operations	(Loss) income before taxes attributable to the Company’s domestic and foreign operations and a reconciliation of the actual income tax rate to the amount computed by applying the effective tax rate of 0% under Bermuda (the Company’s domicile) law to (loss) income before taxes was as follows for the years ended December 31, 2022, 2021 and 2020 (in thousands of U.S. dollars): 2022 2021 2020 Domestic (Bermuda) $ (205,731) $ 636,043 $ 3,894 Foreign (852,964) 125,580 237,204 (Loss) income before taxes $ (1,058,695) $ 761,623 $ 241,098
Reconciliation of effective tax rate	Reconciliation of effective tax rate (% of (loss) income before taxes) Expected tax rate 0.0 % 0.0 % 0.0 % Foreign taxes at local expected tax rates 14.2 5.7 15.5 Impact of foreign exchange gains or losses (0.3) (0.1) (8.1) Unrecognized tax (expense) benefit (0.2) — 1.6 Tax-exempt income and expenses not deductible 0.1 (0.4) (1.4) Foreign branch tax 3.5 0.1 (3.3) Valuation allowance (17.6) 0.6 3.4 Other (2.7) (0.9) (13.1) Actual tax rate (3.0) % 5.0 % (5.4) %
Components of net tax assets and liabilities	The components of net tax assets and liabilities at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Net tax assets $ 164,384 $ 154,472 Net tax liabilities (29,154) (90,974) Net tax assets $ 135,230 $ 63,498 December 31, 2022 December 31, 2021 Net current tax assets $ 108,836 $ 117,872 Net deferred tax assets (liabilities) 37,103 (45,098) Net unrecognized tax benefit (10,709) (9,276) Net tax assets $ 135,230 $ 63,498
Significant components of net deferred tax assets and liabilities	Significant components of the net deferred tax assets and liabilities at December 31, 2022 and 2021 were as follows (in thousands of U.S. dollars): December 31, 2022 December 31, 2021 Deferred tax assets Discounting of loss reserves and adjustment to life policy reserves $ 18,049 $ 18,340 Foreign tax credit carryforwards 211,023 180,510 Tax loss carryforwards 123,597 106,555 Unearned premiums 46,029 36,421 Statutory basis funds held — 58,899 Unrealized depreciation and timing differences on foreign exchange revaluations — 3,838 Unrealized depreciation and timing differences on investments 170,720 — Other deferred tax assets 37,423 47,034 $ 606,841 $ 451,597 Valuation allowance (399,329) (211,798) Deferred tax assets $ 207,512 $ 239,799 Deferred tax liabilities Deferred acquisition costs $ 92,459 $ 75,924 Goodwill and other intangibles 55,882 56,870 Statutory basis reserves — 114,240 Equalization reserves 8,235 7,192 Unrealized appreciation and timing differences on investments — 4,877 Other deferred tax liabilities 13,833 25,794 Deferred tax liabilities $ 170,409 $ 284,897 Net deferred tax assets (liabilities) $ 37,103 $ (45,098)
Total amount of unrecognized tax benefits	The total amount of unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020 was as follows (in thousands of U.S. dollars): 2022 2021 2020 Balance at January 1 $ 9,276 $ 10,273 $ 5,689 Changes in tax positions taken during a prior year 1,933 (199) 3,870 Impact of the change in foreign currency exchange rates (500) (798) 714 Balance at December 31 $ 10,709 $ 9,276 $ 10,273

Share-Based Incentives (Tables)

Share-Based Incentives (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Activity summary of share-based incentives	The following tables provide activity summaries of the Company's Class B shares, Class C shares, and RSUs outstanding: RSUs (1) Outstanding December 31, 2020 — Granted 263,214 Outstanding December 31, 2021 263,214 Forfeitures (2,964) Accelerated vesting and repurchase upon change of control (260,250) Granted 265,805 Outstanding December 31, 2022 265,805 (1) For RSUs, the number of grants in the table are shown at the maximum number that can be attained if the performance conditions are fully met for personal and Company performance. Forfeitures represent adjustments to grants falling below the maximum attainable as a result of not fully meeting the performance conditions. Restricted Class C shares Unrestricted Class C shares Total Class C shares Outstanding December 31, 2020 — — — Granted 7,373 — 7,373 Purchased — 2,072 2,072 Outstanding December 31, 2021 7,373 2,072 9,445 Accelerated vesting and repurchase upon change of control (7,373) (5,819) (13,192) Granted 7,666 3,747 11,413 Outstanding December 31, 2022 7,666 — 7,666 Restricted Class B shares Unrestricted Class B shares Total Class B shares Outstanding December 31, 2019 179,332 102,436 281,768 Granted 167,202 — 167,202 Purchased — 38,838 38,838 Repurchased (129,583) (83,561) (213,144) Expiration of restricted period (27,785) 27,785 — Outstanding December 31, 2020 189,166 85,498 274,664 Repurchased (29,048) (22,957) (52,005) Expiration of restricted period (20,298) 20,298 — Outstanding December 31, 2021 139,820 82,839 222,659 Expiration of restricted period (32,168) 32,168 — Accelerated vesting and repurchase upon change of control (107,652) (115,007) (222,659) Outstanding December 31, 2022 — — —

Retirement Benefit Arrangemen_2

Retirement Benefit Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Funded status	At December 31, 2022 and 2021, the funded status of the Zurich Plan was as follows (in thousands of U.S. dollars): 2022 2021 Underfunded pension obligation at beginning of year $ 32,636 $ 62,050 Change in pension obligation Service cost $ 8,746 $ 11,811 Interest cost 373 228 Plan participants’ contributions 3,792 4,048 Actuarial gain (37,992) (24,211) Benefits paid (4,576) (1,651) Foreign currency adjustments (3,736) (8,735) Settlements — (20,682) Change in pension obligation $ (33,393) $ (39,192) Change in fair value of plan assets Actual return on plan assets $ (14,936) $ 6,847 Employer contributions 7,658 8,035 Plan participants’ contributions 3,792 4,048 Benefits paid (4,576) (1,651) Foreign currency adjustments (2,233) (6,375) Settlements — (20,682) Change in fair value of plan assets $ (10,295) $ (9,778) Underfunded pension obligation at end of year $ 9,538 $ 32,636 Additional information: Projected benefit obligation at end of year (1) $ 169,527 $ 202,920 Fair value of plan assets at end of year $ 159,989 $ 170,284 Underfunded pension obligation at end of year $ 9,538 $ 32,636 Accumulated pension obligation at end of year (2) $ 167,560 $ 194,730 (1) Represents the actuarial present value of all benefits attributed to employee service rendered to December 31, measured using assumptions as to future compensation levels (2) Represents the actuarial present value of benefits (whether vested or non-vested) attributed to employee service rendered and compensation to December 31, with no assumption about future compensation levels
Assumptions used	The assumptions used to determine the Zurich Plan’s pension obligation and net periodic benefit cost for the years ended December 31, 2022, 2021 and 2020 were as follows: 2022 2021 2020 Pension Net periodic Pension Net periodic Pension Net periodic Discount rate 2.20 % 0.20 % 0.20 % 0.10 % 0.10 % 0.25 % Interest crediting rate 2.20 % 1.00 % 1.00 % 1.00 % 1.00 % 1.00 % Expected long-term return on plan assets — 4.25 % — 3.50 % — 3.50 % Rate of compensation increase 2.25 % 2.00 % 2.00 % 2.00 % 2.00 % 2.00 %
Expected future benefit payments	At December 31, 2022, estimated employer contributions to be paid in 2023 related to the Zurich Plan were $8 million and future benefit payments were estimated to be paid as follows (in thousands of U.S. dollars): Year Amount 2023 $ 11,377 2024 $ 9,696 2025 $ 10,739 2026 $ 12,454 2027 $ 11,111 2028 to 2032 $ 52,119

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Additional information related to operating leases	The following table summarizes the balances related to the Company's total lease expense and provides supplemental other information related to operating leases for the year ended December 31, 2022 and 2021 (in thousands of U.S. dollars): 2022 2021 Operating lease costs $ 12,437 $ 14,928 Variable lease costs 1,292 904 Sublease income — (368) Total lease costs $ 13,729 $ 15,464 Other information: Operating lease right-of-use assets (1) $ 71,174 $ 75,010 Operating lease liabilities (2) $ 79,925 $ 85,462 Operating lease right-of-use assets obtained in exchange for lease obligations, non-cash $ 4,016 $ 26,553 Operating cash outflows from operating leases $ 13,545 $ 16,874 Weighted-average remaining lease term on operating leases (3) 7.8 Yrs 8.9 Yrs Weighted-average discount rate on operating leases (4) 2.3 % 2.4 % (1) Included in Other assets (2) Included in Accounts payable, accrued expenses and other (3) Weighted-average remaining lease term is calculated on the basis of the remaining lease term and the lease liability balance for each lease as of the reporting date (4) Weighted-average discount rate is calculated on the basis of the discount rate for the lease that was used to calculate the lease liability balance for each lease as of the reporting date and the remaining balance of the lease payments for each lease as of the reporting date
Contractual maturities of operating lease liabilities	The following table shows the contractual maturities of the Company's operating lease liabilities at December 31, 2022 (in thousands of U.S. dollars): Year Expected cash flows 2023 $ 13,671 2024 13,642 2025 12,303 2026 12,089 2027 10,953 2028 to 2038 24,005 Discount (6,738) Total discounted operating lease liabilities $ 79,925

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Included in the Consolidated Balance Sheets at December 31, 2022 were the following balances related to the Covéa Group (in thousands of U.S. dollars): 2022 Reinsurance balances receivable $ 3,169 Non-life reserves $ 95,013 Life and health reserves $ 1,175 Unearned premiums $ 571

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment reporting table	The segment results for the years ended December 31, 2022, 2021 and 2020 are presented below (in millions of U.S. dollars, except ratios). Segment Information For the year ended December 31, 2022 P&C Specialty Total Life Corporate Total Gross premiums written $ 5,025 $ 1,990 $ 7,015 $ 1,674 $ — $ 8,689 Net premiums written $ 4,234 $ 1,665 $ 5,899 $ 1,645 $ — $ 7,544 (Increase) decrease in unearned premiums (293) 5 (288) 1 — (287) Net premiums earned $ 3,941 $ 1,670 $ 5,611 $ 1,646 $ — $ 7,257 Losses and loss expenses (2,410) (903) (3,313) (1,434) — (4,747) Acquisition costs (995) (435) (1,430) (111) — (1,541) Technical result $ 536 $ 332 $ 868 $ 101 $ — $ 969 Other income — — — 39 1 40 Other expenses (84) (35) (119) (93) (203) (415) Underwriting result $ 452 $ 297 $ 749 $ 47 n/a $ 594 Net investment income 74 324 398 Allocated underwriting result $ 121 n/a n/a Net realized and unrealized investment losses (1,969) (1,969) Interest expense (55) (55) Amortization of intangible assets (9) (9) Net foreign exchange losses (29) (29) Income tax expense (31) (31) Interest in earnings of equity method investments 11 11 Net loss n/a $ (1,090) Loss ratio (1) 61.2 % 54.1 % 59.0 % Acquisition ratio (2) 25.2 26.0 25.5 Technical ratio (3) 86.4 % 80.1 % 84.5 % Other expense ratio (4) 2.1 2.1 2.1 Combined ratio (5) 88.5 % 82.2 % 86.6 % (1) Loss ratio is obtained by dividing losses and loss expenses by net premiums earned. (2) Acquisition ratio is obtained by dividing acquisition costs by net premiums earned. (3) Technical ratio is defined as the sum of the loss ratio and the acquisition ratio. (4) Other expense ratio is obtained by dividing other expenses by net premiums earned. (5) Combined ratio is defined as the sum of the technical ratio and the other expense ratio. Segment Information For the year ended December 31, 2021 P&C Specialty Total Life Corporate Total Gross premiums written $ 4,541 $ 2,016 $ 6,557 $ 1,647 $ — $ 8,204 Net premiums written $ 3,722 $ 1,789 $ 5,511 $ 1,623 $ — $ 7,134 (Increase) decrease in unearned premiums (194) 13 (181) 4 — (177) Net premiums earned $ 3,528 $ 1,802 $ 5,330 $ 1,627 $ — $ 6,957 Losses and loss expenses (2,391) (1,052) (3,443) (1,441) — (4,884) Acquisition costs (864) (415) (1,279) (108) — (1,387) Technical result $ 273 $ 335 $ 608 $ 78 $ — $ 686 Other income — — — 26 3 29 Other expenses (71) (30) (101) (88) (210) (399) Underwriting result $ 202 $ 305 $ 507 $ 16 n/a $ 316 Net investment income 81 295 376 Allocated underwriting result $ 97 n/a n/a Net realized and unrealized investment gains 38 38 Interest expense (56) (56) Amortization of intangible assets (9) (9) Net foreign exchange losses (31) (31) Income tax expense (38) (38) Interest in earnings of equity method investments 127 127 Net income n/a $ 723 Loss ratio 67.8 % 58.4 % 64.6 % Acquisition ratio 24.5 23.0 24.0 Technical ratio 92.3 % 81.4 % 88.6 % Other expense ratio 2.0 1.7 1.9 Combined ratio 94.3 % 83.1 % 90.5 % Segment Information For the year ended December 31, 2020 P&C Specialty Total Life Corporate Total Gross premiums written $ 3,442 $ 1,935 $ 5,377 $ 1,499 $ — $ 6,876 Net premiums written $ 3,044 $ 1,782 $ 4,826 $ 1,475 $ — $ 6,301 Decrease in unearned premiums 119 110 229 7 — 236 Net premiums earned $ 3,163 $ 1,892 $ 5,055 $ 1,482 $ — $ 6,537 Losses and loss expenses (2,389) (1,628) (4,017) (1,318) — (5,335) Acquisition costs (784) (470) (1,254) (102) — (1,356) Technical result $ (10) $ (206) $ (216) $ 62 $ — $ (154) Other (loss) income (1) — (1) 13 1 13 Other expenses (61) (26) (87) (73) (196) (356) Underwriting result $ (72) $ (232) $ (304) $ 2 n/a $ (497) Net investment income 68 293 361 Allocated underwriting result $ 70 n/a n/a Net realized and unrealized investment gains 454 454 Interest expense (39) (39) Amortization of intangible assets (10) (10) Net foreign exchange losses (52) (52) Income tax benefit 13 13 Interest in earnings of equity method investments 24 24 Net income n/a $ 254 Loss ratio 75.5 % 86.0 % 79.5 % Acquisition ratio 24.8 24.8 24.8 Technical ratio 100.3 % 110.8 % 104.3 % Other expense ratio 1.9 1.4 1.7 Combined ratio 102.2 % 112.2 % 106.0 %
Segment geographic distribution of premiums table	The following table provides the geographic distribution of gross premiums written by region for the years ended December 31, 2022, 2021 and 2020 (in millions of U.S. dollars, except percentages): 2022 2021 2020 North America $ 5,040 58 % $ 4,649 57 % $ 3,794 55 % Europe 2,592 30 2,410 29 1,921 28 Asia, Australia and New Zealand 720 8 814 10 806 12 Latin America and the Caribbean 223 3 189 2 220 3 Middle East, Africa, Russia and the Commonwealth of Independent States (CIS) 114 1 142 2 135 2 Total $ 8,689 100 % $ 8,204 100 % $ 6,876 100 %
Premiums by segment and line of business	The following table provides the gross premiums written by segment and line of business for the years ended December 31, 2022, 2021 and 2020 (in millions of U.S. dollars, except percentages): 2022 2021 2020 P&C Casualty $ 2,777 $ 2,145 $ 1,430 Catastrophe 933 924 545 Property 764 809 641 U.S. health 355 351 379 Multiline and other 119 183 289 Motor 77 129 158 Total P&C $ 5,025 $ 4,541 $ 3,442 Specialty Financial risks $ 634 $ 510 $ 568 Aviation and space 362 416 219 Energy 346 314 192 Property 240 277 173 Marine 223 174 142 Agriculture 101 205 468 Multiline and other 45 20 152 Engineering 39 100 17 Casualty — — 4 Total Specialty $ 1,990 $ 2,016 $ 1,935 Life and Health $ 1,674 $ 1,647 $ 1,499 Total $ 8,689 $ 8,204 $ 6,876
Percentage of premiums through brokers	The Company has two brokers that individually accounted for 10% or more of its gross premiums written during the years ended December 31, 2022, 2021 and 2020, as follows: 2022 2021 2020 Marsh & McLennan Companies, Inc 30 % 28 % 30 % Aon PLC 26 % 24 % 21 % The following table summarizes the percentage of gross premiums written through these two brokers by segment for the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 P&C 67 % 63 % 64 % Specialty 70 % 66 % 64 % Life and Health 6 % 6 % 6 %

Significant Accounting Polici_3

Significant Accounting Policies - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)	Jan. 01, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Accounting Policies [Abstract]
Number of segments		3	3
Requisite service period, Class B shares	3 years
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	$ 6,288,350	$ 6,288,350	$ 6,288,350	$ 7,543,986		$ 7,326,997
Accounting Standards Update				Accounting Standards Update 2016-13
Retained earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	4,358,085	4,358,085	4,358,085	$ 5,635,758		5,062,948	$ 4,921,395
Retained earnings | Cumulative effect of adoption of accounting guidance
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity				0		0	(14,305)
Retained earnings | Cumulative effect of adoption of accounting guidance | Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity							(14,000)
Accumulated other comprehensive loss
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	$ (7,669)	$ (7,669)	$ (7,669)	$ (29,706)		$ (96,005)	$ (75,925)
Pro Forma | Accounting Standards Update 2018-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounting Standards Update	Accounting Standards Update 2018-12
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2023	Jan. 01, 2023	Jan. 01, 2023
Pro Forma | Retained earnings | Revision of Prior Period, Accounting Standards Update, Adjustment | Accounting Standards Update 2018-12 | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	$ 5,000	$ 5,000	$ 5,000
Pro Forma | Retained earnings | Revision of Prior Period, Accounting Standards Update, Adjustment | Accounting Standards Update 2018-12 | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	75,000	75,000	75,000
Pro Forma | Retained earnings | Cumulative effect of adoption of accounting guidance | Accounting Standards Update 2018-12 | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity					$ (130,000)
Pro Forma | Retained earnings | Cumulative effect of adoption of accounting guidance | Accounting Standards Update 2018-12 | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity					(200,000)
Pro Forma | Accumulated other comprehensive loss | Revision of Prior Period, Accounting Standards Update, Adjustment | Accounting Standards Update 2018-12 | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	50,000	50,000	50,000
Pro Forma | Accumulated other comprehensive loss | Revision of Prior Period, Accounting Standards Update, Adjustment | Accounting Standards Update 2018-12 | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity	$ 120,000	$ 120,000	$ 120,000
Pro Forma | Accumulated other comprehensive loss | Cumulative effect of adoption of accounting guidance | Accounting Standards Update 2018-12 | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity					(110,000)
Pro Forma | Accumulated other comprehensive loss | Cumulative effect of adoption of accounting guidance | Accounting Standards Update 2018-12 | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total shareholders’ equity					$ (180,000)

Fair Value - Hierarchy table (D

Fair Value - Hierarchy table (Details) - USD ($) $ in Thousands		Dec. 31, 2022		Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		$ 13,021,914		$ 14,071,274
Short-term investments		523,510		205,146
Equities		929,886		1,751,584
Other invested assets		3,117,861		3,317,260
Total		17,593,171		19,345,264
Derivative assets | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		13,705		8,841
Derivative assets | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		258
Derivative assets | Insurance-linked securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		6,657		5,663
Derivative assets | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				153
Derivative assets | Options and warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		8,691
Derivative assets | TBAs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		578
Derivative assets | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				3,059
Corporate loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	[1]	1,302,807		1,391,971
Notes and loan receivables and notes securitization
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		3,166		6,575
Derivative liabilities | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		(17,336)		(6,657)
Derivative liabilities | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		(153)		(10,489)
Derivative liabilities | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				(1,079)
Real estate company investment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		491,602		560,687	[2]
Real estate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		63,568		99,951
Consumer noncyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		10,081		10,424
Diversified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		9,667		7,472
Consumer cyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		4,477		8,735
Energy
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		1,517		3,480
Finance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		120		128
Industrials
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		96		357
Insurance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		42		18
Fund investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		840,318		1,621,019	[3]
Other invested assets		1,307,886		1,358,536	[3]
U.S. government and government sponsored enterprises
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		1,797,934		2,118,772
U.S. states, territories and municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		58,873		108,059
Non US sovereign government supranational and government related
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		1,654,532		2,181,127
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		5,759,149		5,441,908
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		28,364		16,764
Residential mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		3,723,062		4,204,644
Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Short-term investments		0		0
Equities		66,226		106,791
Other invested assets		0		0
Total		66,226		106,791
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | Insurance-linked securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | Options and warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | TBAs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Quoted prices in active markets for identical assets (Level 1) | Derivative assets | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Quoted prices in active markets for identical assets (Level 1) | Corporate loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0	[1]	0
Quoted prices in active markets for identical assets (Level 1) | Notes and loan receivables and notes securitization
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Quoted prices in active markets for identical assets (Level 1) | Derivative liabilities | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Quoted prices in active markets for identical assets (Level 1) | Derivative liabilities | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Quoted prices in active markets for identical assets (Level 1) | Derivative liabilities | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Quoted prices in active markets for identical assets (Level 1) | Real estate company investment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0	[2]
Quoted prices in active markets for identical assets (Level 1) | Real estate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		61,754		97,854
Quoted prices in active markets for identical assets (Level 1) | Consumer noncyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		343
Quoted prices in active markets for identical assets (Level 1) | Diversified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		4
Quoted prices in active markets for identical assets (Level 1) | Consumer cyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		4,449		7,341
Quoted prices in active markets for identical assets (Level 1) | Energy
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		3		1,112
Quoted prices in active markets for identical assets (Level 1) | Finance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Quoted prices in active markets for identical assets (Level 1) | Industrials
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		20		137
Quoted prices in active markets for identical assets (Level 1) | Insurance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Quoted prices in active markets for identical assets (Level 1) | Fund investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0	[3]
Other invested assets		0		0	[3]
Quoted prices in active markets for identical assets (Level 1) | U.S. government and government sponsored enterprises
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Quoted prices in active markets for identical assets (Level 1) | U.S. states, territories and municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Quoted prices in active markets for identical assets (Level 1) | Non US sovereign government supranational and government related
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Quoted prices in active markets for identical assets (Level 1) | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Quoted prices in active markets for identical assets (Level 1) | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Quoted prices in active markets for identical assets (Level 1) | Residential mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		12,957,237		13,959,329
Short-term investments		516,603		205,146
Equities		42		18
Other invested assets		1,012,581		1,096,139
Total		14,486,463		15,260,632
Significant other observable inputs (Level 2) | Derivative assets | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		13,705		8,841
Significant other observable inputs (Level 2) | Derivative assets | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		258
Significant other observable inputs (Level 2) | Derivative assets | Insurance-linked securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Significant other observable inputs (Level 2) | Derivative assets | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Significant other observable inputs (Level 2) | Derivative assets | Options and warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Significant other observable inputs (Level 2) | Derivative assets | TBAs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		578
Significant other observable inputs (Level 2) | Derivative assets | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Significant other observable inputs (Level 2) | Corporate loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		1,015,529	[1]	1,104,444
Significant other observable inputs (Level 2) | Notes and loan receivables and notes securitization
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Significant other observable inputs (Level 2) | Derivative liabilities | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		(17,336)		(6,657)
Significant other observable inputs (Level 2) | Derivative liabilities | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		(153)		(10,489)
Significant other observable inputs (Level 2) | Derivative liabilities | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Significant other observable inputs (Level 2) | Real estate company investment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0	[2]
Significant other observable inputs (Level 2) | Real estate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Consumer noncyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Diversified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Consumer cyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Energy
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Finance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Industrials
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant other observable inputs (Level 2) | Insurance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		42		18
Significant other observable inputs (Level 2) | Fund investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0	[3]
Other invested assets		0		0	[3]
Significant other observable inputs (Level 2) | U.S. government and government sponsored enterprises
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		1,797,934		2,118,772
Significant other observable inputs (Level 2) | U.S. states, territories and municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		10,126		12,878
Significant other observable inputs (Level 2) | Non US sovereign government supranational and government related
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		1,654,532		2,181,127
Significant other observable inputs (Level 2) | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		5,759,149		5,441,908
Significant other observable inputs (Level 2) | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		12,434		0
Significant other observable inputs (Level 2) | Residential mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		3,723,062		4,204,644
Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		64,677		111,945
Short-term investments		6,907		0
Equities		23,300		23,756
Other invested assets		833,668		874,324
Total		928,552		1,010,025
Significant unobservable inputs (Level 3) | Derivative assets | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Significant unobservable inputs (Level 3) | Derivative assets | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Significant unobservable inputs (Level 3) | Derivative assets | Insurance-linked securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		6,657		5,663
Significant unobservable inputs (Level 3) | Derivative assets | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				153
Significant unobservable inputs (Level 3) | Derivative assets | Options and warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		8,691
Significant unobservable inputs (Level 3) | Derivative assets | TBAs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Significant unobservable inputs (Level 3) | Derivative assets | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				3,059
Significant unobservable inputs (Level 3) | Corporate loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	[1]	287,278		287,527
Significant unobservable inputs (Level 3) | Notes and loan receivables and notes securitization
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		3,166		6,575
Significant unobservable inputs (Level 3) | Derivative liabilities | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Significant unobservable inputs (Level 3) | Derivative liabilities | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Significant unobservable inputs (Level 3) | Derivative liabilities | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				(1,079)
Significant unobservable inputs (Level 3) | Real estate company investment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		491,602		560,687	[2]
Significant unobservable inputs (Level 3) | Real estate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		1,814		2,097
Significant unobservable inputs (Level 3) | Consumer noncyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		10,081		10,081
Significant unobservable inputs (Level 3) | Diversified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		9,667		7,468
Significant unobservable inputs (Level 3) | Consumer cyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		28		1,394
Significant unobservable inputs (Level 3) | Energy
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		1,514		2,368
Significant unobservable inputs (Level 3) | Finance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		120		128
Significant unobservable inputs (Level 3) | Industrials
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		76		220
Significant unobservable inputs (Level 3) | Insurance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Significant unobservable inputs (Level 3) | Fund investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0	[3]
Other invested assets		36,274		11,739	[3]
Significant unobservable inputs (Level 3) | U.S. government and government sponsored enterprises
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Significant unobservable inputs (Level 3) | U.S. states, territories and municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		48,747		95,181
Significant unobservable inputs (Level 3) | Non US sovereign government supranational and government related
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Significant unobservable inputs (Level 3) | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Significant unobservable inputs (Level 3) | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		15,930		16,764
Significant unobservable inputs (Level 3) | Residential mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Fair value based on NAV as practical expedient
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Short-term investments		0		0
Equities		840,318		1,621,019
Other invested assets		1,271,612		1,346,797
Total		2,111,930		2,967,816
Fair value based on NAV as practical expedient | Derivative assets | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Derivative assets | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Fair value based on NAV as practical expedient | Derivative assets | Insurance-linked securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Derivative assets | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Fair value based on NAV as practical expedient | Derivative assets | Options and warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Fair value based on NAV as practical expedient | Derivative assets | TBAs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0
Fair value based on NAV as practical expedient | Derivative assets | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Fair value based on NAV as practical expedient | Corporate loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Notes and loan receivables and notes securitization
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Derivative liabilities | Foreign exchange forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Derivative liabilities | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Derivative liabilities | Total return swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets				0
Fair value based on NAV as practical expedient | Real estate company investment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets		0		0
Fair value based on NAV as practical expedient | Real estate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Consumer noncyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0
Fair value based on NAV as practical expedient | Diversified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Consumer cyclical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Energy
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Finance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Industrials
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Insurance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		0		0
Fair value based on NAV as practical expedient | Fund investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equities		840,318		1,621,019	[3]
Other invested assets		1,271,612		1,346,797	[3]
Fair value based on NAV as practical expedient | U.S. government and government sponsored enterprises
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Fair value based on NAV as practical expedient | U.S. states, territories and municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Fair value based on NAV as practical expedient | Non US sovereign government supranational and government related
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Fair value based on NAV as practical expedient | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Fair value based on NAV as practical expedient | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		0		0
Fair value based on NAV as practical expedient | Residential mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturities, at fair value		$ 0		$ 0
[1] Corporate loans includes a portfolio of third-party, individually managed privately issued corporate loans that are managed under an externally managed mandate with a fair value of $1.0 billion and $1.0 billion at December 31, 2022 and 2021, respectively. The mandate primarily invests in U.S. floating rate, first lien, senior secured broadly syndicated loans with a focus on facility sizes greater than $300 million. Corporate loans also includes $0.3 billion and $0.4 billion of other privately issued corporate loans at December 31, 2022 and 2021, respectively .

Fair Value - Level 3 rollforwar

Fair Value - Level 3 rollforward (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		$ 1,010,025		$ 1,113,592
(Losses) gains included in net income		(82,798)		118,172
Purchases		80,126		86,764
Settlements and sales		(85,155)	[1]	(299,826)	[2]
Level 3 transfers, Net		6,354		(8,677)
Balance, end of year		928,552		1,010,025
Change in unrealized (losses) gains relating to assets held at end of year		$ (80,316)		$ 54,670
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Net (loss) income		Net (loss) income
Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Net realized and unrealized investment (losses) gains		Net realized and unrealized investment (losses) gains
Fixed maturities
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		$ 111,945		$ 154,535
(Losses) gains included in net income		(13,862)		(7,165)
Purchases		0		0
Settlements and sales		(33,406)	[1]	(35,425)	[2]
Level 3 transfers, Net		0		0
Balance, end of year		64,677		111,945
Change in unrealized (losses) gains relating to assets held at end of year		(14,108)		(8,818)
Sales		32,000		17,000
Fixed maturities | U.S. states, territories and municipalities
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		95,181		120,477
(Losses) gains included in net income		(13,862)		(7,330)
Purchases		0		0
Settlements and sales		(32,572)		(17,966)
Level 3 transfers, Net		0		0
Balance, end of year		48,747		95,181
Change in unrealized (losses) gains relating to assets held at end of year		(14,108)		(8,818)
Fixed maturities | Asset-backed securities
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		16,764		17,528
(Losses) gains included in net income		0		0
Purchases		0		0
Settlements and sales		(834)		(764)
Level 3 transfers, Net		0		0
Balance, end of year		15,930		16,764
Change in unrealized (losses) gains relating to assets held at end of year		0		0
Fixed maturities | Corporate bonds
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		0		16,530
(Losses) gains included in net income				165
Purchases				0
Settlements and sales				(16,695)
Level 3 transfers, Net				0
Balance, end of year				0
Change in unrealized (losses) gains relating to assets held at end of year				0
Short-term investments
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		0
(Losses) gains included in net income		0
Purchases		6,907
Settlements and sales		0
Level 3 transfers, Net		0
Balance, end of year		6,907		0
Change in unrealized (losses) gains relating to assets held at end of year		0
Equities
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year	[3]	23,756		51,422
(Losses) gains included in net income		(2,721)		63,045	[3]
Purchases		2,759		4,619	[3]
Settlements and sales		(494)	[1]	(90,929)	[2],[3]
Level 3 transfers, Net		0		(4,401)	[3]
Balance, end of year		23,300		23,756	[3]
Change in unrealized (losses) gains relating to assets held at end of year		(2,908)		6,681	[3]
Sales				91,000
Equities | Energy
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		2,368		34,448
(Losses) gains included in net income		(854)		54,509
Purchases		0		6
Settlements and sales		0		(86,595)
Level 3 transfers, Net		0		0
Balance, end of year		1,514		2,368
Change in unrealized (losses) gains relating to assets held at end of year		(854)		1,326
Sales				87,000
Equities | Consumer noncyclical
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		10,081		6,886
(Losses) gains included in net income		0		7,557
Purchases		0		0
Settlements and sales		0		0
Level 3 transfers, Net		0		(4,362)
Balance, end of year		10,081		10,081
Change in unrealized (losses) gains relating to assets held at end of year		0		4,522
Equities | Insurance
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		0		4,000
(Losses) gains included in net income				0
Purchases				0
Settlements and sales				(4,000)
Level 3 transfers, Net				0
Balance, end of year				0
Change in unrealized (losses) gains relating to assets held at end of year				0
Sales				4,000
Equities | Real estate
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		2,097		2,338
(Losses) gains included in net income		(283)		(241)
Purchases		0		0
Settlements and sales		0		0
Level 3 transfers, Net		0		0
Balance, end of year		1,814		2,097
Change in unrealized (losses) gains relating to assets held at end of year		(283)		(241)
Equities | Consumer cyclical
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		1,394		475
(Losses) gains included in net income		(1,366)		(916)
Purchases		0		1,835
Settlements and sales		0		0
Level 3 transfers, Net		0		0
Balance, end of year		28		1,394
Change in unrealized (losses) gains relating to assets held at end of year		(1,366)		(916)
Equities | Industrials
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		220		39
(Losses) gains included in net income		13		245
Purchases		0		309
Settlements and sales		(157)		(334)
Level 3 transfers, Net		0		(39)
Balance, end of year		76		220
Change in unrealized (losses) gains relating to assets held at end of year		(53)		99
Equities | Finance
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		128		138
(Losses) gains included in net income		(8)		(10)
Purchases		0		0
Settlements and sales		0		0
Level 3 transfers, Net		0		0
Balance, end of year		120		128
Change in unrealized (losses) gains relating to assets held at end of year		(8)		(10)
Equities | Diversified
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		7,468		3,098
(Losses) gains included in net income		(223)		1,901
Purchases		2,759		2,469
Settlements and sales		(337)		0
Level 3 transfers, Net		0		0
Balance, end of year		9,667		7,468
Change in unrealized (losses) gains relating to assets held at end of year		(344)		1,901
Other invested assets
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		874,324		907,635
(Losses) gains included in net income		(66,215)		62,292
Purchases		70,460		82,145
Settlements and sales		(51,255)	[1]	(173,472)	[2]
Level 3 transfers, Net		6,354		(4,276)
Balance, end of year		833,668		874,324
Change in unrealized (losses) gains relating to assets held at end of year		(63,300)		56,807
Sales		36,000		119,000
Other invested assets | Derivatives, net
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		7,796		(862)
(Losses) gains included in net income		1,929		5,718
Purchases		5,631		3,059
Settlements and sales		(8)		(119)
Level 3 transfers, Net		0		0
Balance, end of year		15,348		7,796
Change in unrealized (losses) gains relating to assets held at end of year		996		4,018
Other invested assets | Corporate loans
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year	[3]	287,527		374,556
(Losses) gains included in net income		1,443		(9,883)	[3]
Purchases		34,543		78,673	[3]
Settlements and sales		(42,589)		(151,543)	[3]
Level 3 transfers, Net		6,354		(4,276)	[3]
Balance, end of year		287,278		287,527	[3]
Change in unrealized (losses) gains relating to assets held at end of year		2,166		(6,844)	[3]
Sales		33,000
Other invested assets | Notes and loan receivables and notes securitization
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year		6,575		7,121
(Losses) gains included in net income		(594)		(71)
Purchases		0		21
Settlements and sales		(2,815)		(496)
Level 3 transfers, Net		0		0
Balance, end of year		3,166		6,575
Change in unrealized (losses) gains relating to assets held at end of year		2,301		(6,895)
Sales		3,000
Other invested assets | Fund investments
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year	[3]	11,739		32,810
(Losses) gains included in net income		92		(149)	[3]
Purchases		30,286		392	[3]
Settlements and sales		(5,843)		(21,314)	[3]
Level 3 transfers, Net		0		0	[3]
Balance, end of year		36,274		11,739	[3]
Change in unrealized (losses) gains relating to assets held at end of year		322		(149)	[3]
Other invested assets | Real estate company investment
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, beginning of year	[3]	560,687		494,010
(Losses) gains included in net income		(69,085)		66,677	[3]
Purchases		0		0	[3]
Settlements and sales		0		0	[3]
Level 3 transfers, Net		0		0	[3]
Balance, end of year		491,602		560,687	[3]
Change in unrealized (losses) gains relating to assets held at end of year		$ (69,085)		$ 66,677	[3]
[1]Included sales of Fixed maturities and Other invested assets of $32 million and $36 million, respectively. Sales of Fixed maturities were comprised of U.S. states, territories and municipalities. Sales of Other invested assets included sales of corporate loans of $33 million and sales of notes and loan receivables and notes securitization of $3 million.[2]Included sales of Fixed maturities, Equities and Other invested assets of $17 million, $91 million and $119 million, respectively. Sales of Fixed maturities were comprised of U.S. states, territories and municipalities. Sales of Equities included sales of $87 million in energy and $4 million in insurance. Sales of Other invested assets included sales of corporate loans.[3]The Level 3 reconciliation for the year ended December 31, 2021 has been recast to reflect the reclassification of certain investments within the fair value table as discussed above.

Fair Value - Valuation Techniqu

Fair Value - Valuation Technique and Inputs (Details) $ in Thousands	Dec. 31, 2022 USD ($) $ / ft²	Dec. 31, 2021 USD ($) $ / ft²
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, at fair value	$ 13,021,914	$ 14,071,274
Short-term investments, at fair value (amortized cost: 2021, $nil; 2020, $nil)	523,510	205,146
Other invested assets carried at fair value	3,117,861	3,317,260
Significant unobservable inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, at fair value	64,677	111,945
Short-term investments, at fair value (amortized cost: 2021, $nil; 2020, $nil)	6,907	0
Other invested assets carried at fair value	833,668	874,324
Real estate company investment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value	491,602	560,687	[1]
Real estate company investment | Significant unobservable inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value	491,602	560,687	[1]
U.S. states, territories and municipalities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, at fair value	58,873	108,059
U.S. states, territories and municipalities | Significant unobservable inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, at fair value	48,747	95,181
Fixed maturities | U.S. states, territories and municipalities | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, at fair value	$ 48,747	$ 95,181
Fixed maturities | U.S. states, territories and municipalities | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, measurement input	0.027	0.025
Fixed maturities | U.S. states, territories and municipalities | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, measurement input	0.036	2.545
Fixed maturities | U.S. states, territories and municipalities | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed maturities, measurement input	0.034	0.143
Short-term investments | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Short-term investments, at fair value (amortized cost: 2021, $nil; 2020, $nil)	$ 6,907
Short-term investments | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Short-Term Investments Measurement Input	0.025
Short-term investments | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Short-Term Investments Measurement Input	0.025
Short-term investments | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Short-Term Investments Measurement Input	0.025
Other invested assets | Insurance-linked securities longevity swaps | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value	$ 6,657	$ 5,663
Other invested assets | Insurance-linked securities longevity swaps | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives, measurement input	0.057	0.017
Other invested assets | Insurance-linked securities longevity swaps | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives, measurement input	0.057	0.017
Other invested assets | Insurance-linked securities longevity swaps | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives, measurement input	0.057	0.017
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value		$ 1,791
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input		0.175
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input		0.175
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input		0.175
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow | Gross revenue/fair value | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input		1.1
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow | Gross revenue/fair value | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input		1.1
Other invested assets | Notes and loan receivables | Significant unobservable inputs (Level 3) | Discounted cash flow | Gross revenue/fair value | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input		1.1
Other invested assets | Note securitization | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value	$ 188	$ 403
Other invested assets | Note securitization | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.025	0.025
Other invested assets | Note securitization | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.025	0.025
Other invested assets | Note securitization | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.025	0.025
Other invested assets | Fund investments | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value	$ 6,008	$ 8,832
Other invested assets | Fund investments | Significant unobservable inputs (Level 3) | Discounted cash flow | Effective yield | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.006	0.035
Other invested assets | Fund investments | Significant unobservable inputs (Level 3) | Discounted cash flow | Effective yield | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.006	0.035
Other invested assets | Fund investments | Significant unobservable inputs (Level 3) | Discounted cash flow | Effective yield | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.006	0.035
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Income Capitalization And Comparable Method Valuation Techniques
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value	$ 491,602	$ 560,687
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Estimated Rental Value | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input | $ / ft²	84	92
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Estimated Rental Value | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input | $ / ft²	90	100
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Estimated Rental Value | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input | $ / ft²	87	96
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Reversionary Yield | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.046	0.044
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Reversionary Yield | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.053	0.049
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Reversionary Yield | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.049	0.047
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Net Initial Yield | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.022	0.022
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Net Initial Yield | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.046	0.045
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation, Income Approach | Measurement Input Net Initial Yield | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input	0.039	0.039
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation Technique Comparable Method | Measurement Input, Appraised Value | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input | $ / ft²	1,617	1,763
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation Technique Comparable Method | Measurement Input, Appraised Value | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input | $ / ft²	5,459	5,916
Other invested assets | Real estate company investment | Significant unobservable inputs (Level 3) | Valuation Technique Comparable Method | Measurement Input, Appraised Value | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets, measurement input | $ / ft²	4,836	5,222
Derivative liabilities | Total return swaps | Significant unobservable inputs (Level 3) | Discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Other invested assets carried at fair value		$ (926)
Derivative liabilities | Total return swaps | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives, measurement input		0.024
Derivative liabilities | Total return swaps | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives, measurement input		0.413
Derivative liabilities | Total return swaps | Significant unobservable inputs (Level 3) | Discounted cash flow | Credit spreads | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives, measurement input		0.365
[1]A certain investment previously disclosed as equity method and excluded from the fair value table is now included and presented as a Level 3 investment in order to align the disclosure with the valuation methodology used by the Company. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. This revision is not considered to be material to previously issued financial statements. Accordingly, no changes were made to the prior period Consolidated Balance Sheet or Consolidated Statements of Operations.

Fair Value - Change in fair val

Fair Value - Change in fair value option table (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Option, Quantitative Disclosures [Line Items]
Change in unrealized gain/loss	$ (2,448,700)	$ (175,477)	$ 451,071
Fixed maturities and short term investments
Fair Value, Option, Quantitative Disclosures [Line Items]
Change in unrealized gain/loss	(1,807,048)	(558,466)	219,946
Equities
Fair Value, Option, Quantitative Disclosures [Line Items]
Change in unrealized gain/loss	(505,072)	198,780	167,456
Other invested assets
Fair Value, Option, Quantitative Disclosures [Line Items]
Change in unrealized gain/loss	$ (136,580)	$ 184,209	$ 63,669

Fair Value - Investments measur

Fair Value - Investments measured at fair value using NAV as a practical expedient (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	$ 2,111,930	$ 2,967,816
Remaining unfunded commitment	365,682	495,341
Equities	929,886	1,751,584
Other invested assets	3,117,861	3,317,260
Fair value based on NAV as practical expedient
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Equities	840,318	1,621,019
Other invested assets	1,271,612	1,346,797
Fund investments
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Equities	840,318	1,621,019	[1]
Other invested assets	1,307,886	1,358,536	[1]
Fund investments | Fair value based on NAV as practical expedient
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Equities	840,318	1,621,019	[1]
Other invested assets	1,271,612	1,346,797	[1]
Public equity funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	629,125	1,461,620
Remaining unfunded commitment	0	0
Public equity funds | Three years
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	$ 422,000
Public equity funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Notice period	30 days
Public equity funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Notice period	60 days
Private equity funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	$ 389,736	499,289
Remaining unfunded commitment	$ 150,458	195,871
Private equity funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Liquidating investment, period	5 years
Private equity funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Liquidating investment, period	10 years
Private credit funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	$ 404,065	294,760
Remaining unfunded commitment	$ 67,815	184,590
Private credit funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Liquidating investment, period	5 years
Private credit funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Liquidating investment, period	10 years
Multi-strategy funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	$ 689,004	712,147
Remaining unfunded commitment	147,409	114,880
Multi-strategy funds | Quarterly Redemption Rights
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Total fund investments	$ 314,000	$ 384,000
Notice period	60 days
Redemption restriction period	36 months
Multi-strategy funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Liquidating investment, period	5 years
Multi-strategy funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Liquidating investment, period	10 years
[1]The classification of fund investments was revised from Level 3 to "Fair values based on NAV practical expedient" in order to align the disclosure with the valuation methodology used by the Company. In addition, the classification of certain investments in corporate loans was revised from Level 3 to Level 2 to reflect the appropriate fair value hierarchy level for investments with quoted prices, and one investment was reclassified from corporate loans to fund investments. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. These revisions are not considered to be material to previously issued financial statements.

Fair Value - Narrative items (D

Fair Value - Narrative items (Details) $ in Thousands		12 Months Ended
		Dec. 31, 2022 USD ($) securities	Dec. 31, 2021 USD ($) securities
Fair Value - Other Details [Line Items]
Other invested assets carried at fair value		$ 3,117,861	$ 3,317,260
Other invested assets
Fair Value - Other Details [Line Items]
Equity method investments		237,000	$ 284,000
Other invested assets
Fair Value - Other Details [Line Items]
Equity method investments		237,000
Equities
Fair Value - Other Details [Line Items]
Number of securities transferred out of level 3 | securities			2
Transfers out of level 3			$ (4,000)
Individually managed private issue corporate loans
Fair Value - Other Details [Line Items]
Other invested assets carried at fair value		1,000,000	1,000,000
Minimum threshold for inclusion in managed loan portfolio		300,000	300,000
Other private issue corporate loans
Fair Value - Other Details [Line Items]
Other invested assets carried at fair value		300,000	400,000
Corporate loans
Fair Value - Other Details [Line Items]
Other invested assets carried at fair value	[1]	$ 1,302,807	$ 1,391,971
Corporate loans | Other invested assets
Fair Value - Other Details [Line Items]
Number of securities transferred into level 3 | securities		5	1
Transfers into level 3		$ 15,000	$ 3,000
Number of securities transferred out of level 3 | securities		5	4
Transfers out of level 3		$ (9,000)	$ (7,000)
[1] Corporate loans includes a portfolio of third-party, individually managed privately issued corporate loans that are managed under an externally managed mandate with a fair value of $1.0 billion and $1.0 billion at December 31, 2022 and 2021, respectively. The mandate primarily invests in U.S. floating rate, first lien, senior secured broadly syndicated loans with a focus on facility sizes greater than $300 million. Corporate loans also includes $0.3 billion and $0.4 billion of other privately issued corporate loans at December 31, 2022 and 2021, respectively .

Investments - Net Realized and

Investments - Net Realized and Unrealized Investment (Losses) Gains (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments [Abstract]
Net realized investment gains on fixed maturities and short-term investments	$ 859	$ 19,893	$ 24,828
Net realized investment gains on equities	461,041	78,501	21,538
Net realized investment gains (losses) on other invested assets	9,781	103,011	(30,436)
Net realized investment gains	471,681	201,405	15,930
Change in net unrealized investment (losses) gains on fixed maturities and short-term investments	(1,807,048)	(558,466)	219,946
Change in net unrealized investment (losses) gains on equities	(505,072)	198,780	167,456
Change in net unrealized investment (losses) gains on other invested assets	(123,694)	196,926	58,452
Net other realized and unrealized investment losses	(2,672)	(848)	(1,346)
Change in net unrealized investment (losses) gains	(2,438,486)	(163,608)	444,508
Impairment loss on investments in real estate	(2,209)	0	(6,119)
Net realized and unrealized investment (losses) gains	$ (1,969,014)	$ 37,797	$ 454,319

Investments - Investment Income

Investments - Investment Income (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net Investment Income [Line Items]
Net investment income		$ 398,348	$ 376,469	$ 360,668
Funds held interest rate, low end of range		0.10%	0.10%	0.10%
Funds held interest rate, high end of range		10.90%	7.30%	6.50%
Fixed maturities
Net Investment Income [Line Items]
Net investment income		$ 310,152	$ 301,391	$ 290,259
Short-term investments and cash and cash equivalents
Net Investment Income [Line Items]
Net investment income		17,477	4,860	12,000
Other invested assets
Net Investment Income [Line Items]
Net investment income		99,375	90,442	89,129
Equities
Net Investment Income [Line Items]
Net investment income		11,118	12,686	3,918
Funds held and other (1)
Net Investment Income [Line Items]
Net investment income	[1]	10,801	17,871	16,559
Investment Expenses
Net Investment Income [Line Items]
Net investment income		$ (50,575)	$ (50,781)	$ (51,197)
[1] The Company generally earns investment income on funds held by reinsured companies based upon a predetermined interest rate, either fixed contractually at the inception of the contract or based upon a recognized index. Interest rates ranged from 0.1% to 10.9%, 0.1% to 7.3% and 0.1% to 6.5% for the years ended December 31, 2022, 2021 and 2020, respectively.

Investments - Pledged assets an

Investments - Pledged assets and net payable receivable for securities purchased sold (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Pledged assets and net payable for securities purchased [Line Items]
Restricted cash and cash equivalents	$ 137,782	$ 104,971
Restricted securities	5,258,000	5,483,000
Other assets
Pledged assets and net payable for securities purchased [Line Items]
Receivable for securities sold	52,000	45,000
Accounts payable, accrued expenses, and other
Pledged assets and net payable for securities purchased [Line Items]
Payable for securities purchased	$ 149,000	$ 202,000

Investments - Equity Method Inv

Investments - Equity Method Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Other invested assets	$ 3,117,861	$ 3,317,260
Equity Method And Other Shareholdings, Carrying Value	1,856,000	1,862,000
Proceeds from Equity Method Investment, Distribution	2,000	10,000
Real estate company investment
Schedule of Equity Method Investments [Line Items]
Other invested assets	491,602	560,687	[1]
Almacantar Group S.A. | Real estate company investment
Schedule of Equity Method Investments [Line Items]
Other invested assets	492,000	561,000
Other invested assets
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 237,000	$ 284,000
Other invested assets | Almacantar Group S.A.
Schedule of Equity Method Investments [Line Items]
Ownership percentage	36%	36%
[1]A certain investment previously disclosed as equity method and excluded from the fair value table is now included and presented as a Level 3 investment in order to align the disclosure with the valuation methodology used by the Company. The comparative disclosures as of December 31, 2021 have been revised to align with the presentation at December 31, 2022. This revision is not considered to be material to previously issued financial statements. Accordingly, no changes were made to the prior period Consolidated Balance Sheet or Consolidated Statements of Operations.

Derivatives - Balance Sheet (De

Derivatives - Balance Sheet (Details) - USD ($)		Dec. 31, 2022	Dec. 31, 2021
Derivative [Line Items]
Asset derivatives at fair value	[1]	$ 29,889,000	$ 17,716,000
Liability derivatives at fair value	[1]	(17,489,000)	(18,225,000)
Derivatives designated as hedges
Derivative [Line Items]
Net notional exposure		0	0
Derivatives not designated as hedges
Derivative [Line Items]
Asset derivatives at fair value		29,889,000	17,716,000
Liability derivatives at fair value		(17,489,000)	(18,225,000)
Fair value		12,400,000	(509,000)
Derivatives not designated as hedges | Foreign exchange forward contracts
Derivative [Line Items]
Asset derivatives at fair value		13,705,000	8,841,000
Liability derivatives at fair value		(17,336,000)	(6,657,000)
Fair value		(3,631,000)	2,184,000
Net notional exposure		4,277,894,000	3,092,396,000
Derivatives not designated as hedges | Insurance-linked securities
Derivative [Line Items]
Asset derivatives at fair value	[2]	6,657,000	5,663,000
Liability derivatives at fair value	[2]	0	0
Fair value	[2]	6,657,000	5,663,000
Net notional exposure	[2]	16,937,000	15,200,000
Derivatives not designated as hedges | Total return swaps
Derivative [Line Items]
Asset derivatives at fair value			153,000
Liability derivatives at fair value			(1,079,000)
Fair value			(926,000)
Net notional exposure			31,519,000
Derivatives not designated as hedges | Interest rate swaps
Derivative [Line Items]
Asset derivatives at fair value	[3]	258,000	0
Liability derivatives at fair value	[3]	(153,000)	(10,489,000)
Fair value	[3]	105,000	(10,489,000)
Net notional exposure	[3]	0	0
Derivatives not designated as hedges | TBAs
Derivative [Line Items]
Asset derivatives at fair value		578,000
Liability derivatives at fair value		0
Fair value		578,000
Net notional exposure		0
Derivatives not designated as hedges | Other Investments
Derivative [Line Items]
Asset derivatives at fair value		8,691,000	3,059,000
Liability derivatives at fair value		0	0
Fair value		8,691,000	3,059,000
Net notional exposure		$ 8,815,000	$ 0
[1]Amounts include all derivative instruments, irrespective of whether there is a legally enforceable master netting arrangement in place.[2]Insurance-linked securities include longevity swaps for which the notional amounts are not reflective of the overall potential exposure of the swaps. The net notional exposure above includes the Company's best estimate of the present value of future expected claims.[3]The Company enters into interest rate swaps to mitigate notional exposures on certain total return swaps and certain fixed maturities. The net notional exposure for interest rate swaps above relates to fixed maturities.

Derivatives - Income Statement

Derivatives - Income Statement (Details) - Derivatives not designated as hedges - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net foreign exchange losses	$ (34,902)	$ (16,788)	$ (32,611)
Total included in Net realized and unrealized investment gains (losses)	13,554	12,903	(7,451)
Total derivatives not designated as hedges	(21,348)	(3,885)	(40,062)
Foreign exchange forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net foreign exchange losses	(34,902)	(16,788)	(32,611)
Insurance-linked securities
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net realized and unrealized investment gains (losses)	2,049	4,807	(2,341)
Total return swaps
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net realized and unrealized investment gains (losses)	934	1,430	(845)
Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net realized and unrealized investment gains (losses)	10,594	7,020	(5,131)
TBAs
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net realized and unrealized investment gains (losses)	(23)	(56)	(510)
Other
Derivative Instruments, Gain (Loss) [Line Items]
Total included in Net realized and unrealized investment gains (losses)	$ 0	$ (298)	$ 1,376

Derivatives - Offsetting (Detai

Derivatives - Offsetting (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross amounts of recognized, asset	[1]	$ 29,889	$ 17,716
Gross amount offset in the balance sheet		0	0
Net amounts of asset/ liabilities presented in the balance sheet, asset		29,889	17,716
Gross amounts not offset in the balance sheet, financial instruments, asset		(258)	0
Gross amounts not offset in the balance sheet, cash collateral received/ pledged		(37,262)	(34,764)
Net amount, asset		(7,631)	(17,048)
Gross amounts of recognized, liability	[1]	(17,489)	(18,225)
Gross amount offset in the balance sheet		0	0
Net amounts presented in the balance sheet, liability		(17,489)	(18,225)
Gross amounts not offset in the balance sheet, financial instruments, liability		258	0
Gross amounts not offset in the balance sheet, cash collateral received		15,978	1,671
Net amount, liability		$ (1,253)	$ (16,554)
[1]Amounts include all derivative instruments, irrespective of whether there is a legally enforceable master netting arrangement in place.

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill And Intangible Assets [Line Items]
Balance at beginning of year	$ 456,380	$ 456,380	$ 456,380
Foreign currency translation	0	0	0
Balance at end of year	456,380	456,380	456,380
Balance at beginning of year	98,818	107,669	117,538
Total foreign currency translation	(137)	10	119
Amortization of intangible assets	(8,912)	(8,861)	(9,988)
Balance at end of year	89,769	98,818	107,669
Definite-lived intangible assets
Goodwill And Intangible Assets [Line Items]
Balance at beginning of year	89,263	98,114	107,983
Foreign currency translation	(137)	10	119
Amortization of intangible assets	(8,912)	(8,861)	(9,988)
Balance at end of year	80,214	89,263	98,114
Indefinite-lived intangible assets
Goodwill And Intangible Assets [Line Items]
Balance at beginning of year	9,555	9,555	9,555
Foreign currency translation	0	0	0
Balance at end of year	$ 9,555	$ 9,555	$ 9,555

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Gross Values And Amortization Of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill And Intangible Assets [Line Items]
Gross intangible assets excluding goodwill	$ 200,912	$ 201,049
Accumulated amortization	(111,143)	(102,231)
Intangible assets	89,769	98,818	$ 107,669	$ 117,538
Definite-lived intangible assets
Goodwill And Intangible Assets [Line Items]
Gross intangible assets excluding goodwill	191,357	191,494
Accumulated amortization	(111,143)	(102,231)
Intangible assets	80,214	89,263	98,114	107,983
Definite-lived intangible assets | Renewal rights
Goodwill And Intangible Assets [Line Items]
Gross intangible assets excluding goodwill	48,163	48,163
Accumulated amortization	(43,032)	(40,786)
Intangible assets	5,131	7,377
Definite-lived intangible assets | Customer relationships
Goodwill And Intangible Assets [Line Items]
Gross intangible assets excluding goodwill	67,611	67,748
Accumulated amortization	(56,850)	(52,661)
Intangible assets	10,761	15,087
Definite-lived intangible assets | Life VOBA
Goodwill And Intangible Assets [Line Items]
Gross intangible assets excluding goodwill	75,583	75,583
Accumulated amortization	(11,261)	(8,784)
Intangible assets	$ 64,322	66,799
Estimated useful life of intangible assets	100 years
Indefinite-lived intangible assets
Goodwill And Intangible Assets [Line Items]
Intangible assets	$ 9,555	9,555	$ 9,555	$ 9,555
Indefinite-lived intangible assets | Licensing Agreements
Goodwill And Intangible Assets [Line Items]
Gross intangible assets excluding goodwill	9,555	9,555
Intangible assets	$ 9,555	$ 9,555
Minimum | Definite-lived intangible assets | Renewal rights
Goodwill And Intangible Assets [Line Items]
Estimated useful life of intangible assets	10 years
Minimum | Definite-lived intangible assets | Customer relationships
Goodwill And Intangible Assets [Line Items]
Estimated useful life of intangible assets	10 years
Maximum | Definite-lived intangible assets | Renewal rights
Goodwill And Intangible Assets [Line Items]
Estimated useful life of intangible assets	13 years
Maximum | Definite-lived intangible assets | Customer relationships
Goodwill And Intangible Assets [Line Items]
Estimated useful life of intangible assets	13 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Allocation to Segments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill allocation to segments
Goodwill	$ 456,380	$ 456,380	$ 456,380	$ 456,380
P&C
Goodwill allocation to segments
Goodwill	242,376	242,376
Specialty
Goodwill allocation to segments
Goodwill	196,047	196,047
Life and Health
Goodwill allocation to segments
Goodwill	$ 17,957	$ 17,957

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Future Amortization of Finite Intangibles (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Estimated amortization expense
2023	$ 7,913
2024	7,256
2025	6,437
2026	2,294
2027	2,640
Thereafter	53,674
Total	80,214
VOBA
Estimated amortization expense
2023	2,272
2024	2,296
2025	2,070
2026	1,892
2027	2,238
Thereafter	53,554
Total	64,322
Other definite- lived intangible assets
Estimated amortization expense
2023	5,641
2024	4,960
2025	4,367
2026	402
2027	402
Thereafter	120
Total	$ 15,892

Non-life and Life and Health _3

Non-life and Life and Health Reserves - Components of Non-life reserves (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components of non-life reserves [Line Items]
Non-life reserves	$ 12,725,631	$ 12,047,792
Non Life
Components of non-life reserves [Line Items]
Case reserves	5,110,575	4,881,892
ACRs	159,821	140,464
IBNR reserves	7,455,235	7,025,436
Non-life reserves	$ 12,725,631	$ 12,047,792	$ 11,395,321	$ 10,363,383

Non-life and Life and Health _4

Non-life and Life and Health Reserves - Non Life loss and loss expenses rollforward (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Gross liability at beginning of year			$ 12,047,792
Reinsurance recoverable at beginning of year			1,787,493
Net paid losses related to:
Reinsurance recoverable at end of year			1,959,652	$ 1,787,493
Gross liability at end of year			12,725,631	12,047,792
Non Life
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Gross liability at beginning of year			12,047,792	11,395,321	$ 10,363,383
Reinsurance recoverable at beginning of year			1,532,666	782,330	754,795
Net liability at beginning of year			10,515,126	10,612,991	9,608,588
Net incurred losses related to:
Current year			3,533,087	3,637,671	3,945,248
Prior years			(219,853)	(194,426)	71,456
Net incurred losses			3,313,234	3,443,245	4,016,704
Net paid losses related to:
Current year			(419,633)	(437,938)	(459,718)
Prior years			(2,238,503)	(2,535,057)	(2,772,886)
Total Non-life Claims Paid			(2,658,136)	(2,972,995)	(3,232,604)
Retroactive reinsurance recoverable		$ (81,000)	(35,695)	(357,864)	0
Effects of foreign exchange rate changes and other			(260,709)	(210,251)	220,303
Net liability at end of year	$ 10,612,991	9,608,588	10,873,820	10,515,126	10,612,991
Reinsurance recoverable at end of year	782,330	754,795	1,851,811	1,532,666	782,330
Gross liability at end of year	11,395,321	$ 10,363,383	12,725,631	12,047,792	11,395,321
Loss portfolio transfer, reinsurance recoverable, amount			394,000	358,000
Loss portfolio transfer and adverse development cover agreement deferred gain			$ 47,000	$ 20,000
Loss portfolio transfer agreement percentage		100%
Wholesale transaction deferred gain		$ 14,000
Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments wholesale transaction	70,000
Liability for Claims and Claims Adjustment Expense wholesale transaction	$ 70,000				70,000
Wholesale transaction gain					14,000
Portfolio Transfer Settlement, Invested Assets Amount					$ 64,000

Non-life and Life and Health _5

Non-life and Life and Health Reserves - Asbestos, and environmental claims (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense [Abstract]
Net non-life reserves related to asbestos and environmental claims	$ 42	$ 44
Gross non-life reserves related to asbestos and environmental claims	$ 49	$ 52

Non-life and Life and Health _6

Non-life and Life and Health Reserves - Life and health reserve rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Reconciliation of Loss and Loss Expenses Including Life Policy Benefits [Line Items]
Reinsurance recoverable at beginning of year	$ 1,787,493
Reinsurance recoverable at end of year	1,959,652		$ 1,787,493
Life and Health
Reconciliation of Loss and Loss Expenses Including Life Policy Benefits [Line Items]
Gross liability at beginning of period	2,638,086		2,704,229		$ 2,417,044
Reinsurance recoverable at beginning of year	21,000		35,662		16,183
Net liability at beginning of period	2,617,086		2,668,567		2,400,861
Net incurred losses	1,434,169	[1]	1,440,739	[1]	1,318,196
Net losses paid	(1,390,848)		(1,413,316)		(1,230,383)
Effects of foreign exchange rate changes and other	(181,789)		(78,904)		179,893
Net liability at end of period	2,478,618		2,617,086		2,668,567
Reinsurance recoverable at end of year	31,675		21,000		35,662
Gross liability at end of period	2,510,293		2,638,086		2,704,229
Treaties recaptured gains	15,000		28,000
Life and Health | Disability
Reconciliation of Loss and Loss Expenses Including Life Policy Benefits [Line Items]
Prior years' loss development	$ 46,000		$ (5,000)		$ 52,000
Life and Health | Minimum
Reconciliation of Loss and Loss Expenses Including Life Policy Benefits [Line Items]
Interest rate assumption related to policy benefits for life and annuity contracts	0%		0%		0%
Life and Health | Maximum
Reconciliation of Loss and Loss Expenses Including Life Policy Benefits [Line Items]
Interest rate assumption related to policy benefits for life and annuity contracts	11%		11%		11%
[1]During 2021 and 2020, certain life and health treaties were recaptured, resulting in total gains upon recapture of $15 million and $28 million respectively, recorded as a reduction to net incurred losses.

Non-life and Life and Health _7

Non-life and Life and Health Reserves - Loss and loss expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Losses and Loss Expenses by Segment [Line Items]
Losses and loss expenses	$ 4,747,403	$ 4,883,984	$ 5,334,900
Non Life
Losses and Loss Expenses by Segment [Line Items]
Losses and loss expenses	3,313,234	3,443,245	4,016,704
Life and Health
Losses and Loss Expenses by Segment [Line Items]
Losses and loss expenses	$ 1,434,169	$ 1,440,739	$ 1,318,196

Non-life and Life and Health _8

Non-life and Life and Health Reserves - Claims development (Details) - Non Life - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Claims Development [Line Items]
Net incurred losses and loss expenses	$ 28,314,605
Net paid losses and loss expenses	18,981,132
Net reserves for accident years and exposures included in the triangles	9,333,473
All outstanding liabilities before accident year 2013, net of reinsurance	1,239,090
Net liability at end of year	10,572,563
Total of IBNR plus expected development on reported claims	$ 6,203,312
Average annual percentage payout of incurred claims by age:
Year One	13%
Year Two	33%
Year Three	15%
Year Four	10%
Year Five	6%
Year Six	4%
Year Seven	3%
Year Eight	2%
Year Nine	1%
Year Ten	1%
2013
Claims Development [Line Items]
Net incurred losses and loss expenses	$ 2,242,254	$ 2,262,098	$ 2,276,767	$ 2,301,835	$ 2,313,004	$ 2,787,608	$ 3,277,749	$ 2,400,977	$ 2,722,788	$ 2,664,745
Net paid losses and loss expenses	2,146,574	2,121,980	2,097,390	2,061,865	1,997,543	1,900,282	1,771,134	1,577,293	1,237,315	267,413
Total of IBNR plus expected development on reported claims	23,890
2014
Claims Development [Line Items]
Net incurred losses and loss expenses	2,232,454	2,262,546	2,277,135	2,315,021	2,353,759	2,349,869	2,368,967	2,514,200	2,481,720
Net paid losses and loss expenses	2,196,720	2,164,676	2,118,939	2,044,804	1,946,054	1,810,171	1,594,146	1,291,273	336,270
Total of IBNR plus expected development on reported claims	35,019
2015
Claims Development [Line Items]
Net incurred losses and loss expenses	2,432,324	2,451,141	2,475,960	2,520,182	2,550,830	2,527,784	2,611,184	2,502,854
Net paid losses and loss expenses	2,198,481	2,142,234	2,067,935	1,959,722	1,798,537	1,564,173	1,159,655	306,562
Total of IBNR plus expected development on reported claims	89,338
2016
Claims Development [Line Items]
Net incurred losses and loss expenses	2,476,383	2,484,069	2,467,920	2,486,199	2,516,126	2,559,851	2,451,204
Net paid losses and loss expenses	2,211,977	2,123,169	2,030,728	1,893,694	1,627,697	1,272,443	321,351
Total of IBNR plus expected development on reported claims	130,477
2017
Claims Development [Line Items]
Net incurred losses and loss expenses	2,658,571	2,663,904	2,651,730	2,698,916	2,801,179	2,549,737
Net paid losses and loss expenses	2,314,529	2,195,236	2,072,838	1,804,959	1,421,140	394,394
Total of IBNR plus expected development on reported claims	179,473
2018
Claims Development [Line Items]
Net incurred losses and loss expenses	3,009,359	2,972,766	2,969,810	2,974,243	2,596,552
Net paid losses and loss expenses	2,283,931	2,093,543	1,811,055	1,276,542	271,827
Total of IBNR plus expected development on reported claims	387,763
2019
Claims Development [Line Items]
Net incurred losses and loss expenses	3,523,443	3,510,991	3,519,556	2,931,280
Net paid losses and loss expenses	2,341,116	1,961,928	1,438,793	462,939
Total of IBNR plus expected development on reported claims	681,501
2020
Claims Development [Line Items]
Net incurred losses and loss expenses	3,499,097	3,586,462	4,186,395
Net paid losses and loss expenses	1,805,063	1,277,034	480,122
Total of IBNR plus expected development on reported claims	976,332
2021
Claims Development [Line Items]
Net incurred losses and loss expenses	2,829,876	2,880,141
Net paid losses and loss expenses	1,088,143	373,191
Total of IBNR plus expected development on reported claims	1,580,019
Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Net incurred losses and loss expenses	3,410,844
Net paid losses and loss expenses	394,598
Total of IBNR plus expected development on reported claims	2,119,500
Property
Claims Development [Line Items]
Net incurred losses and loss expenses	7,390,912
Net paid losses and loss expenses	5,457,671
Net reserves for accident years and exposures included in the triangles	1,933,241
All outstanding liabilities before accident year 2013, net of reinsurance	122,792
Net liability at end of year	2,056,033
Total of IBNR plus expected development on reported claims	$ 959,162
Average annual percentage payout of incurred claims by age:
Year One	15%
Year Two	47%
Year Three	16%
Year Four	6%
Year Five	2%
Year Six	1%
Year Seven	1%
Year Eight	0%
Year Nine	0%
Year Ten	0%
Property | 2013
Claims Development [Line Items]
Net incurred losses and loss expenses	$ 485,091	487,571	489,268	490,699	492,673	500,527	505,636	519,883	560,072	622,984
Net paid losses and loss expenses	479,578	479,023	479,094	477,180	472,517	469,346	453,191	419,541	320,510	90,086
Total of IBNR plus expected development on reported claims	421
Property | 2014
Claims Development [Line Items]
Net incurred losses and loss expenses	444,808	447,894	447,816	450,487	452,907	458,609	463,409	488,446	469,568
Net paid losses and loss expenses	445,375	444,798	442,581	438,152	432,567	423,339	395,102	323,309	95,013
Total of IBNR plus expected development on reported claims	588
Property | 2015
Claims Development [Line Items]
Net incurred losses and loss expenses	523,475	525,203	519,568	524,147	528,106	537,792	565,816	537,193
Net paid losses and loss expenses	501,524	498,557	489,195	481,879	469,036	435,539	330,876	85,015
Total of IBNR plus expected development on reported claims	1,175
Property | 2016
Claims Development [Line Items]
Net incurred losses and loss expenses	623,593	624,375	622,562	625,873	644,349	681,050	663,490
Net paid losses and loss expenses	609,257	604,980	595,159	579,381	538,988	446,804	132,914
Total of IBNR plus expected development on reported claims	2,622
Property | 2017
Claims Development [Line Items]
Net incurred losses and loss expenses	910,105	915,166	923,025	952,613	1,022,186	971,607
Net paid losses and loss expenses	870,638	862,942	853,945	805,627	694,240	214,026
Total of IBNR plus expected development on reported claims	3,934
Property | 2018
Claims Development [Line Items]
Net incurred losses and loss expenses	766,591	778,867	799,735	820,675	805,960
Net paid losses and loss expenses	687,439	666,919	628,458	494,608	81,830
Total of IBNR plus expected development on reported claims	10,844
Property | 2019
Claims Development [Line Items]
Net incurred losses and loss expenses	711,928	720,079	782,453	703,097
Net paid losses and loss expenses	586,587	545,163	426,566	78,527
Total of IBNR plus expected development on reported claims	45,376
Property | 2020
Claims Development [Line Items]
Net incurred losses and loss expenses	1,061,772	1,070,935	1,252,575
Net paid losses and loss expenses	681,851	515,030	115,165
Total of IBNR plus expected development on reported claims	134,726
Property | 2021
Claims Development [Line Items]
Net incurred losses and loss expenses	918,629	919,517
Net paid losses and loss expenses	491,546	121,453
Total of IBNR plus expected development on reported claims	202,188
Property | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Net incurred losses and loss expenses	944,920
Net paid losses and loss expenses	103,876
Total of IBNR plus expected development on reported claims	557,288
Casualty
Claims Development [Line Items]
Net incurred losses and loss expenses	9,352,855
Net paid losses and loss expenses	4,739,470
Net reserves for accident years and exposures included in the triangles	4,613,385
All outstanding liabilities before accident year 2013, net of reinsurance	1,023,715
Net liability at end of year	5,637,100
Total of IBNR plus expected development on reported claims	$ 3,731,440
Average annual percentage payout of incurred claims by age:
Year One	8%
Year Two	14%
Year Three	13%
Year Four	13%
Year Five	12%
Year Six	9%
Year Seven	7%
Year Eight	5%
Year Nine	3%
Year Ten	3%
Casualty | 2013
Claims Development [Line Items]
Net incurred losses and loss expenses	$ 678,905	691,195	695,346	714,114	726,420	732,716	734,732	757,402	853,023	747,448
Net paid losses and loss expenses	578,496	558,218	533,983	510,855	470,029	410,241	339,320	260,249	152,575	49,468
Total of IBNR plus expected development on reported claims	19,235
Casualty | 2014
Claims Development [Line Items]
Net incurred losses and loss expenses	739,605	753,383	766,415	791,768	826,000	810,349	814,622	848,698	804,571
Net paid losses and loss expenses	654,893	631,367	594,035	536,883	470,964	387,182	292,152	189,458	69,119
Total of IBNR plus expected development on reported claims	28,354
Casualty | 2015
Claims Development [Line Items]
Net incurred losses and loss expenses	714,608	726,451	751,652	770,242	803,497	761,091	783,275	699,327
Net paid losses and loss expenses	667,748	627,964	577,907	505,067	398,790	303,213	184,520	73,252
Total of IBNR plus expected development on reported claims	76,827
Casualty | 2016
Claims Development [Line Items]
Net incurred losses and loss expenses	747,402	750,268	740,047	747,814	767,366	756,954	670,767
Net paid losses and loss expenses	586,050	520,069	455,982	369,651	244,560	140,081	28,304
Total of IBNR plus expected development on reported claims	103,979
Casualty | 2017
Claims Development [Line Items]
Net incurred losses and loss expenses	720,732	716,862	709,881	720,966	743,114	621,095
Net paid losses and loss expenses	488,164	411,806	334,296	246,615	157,792	55,617
Total of IBNR plus expected development on reported claims	136,389
Casualty | 2018
Claims Development [Line Items]
Net incurred losses and loss expenses	920,169	903,353	895,978	905,491	767,559
Net paid losses and loss expenses	532,717	425,887	323,510	201,190	59,105
Total of IBNR plus expected development on reported claims	258,229
Casualty | 2019
Claims Development [Line Items]
Net incurred losses and loss expenses	1,273,687	1,272,980	1,226,210	999,955
Net paid losses and loss expenses	580,304	430,192	274,821	100,639
Total of IBNR plus expected development on reported claims	519,757
Casualty | 2020
Claims Development [Line Items]
Net incurred losses and loss expenses	1,094,890	1,115,751	1,344,430
Net paid losses and loss expenses	304,592	176,740	112,281
Total of IBNR plus expected development on reported claims	624,521
Casualty | 2021
Claims Development [Line Items]
Net incurred losses and loss expenses	967,726	1,013,896
Net paid losses and loss expenses	225,846	80,434
Total of IBNR plus expected development on reported claims	920,590
Casualty | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Net incurred losses and loss expenses	1,495,131
Net paid losses and loss expenses	120,660
Total of IBNR plus expected development on reported claims	1,043,559
Specialty
Claims Development [Line Items]
Net incurred losses and loss expenses	11,570,838
Net paid losses and loss expenses	8,783,991
Net reserves for accident years and exposures included in the triangles	2,786,847
All outstanding liabilities before accident year 2013, net of reinsurance	92,583
Net liability at end of year	2,879,430
Total of IBNR plus expected development on reported claims	$ 1,512,710
Average annual percentage payout of incurred claims by age:
Year One	15%
Year Two	39%
Year Three	16%
Year Four	10%
Year Five	4%
Year Six	3%
Year Seven	1%
Year Eight	1%
Year Nine	0%
Year Ten	0%
Specialty | 2013
Claims Development [Line Items]
Net incurred losses and loss expenses	$ 1,078,258	1,083,332	1,092,153	1,097,022	1,093,911	1,554,365	2,037,381	1,123,692	1,309,693	1,294,313
Net paid losses and loss expenses	1,088,500	1,084,739	1,084,313	1,073,830	1,054,997	1,020,695	978,623	897,503	764,230	$ 127,859
Total of IBNR plus expected development on reported claims	4,234
Specialty | 2014
Claims Development [Line Items]
Net incurred losses and loss expenses	1,048,041	1,061,269	1,062,904	1,072,766	1,074,852	1,080,911	1,090,936	1,177,056	1,207,581
Net paid losses and loss expenses	1,096,452	1,088,511	1,082,323	1,069,769	1,042,523	999,650	906,892	778,506	$ 172,138
Total of IBNR plus expected development on reported claims	6,077
Specialty | 2015
Claims Development [Line Items]
Net incurred losses and loss expenses	1,194,241	1,199,487	1,204,740	1,225,793	1,219,227	1,228,901	1,262,093	1,266,334
Net paid losses and loss expenses	1,029,209	1,015,713	1,000,833	972,776	930,711	825,421	644,259	$ 148,295
Total of IBNR plus expected development on reported claims	11,336
Specialty | 2016
Claims Development [Line Items]
Net incurred losses and loss expenses	1,105,388	1,109,426	1,105,311	1,112,512	1,104,411	1,121,847	1,116,947
Net paid losses and loss expenses	1,016,670	998,120	979,587	944,662	844,149	685,558	$ 160,133
Total of IBNR plus expected development on reported claims	23,876
Specialty | 2017
Claims Development [Line Items]
Net incurred losses and loss expenses	1,027,734	1,031,876	1,018,824	1,025,337	1,035,879	957,035
Net paid losses and loss expenses	955,727	920,488	884,597	752,717	569,108	$ 124,751
Total of IBNR plus expected development on reported claims	39,150
Specialty | 2018
Claims Development [Line Items]
Net incurred losses and loss expenses	1,322,599	1,290,546	1,274,097	1,248,077	1,023,033
Net paid losses and loss expenses	1,063,775	1,000,737	859,087	580,744	$ 130,892
Total of IBNR plus expected development on reported claims	118,690
Specialty | 2019
Claims Development [Line Items]
Net incurred losses and loss expenses	1,537,828	1,517,932	1,510,893	1,228,228
Net paid losses and loss expenses	1,174,225	986,573	737,406	$ 283,773
Total of IBNR plus expected development on reported claims	116,368
Specialty | 2020
Claims Development [Line Items]
Net incurred losses and loss expenses	1,342,435	1,399,776	1,589,390
Net paid losses and loss expenses	818,620	585,264	$ 252,676
Total of IBNR plus expected development on reported claims	217,085
Specialty | 2021
Claims Development [Line Items]
Net incurred losses and loss expenses	943,521	946,728
Net paid losses and loss expenses	370,751	$ 171,304
Total of IBNR plus expected development on reported claims	457,241
Specialty | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Net incurred losses and loss expenses	970,793
Net paid losses and loss expenses	170,062
Total of IBNR plus expected development on reported claims	$ 518,653

Non-life and Life and Health _9

Non-life and Life and Health Reserves - Reconciliation of claims development to liability (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Reinsurance recoverable on paid and unpaid losses		$ 1,959,652	$ 1,787,493
Gross liability at end of year		12,725,631	12,047,792
Non Life
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Total outstanding liability for unpaid claims		10,572,563
Other liabilities		301,257
Net liability at end of year		10,873,820	10,515,126	$ 10,612,991	$ 9,608,588
Reinsurance recoverable on paid and unpaid losses		1,851,811	1,532,666	782,330	754,795
Gross liability at end of year		12,725,631	$ 12,047,792	$ 11,395,321	$ 10,363,383
Non Life | Unallocated loss expenses
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Other liabilities		119,274
Non Life | US Health net reserves
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Other liabilities	[1]	168,146
Non Life | Other
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Other liabilities		13,837
Non Life | Property
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Total outstanding liability for unpaid claims		2,056,033
Reinsurance recoverable on paid and unpaid losses		922,141
Non Life | Casualty
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Total outstanding liability for unpaid claims		5,637,100
Reinsurance recoverable on paid and unpaid losses		585,737
Non Life | Specialty
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Total outstanding liability for unpaid claims		2,879,430
Reinsurance recoverable on paid and unpaid losses		$ 343,933
[1]U.S. health business is not meaningful to include in the development tables as the estimated average duration of the health reserves is less than one year and substantially all claims are expected to be paid within two years, based on historical payout patterns.

Reinsurance (Narrative) (Detail

Reinsurance (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Reinsurance Disclosures [Abstract]
Allowance for credit loss on reinsurance recoverable	$ 3	$ 3

Reinsurance (Details)

Reinsurance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Premiums Written, Net [Abstract]
Gross premiums written	$ 8,689,279	$ 8,203,925	$ 6,875,925
Ceded Premiums Written	1,145,084	1,069,907	575,067
Net premiums written	7,544,195	7,134,018	6,300,858
Premiums Earned, Net [Abstract]
Assumed from other companies	8,370,860	7,925,903	7,077,020
Ceded to other companies	1,113,743	969,381	540,194
Net premiums earned	7,257,117	6,956,522	6,536,826
Loss and Loss Expenses and Life Policy Benefits
Assumed losses and loss expenses	5,501,284	5,666,530	5,703,092
Ceded losses and loss expenses	753,881	782,546	368,192
Losses and loss expenses	4,747,403	4,883,984	5,334,900
Reinsurance recoverable on paid and unpaid losses	1,959,652	1,787,493
Affiliated Entity | Lorenz Re
Premiums Written, Net [Abstract]
Ceded Premiums Written	664,000	634,000	81,000
Loss and Loss Expenses and Life Policy Benefits
Reinsurance recoverable on paid and unpaid losses	921,000	592,000
Non Life
Premiums Written, Net [Abstract]
Gross premiums written	7,015,422	6,557,055	5,376,703
Ceded Premiums Written	1,116,672	1,046,227	550,784
Net premiums written	5,898,750	5,510,828	4,825,919
Premiums Earned, Net [Abstract]
Assumed from other companies	6,696,769	6,274,418	5,571,201
Ceded to other companies	1,085,317	944,862	516,672
Net premiums earned	5,611,452	5,329,556	5,054,529
Loss and Loss Expenses and Life Policy Benefits
Assumed losses and loss expenses	4,024,931	4,212,465	4,358,975
Ceded losses and loss expenses	711,697	769,220	342,271
Losses and loss expenses	3,313,234	3,443,245	4,016,704
Reinsurance recoverable on paid and unpaid losses	1,851,811	1,532,666	782,330	$ 754,795
Life and Health
Premiums Written, Net [Abstract]
Gross premiums written	1,673,857	1,646,870	1,499,222
Ceded Premiums Written	28,412	23,680	24,283
Net premiums written	1,645,445	1,623,190	1,474,939
Premiums Earned, Net [Abstract]
Assumed from other companies	1,674,091	1,651,485	1,505,819
Ceded to other companies	28,426	24,519	23,522
Net premiums earned	1,645,665	1,626,966	1,482,297
Loss and Loss Expenses and Life Policy Benefits
Assumed losses and loss expenses	1,476,353	1,454,065	1,344,117
Ceded losses and loss expenses	42,184	13,326	25,921
Losses and loss expenses	1,434,169	1,440,739	1,318,196
Reinsurance recoverable on paid and unpaid losses	$ 31,675	$ 21,000	$ 35,662	$ 16,183

Debt - Summary of debt outstand

Debt - Summary of debt outstanding (Details) $ in Thousands, € in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Sep. 30, 2016 EUR (€)	Nov. 30, 2006 USD ($)
Debt Instrument [Line Items]
Debt	$ 1,848,003	$ 1,897,499
Fair Value
Debt Instrument [Line Items]
Debt	1,666,825	2,024,995
Carrying Value
Debt Instrument [Line Items]
Debt	1,848,003	1,897,499
Senior Notes | 3.7% notes maturing 2029 Issued By PartnerRe Finance B LLC
Debt Instrument [Line Items]
Commitment				$ 500,000
Senior Notes | 3.7% notes maturing 2029 Issued By PartnerRe Finance B LLC | Fair Value
Debt Instrument [Line Items]
Debt related to senior notes	462,521	561,099
Senior Notes | 3.7% notes maturing 2029 Issued By PartnerRe Finance B LLC | Carrying Value
Debt Instrument [Line Items]
Debt related to senior notes	497,073	496,620
2016 Euro Senior Notes | Notes Issued By PartnerRe Ireland Finance DAC
Debt Instrument [Line Items]
Commitment | €					€ 750
2016 Euro Senior Notes | Notes Issued By PartnerRe Ireland Finance DAC | Fair Value
Debt Instrument [Line Items]
Debt related to senior notes	721,807	882,126
2016 Euro Senior Notes | Notes Issued By PartnerRe Ireland Finance DAC | Carrying Value
Debt Instrument [Line Items]
Debt related to senior notes	794,368	843,950
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC
Debt Instrument [Line Items]
Commitment			$ 500,000
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC | Fair Value
Debt Instrument [Line Items]
Junior Subordinated Notes	428,250	526,522
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC | Carrying Value
Debt Instrument [Line Items]
Junior Subordinated Notes	494,638	494,445
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc
Debt Instrument [Line Items]
Commitment	61,924	62,000				$ 250,000
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc | Fair Value
Debt Instrument [Line Items]
Junior Subordinated Notes	54,247	55,248
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc | Carrying Value
Debt Instrument [Line Items]
Junior Subordinated Notes	$ 61,924	$ 62,484

Debt - Narrative (Details)

Debt - Narrative (Details) $ in Thousands, € in Millions		1 Months Ended					12 Months Ended
	Dec. 01, 2016	Dec. 31, 2022 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Sep. 30, 2016 EUR (€)	Mar. 31, 2009 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021	Nov. 30, 2006 USD ($)
Senior Notes | 3.7% notes maturing 2029 Issued By PartnerRe Finance B LLC
Debt Instrument [Line Items]
Commitment				$ 500,000
Stated interest rate of debt instrument		3.70%		3.70%			3.70%
Debt issuance percentage of fair value				99.783%
Issuance of senior notes				$ 496,000
Maturity date							Jul. 02, 2029
Payment frequency							semi-annually
Date of first required interest payment							Jan. 02, 2020
2016 Euro Senior Notes | Notes Issued By PartnerRe Ireland Finance DAC
Debt Instrument [Line Items]
Commitment | €					€ 750
Stated interest rate of debt instrument					1.25%
Debt issuance percentage of fair value					99.144%
Maturity date					Sep. 15, 2026
Payment frequency					annually
Date of first required interest payment					Sep. 15, 2017
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC
Debt Instrument [Line Items]
Commitment			$ 500,000
Stated interest rate of debt instrument			4.50%
Maturity date			Oct. 01, 2050
Payment frequency			semi-annually
Date of first required interest payment			Apr. 01, 2021
Maturity date range start			Oct. 01, 2030
Proceeds from issuance of subordinated debt			$ 494,000
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC | October 1, 2030 To October 1, 2050
Debt Instrument [Line Items]
Reference rate for variable rate interest payments			five-year treasury rate
Spread on variable rate (as a percent)			3.815%
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC | April 1, 2021 - October 1, 2030 [Member]
Debt Instrument [Line Items]
Stated interest rate of debt instrument									4.50%
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc
Debt Instrument [Line Items]
Commitment		$ 61,924					$ 61,924	$ 62,000		$ 250,000
Amount of debt extinguished		$ 560		$ 900		$ 187,000
Interest payment deferral period	10 years
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc | December 1, 2016 - December 1, 2066
Debt Instrument [Line Items]
Payment frequency							quarterly
Reference rate for variable rate interest payments							3-month LIBOR
Spread on variable rate (as a percent)							2.325%

Shareholders' Equity - Authoriz

Shareholders' Equity - Authorized share capital and common shares (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common shares, shares issued	100,000,000	100,000,000
Common shares, par value	$ 0.00	$ 0.00
Authorized Shares
Authorized Share Capital Value	$ 200	$ 200
Class A shares
Class of Stock [Line Items]
Common shares, shares issued	100,000,000	100,000,000
Common shares, par value	$ 0.00	$ 0.00

Shareholders' Equity - Redeemab

Shareholders' Equity - Redeemable preferred shares (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	May 03, 2021	Mar. 15, 2021	Oct. 22, 2020	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Preferred shares, par value per share				$ 1	$ 1
Preferred shares, shares outstanding				8,000,000	8,000,000
Underwriting discounts and commissions	$ 21,000
Aggregate liquidation preference	637,000			$ 200,000	$ 200,000
Accrued dividends at redemption	$ 7,000
Series J Preferred Stock
Class of Stock [Line Items]
Preferred shares, par value per share		$ 1
Shares issued during the period (in shares)		8,000,000
Annual dividend rate		4.875%		4.875%
Underwriting discounts and commissions		$ 6,000
Aggregate liquidation preference		$ 200,000
Liquidation preference per share		$ 25
Preferred shares, redemption price per share (in dollars per share)		$ 25
Preferred Stock, Call or Exercise Features		March 15, 2026
Series G 6.5% cumulative
Class of Stock [Line Items]
Preferred shares, redemption price per share (in dollars per share)	$ 25
Preferred Stock, Redemption Date	May 03, 2021
Series H 7.25% cumulative
Class of Stock [Line Items]
Preferred shares, redemption price per share (in dollars per share)	$ 25
Preferred Stock, Redemption Date	May 03, 2021
Series I 5.875% non-cumulative
Class of Stock [Line Items]
Preferred shares, redemption price per share (in dollars per share)	$ 25
Preferred Stock, Redemption Date	May 03, 2021
Series F 5.875% non-cumulative
Class of Stock [Line Items]
Underwriting discounts and commissions			$ 2,000
Aggregate liquidation preference			$ 67,000
Preferred shares, redemption price per share (in dollars per share)			$ 25
Preferred Stock, Redemption Date			Oct. 22, 2020
Shares redeemed during the period (in shares)			2,679,426
Accrued dividends at redemption			$ 1,000

Dividend Restrictions and Sta_3

Dividend Restrictions and Statutory Requirements (Details) $ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 SGD ($)
PartnerRe Bermuda
Statutory Accounting Practices [Line Items]
Minimum required liquidity ratio (as a percent)	75%			75%
Percentage of statutory capital and surplus requirement for payment of dividends	120%			120%
Amount available for dividends without regulatory approval	$ 789
Statutory net income (loss)	(139)	$ 900	$ (52)
Required statutory capital and surplus	2,725	2,846
Actual statutory capital and surplus	5,816	6,004
PartnerRe Europe
Statutory Accounting Practices [Line Items]
Statutory net income (loss)	(329)	28	237
Required statutory capital and surplus	1,537	1,873
Actual statutory capital and surplus	$ 2,672	2,744
PartnerRe U.S.
Statutory Accounting Practices [Line Items]
Percentage of statutory capital and surplus requirement for payment of dividends	10%			10%
Statutory net income (loss)	$ 242	68	28
Required statutory capital and surplus	1,356	1,244
Actual statutory capital and surplus	$ 1,928	1,369
Statutory Accounting Practices, Future Dividend Payments Restrictions	two year period
PartnerRe Asia
Statutory Accounting Practices [Line Items]
Percentage of basic capital requirement for payment of dividends	120%			120%
Statutory net income (loss)	$ (31)	(6)	(2)
Required statutory capital and surplus	47	50
Actual statutory capital and surplus	215	249
PartnerRe Asia | Minimum
Statutory Accounting Practices [Line Items]
Required statutory capital and surplus				$ 25
PartnerRe Canada
Statutory Accounting Practices [Line Items]
Statutory net income (loss)	(14)	(12)	$ 13
Required statutory capital and surplus	1,144	999
Actual statutory capital and surplus	$ 1,392	$ 1,240

Taxation - Components of income

Taxation - Components of income tax expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current income tax expense
Current income tax expense (benefit)	$ 114,528	$ 49,509	$ (52,391)
Deferred income tax expense (benefit)
Deferred income tax (benefit) expense	(85,127)	(11,091)	35,372
Unrecognized tax expense (benefit)
Unrecognized tax expense (benefit)	1,933	(199)	3,928
Total income tax expense
Income tax (expense) benefit	31,334	38,219	(13,091)
Income before taxes by jurisdiction
Domestic (Bermuda)	(205,731)	636,043	3,894
Foreign	(852,964)	125,580	237,204
(Loss) income before taxes	(1,058,695)	761,623	241,098
US
Current income tax expense
Current income tax expense (benefit)	93,906	31,216	(97,155)
Deferred income tax expense (benefit)
Deferred income tax (benefit) expense	(14,428)	(9,404)	60,932
Unrecognized tax expense (benefit)
Unrecognized tax expense (benefit)	0	0	0
Total income tax expense
Income tax (expense) benefit	79,478	21,812	(36,223)
Non-US
Current income tax expense
Current income tax expense (benefit)	20,622	18,293	44,764
Deferred income tax expense (benefit)
Deferred income tax (benefit) expense	(70,699)	(1,687)	(25,560)
Unrecognized tax expense (benefit)
Unrecognized tax expense (benefit)	1,933	(199)	3,928
Total income tax expense
Income tax (expense) benefit	$ (48,144)	$ 16,407	$ 23,132

Taxation - Reconciliation of ef

Taxation - Reconciliation of effective tax rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of effective tax rate (% of income before taxes)
Expected tax rate	0%	0%	0%
Foreign taxes at local expected tax rates	14.20%	5.70%	15.50%
Impact of foreign exchange gains or losses	(0.30%)	(0.10%)	(8.10%)
Unrecognized tax (expense) benefit	(0.20%)	0%	1.60%
Tax-exempt income and expenses not deductible	0.10%	(0.40%)	(1.40%)
Foreign branch tax	3.50%	0.10%	(3.30%)
Valuation allowance	(17.60%)	0.60%	3.40%
Other	(2.70%)	(0.90%)	(13.10%)
Actual tax rate	(3.00%)	5%	(5.40%)

Taxation - Components of net ta

Taxation - Components of net tax assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components Of Net Tax Assets And Liabilities [Abstract]
Net tax assets	$ 164,384	$ 154,472
Net tax liabilities	(29,154)	(90,974)
Net tax assets	135,230	63,498
Net Tax Liabilities By Type [Abstract]
Net current tax assets	108,836	117,872
Net deferred tax assets	37,103
Net deferred tax liabilities		(45,098)
Net unrecognized tax benefit	(10,709)	(9,276)	$ (10,273)	$ (5,689)
Net tax assets	$ 135,230	$ 63,498

Taxation - Components of net de

Taxation - Components of net deferred tax assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Discounting of loss reserves and adjustment to life policy reserves	$ 18,049	$ 18,340
Foreign tax credit carryforwards	211,023	180,510
Tax loss carryforwards	123,597	106,555
Unearned premiums	46,029	36,421
Statutory basis funds held	0	58,899
Unrealized depreciation and timing differences on foreign exchange revaluations	0	3,838
Unrealized depreciation and timing differences on investments	170,720	0
Other deferred tax assets	37,423	47,034
Deferred tax assets before valuation allowance	606,841	451,597
Valuation allowance	(399,329)	(211,798)
Deferred tax assets	207,512	239,799
Deferred tax liabilities
Deferred acquisition costs	92,459	75,924
Goodwill and other intangibles	55,882	56,870
Statutory basis reserves	0	114,240
Equalization reserves	8,235	7,192
Unrealized appreciation and timing differences on investments	0	4,877
Other deferred tax liabilities	13,833	25,794
Deferred tax liabilities	170,409	284,897
Net deferred tax assets	37,103
Net deferred tax liabilities		(45,098)
Deferred tax asset on tax loss carryforwards	$ 70,000	$ 76,000

Taxation - Income tax uncertain

Taxation - Income tax uncertainties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Unrecognized tax benefits, rollforward
January 1	$ 9,276	$ 10,273	$ 5,689
Changes in tax positions taken during a prior period - increase	1,933		3,870
Changes in tax positions taken during a prior period - decrease		(199)
Impact of change in foreign currency exchange rates - Increase			714
Impact of change in foreign currency exchange rates - Decrease	(500)	(798)
December 31	10,709	9,276	10,273
Unrecognized tax benefits impacting effective tax rate	$ 0	$ 0	$ 0

Taxation - Narrative (Details)

Taxation - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Taxation - Other Details [Line Items]
Valuation allowance on deferred tax assets	$ 399,329	$ 211,798
Deferred tax asset on tax loss carryforwards	$ 70,000	$ 76,000
Other	(2.70%)	(0.90%)	(13.10%)
Unrealized depreciation and timing differences on investments	$ 170,720	$ 0
Ireland
Taxation - Other Details [Line Items]
Valuation allowance of foreign tax credit carryforwards	211,000	181,000
Deferred tax asset on tax loss carryforwards	9,000
Hong Kong
Taxation - Other Details [Line Items]
Deferred tax asset on tax loss carryforwards	2,000	2,000
Singapore
Taxation - Other Details [Line Items]
Deferred tax asset on tax loss carryforwards	20,000	19,000
US
Taxation - Other Details [Line Items]
Income tax benefit resulting from reduction in corporate tax rate			$ 35,000
Valuation allowance on deferred tax assets	22,000	13,000
Deferred tax asset on tax loss carryforwards	10,000	44,000
Other			14.40%
Unrealized depreciation and timing differences on investments	148,000
Canada
Taxation - Other Details [Line Items]
Valuation allowance on deferred tax assets	7,000	6,000
Deferred tax asset on tax loss carryforwards	1,000	5,000
United Kingdom
Taxation - Other Details [Line Items]
Valuation allowance on deferred tax assets	11,000	12,000
Deferred tax asset on tax loss carryforwards	2,000
Switzerland
Taxation - Other Details [Line Items]
Deferred tax asset on tax loss carryforwards	$ 26,000	$ 6,000

Share-Based Incentives rollforw

Share-Based Incentives rollforward (Details) - shares	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	100,000,000
Shares outstanding, end of year	100,000,000		100,000,000
Class B Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	222,659		274,664	281,768
Granted				167,202
Purchased				38,838
Repurchased			(52,005)	(213,144)
Net expirations and exercises	0		0	0
Accelerated vesting and repurchase upon change of control	(222,659)
Shares outstanding, end of year	0		222,659	274,664
Class B Shares | Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	139,820		189,166	179,332
Granted				167,202
Purchased				0
Repurchased			(29,048)	(129,583)
Expiration of restricted period	(32,168)		(20,298)	(27,785)
Accelerated vesting and repurchase upon change of control	(107,652)
Shares outstanding, end of year	0		139,820	189,166
Class B Shares | Unrestricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	82,839		85,498	102,436
Granted				0
Purchased				38,838
Repurchased			(22,957)	(83,561)
Exercised	32,168		20,298	27,785
Accelerated vesting and repurchase upon change of control	(115,007)
Shares outstanding, end of year	0		82,839	85,498
Common Class C
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	9,445		0
Granted	11,413		7,373
Purchased			2,072
Accelerated vesting and repurchase upon change of control	(13,192)
Shares outstanding, end of year	7,666		9,445	0
Common Class C | Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	7,373		0
Granted	7,666		7,373
Purchased			0
Accelerated vesting and repurchase upon change of control	(7,373)
Shares outstanding, end of year	7,666		7,373	0
Common Class C | Unrestricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	2,072		0
Granted	3,747		0
Purchased			2,072
Accelerated vesting and repurchase upon change of control	(5,819)
Shares outstanding, end of year	0		2,072	0
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding, beginning of year	263,214		0
Granted	265,805	[1]	263,214
Accelerated vesting and repurchase upon change of control	(260,250)
Forfeitures	(2,964)
Shares outstanding, end of year	265,805		263,214	0
[1]For RSUs, the number of grants in the table are shown at the maximum number that can be attained if the performance conditions are fully met for personal and Company performance. Forfeitures represent adjustments to grants falling below the maximum attainable as a result of not fully meeting the performance conditions.

Share-Based Incentives Narrativ

Share-Based Incentives Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period, Class B shares		3 years
Accounts payable, accrued expenses and other		$ 488,594	$ 560,561
Redemption of unrestricted Class B common shares (1)	[1]	6,346	581	$ 5,157
Share-Based Payment Arrangement, Cash Used to Settle Award		43,000
Payment, Tax Withholding, Share-Based Payment Arrangement		$ 3,000
Common Class C,B and RSU stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shared Based Compensation, Minimum Multiplier of Target Value		200%
Share based compensation expense		$ 29,000	13,000	$ 11,000
Accounts payable, accrued expenses and other		$ 7,000	$ 24,000
Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period		1 year
Exercise price of share based awards		$ 0
Requisite service period, Class B shares		3 years
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount		$ 17,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		2 years
Share-Based Payment Arrangement, Cash Used to Settle Award		$ 40,000
Restricted Shares | Minimum | Personal Performance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance target percentage		75%
Restricted Shares | Minimum | Company performance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance target percentage		50%
Restricted Shares | Maximum | Personal Performance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance target percentage		125%
Restricted Shares | Maximum | Company performance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance target percentage		150%
Restricted Shares | Class B Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of share based awards		$ 0
Requisite service period, Class B shares		3 years
Unrestricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Payment Arrangement, Cash Used to Settle Award		$ 3,000
[1]Class B shares are liability-accounted on the Company's Consolidated Balance Sheet. See Note 13 for further details.

Retirement Benefit Arrangemen_3

Retirement Benefit Arrangements - Active Defined Benefit Plan (Details) - Zurich Plan - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Funded status:
Unfunded pension obligation at beginning of year		$ 32,636	$ 62,050
Change in pension obligation:
Service cost		8,746	11,811
Interest cost		373	228
Plan participants’ contributions		3,792	4,048
Actuarial gain		(37,992)	(24,211)
Benefits paid		(4,576)	(1,651)
Foreign currency adjustments		(3,736)	(8,735)
Settlements		0	(20,682)
Change in pension obligation		(33,393)	(39,192)
Change in fair value of plan assets:
Actual return on plan assets		(14,936)	6,847	$ 3,000
Employer contributions		7,658	8,035
Plan participants’ contributions		3,792	4,048
Benefits paid		(4,576)	(1,651)
Foreign currency adjustments		(2,233)	(6,375)
Settlements		0	(20,682)
Change in fair value of plan assets		(10,295)	(9,778)
Funded status:
Unfunded pension obligation at end of year		9,538	32,636	$ 62,050
Additional information:
Projected benefit obligation at end of year	[1]	169,527	202,920
Accumulated pension obligation at end of year	[2]	$ 167,560	$ 194,730
Pension obligation - assumptions used
Discount rate		2.20%	0.20%	0.10%
Interest crediting rate		2.20%	1%	1%
Rate of compensation increase		2.25%	2%	2%
Net periodic benefit cost - assumptions used
Discount rate		0.20%	0.10%	0.25%
Interest crediting rate		1%	1%	1%
Expected return on plan assets		4.25%	3.50%	3.50%
Rate of compensation increase		2%	2%	2%
Defined Benefit Plan Estimated Future Benefit Payments Abstract
2023		$ 11,377
2024		9,696
2025		10,739
2026		12,454
2027		11,111
2028 to 2032		52,119
Significant other observable inputs (Level 2) | Insured funds
Additional information:
Fair value of plan assets at end of year		$ 159,989	$ 170,284
[1]Represents the actuarial present value of all benefits attributed to employee service rendered to December 31, measured using assumptions as to future compensation levels[2]Represents the actuarial present value of benefits (whether vested or non-vested) attributed to employee service rendered and compensation to December 31, with no assumption about future compensation levels

Retirement Benefit Arrangemen_4

Retirement Benefit Arrangements - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Incurred expense for defined contribution arrangements	$ 13,000	$ 13,000	$ 13,000
Maximum
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plans, Accumulated Benefits, Vesting Period	4 years
Zurich Plan
Additional information:
Unfunded pension obligation	$ (9,538)	(32,636)	(62,050)
Amounts recognized in AOCI	6,000	(7,000)
Unfunded pension obligation, tax impact	1,000	2,000
Net periodic benefit cost	1,000	$ 8,000	5,000
Expected employer contributions in 2023	$ 8,000
Coverage ration on partially insured pension scheme	101%	115%
Actual return on plan assets	$ (14,936)	$ 6,847	$ 3,000
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)	(33,393)	(39,192)
Foreign currency adjustments	(3,736)	(8,735)
Foreign currency adjustments	(2,233)	(6,375)
Employer contributions	7,658	8,035
Change in fair value of plan assets	(10,295)	(9,778)
Settlements	0	20,682
Settlements	0	20,682
Zurich Plan | Significant other observable inputs (Level 2) | Insured funds
Additional information:
Fair value of plan assets at end of year	$ 159,989	$ 170,284

Commitments and Contingencies -

Commitments and Contingencies - Concentrations of Credit Risk (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Provision for uncollectible premiums receivable	$ 12	$ 10
Funds Held under Reinsurance Agreements, Allowance for Credit loss	4	4
Deposit contracts, allowance for credit loss	$ 1	$ 1

Commitments and Contingencies_2

Commitments and Contingencies - Lease Arrangements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease costs	$ 12,437		$ 14,928
Variable lease costs	1,292		904
Sublease Income	0		(368)
Total lease costs	13,729		15,464
Operating lease right-of-use assets	71,174	[1]	75,010
Operating lease right-of-use assets obtained in exchange for lease obligations, non-cash	4,016		26,553
Operating cash outflows from operating leases	$ 13,545		$ 16,874
Weighted-average remaining lease term on operating leases	7 years 9 months 18 days	[2]	8 years 10 months 24 days
Weighted-average discount rate on operating leases	2.30%	[3]	2.40%
Right-of-use asset, balance sheet location	Other assets		Other assets
Operating lease liability, balance sheet location	Accounts payable, accrued expenses and other		Accounts payable, accrued expenses and other
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2023	$ 13,671
2024	13,642
2025	12,303
2026	12,089
2027	10,953
2028 to 2038	24,005
Discount	(6,738)
Total discounted operating lease liabilities	79,925	[4]	$ 85,462
Lease commitments for leases not yet commenced	$ 4,000
Leases not yet commenced, term of contract	8 years
[1]Included in Other assets Accounts payable, accrued expenses and other

Commitments and Contingencies_3

Commitments and Contingencies - Other Agreements (Details) $ in Millions	Dec. 31, 2022 USD ($)
Investment commitments
Unrecorded Unconditional Purchase Obligation [Line Items]
2023	$ 237
2024	132
2025	45
2026	20
2027	13
Total	447
Technology support and equipment
Unrecorded Unconditional Purchase Obligation [Line Items]
2023	17
2024	6
Total	$ 28

Credit Agreements (Details)

Credit Agreements (Details) $ in Millions	Dec. 31, 2022 USD ($)
Line of Credit Facility [Line Items]
Total amount of credit facilities available	$ 752
Combined Credit Facility
Line of Credit Facility [Line Items]
Total amount of credit facilities available	400
Amount of unsecured borrowing capacity	100
Committed Secured Letter Of Credit Facility
Line of Credit Facility [Line Items]
Total amount of credit facilities available	250
Committed Secured Letter Of Credit Facility B [Member]
Line of Credit Facility [Line Items]
Total amount of credit facilities available	100
Outstanding Unsecured Letter Of Credit
Line of Credit Facility [Line Items]
Letters of credit outstanding amount	102
Outstanding Secured Letter Of Credit
Line of Credit Facility [Line Items]
Letters of credit outstanding amount	$ 479

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Related Party Transaction [Line Items]
Reinsurance balances receivable		$ 3,342,612	$ 3,063,153
Non-life reserves		12,725,631	12,047,792
Life and health reserves		2,510,293	2,638,086
Unearned premiums		2,745,371	2,501,161
Private equity funds | Exor
Related Party Transaction [Line Items]
Investment carrying value		396,000
Public equity funds | Exor
Related Party Transaction [Line Items]
Investment carrying value		422,000
Majority Shareholder | Exor
Related Party Transaction [Line Items]
Related Party Advisory Services Agreement		184	350	$ 500
Majority Shareholder | Real estate services | Exor
Related Party Transaction [Line Items]
Related Party Consulting Services Agreement		265	433	310
Majority Shareholder | Investment advisory services | Exor
Related Party Transaction [Line Items]
Related Party Consulting Services Agreement		3,900	2,600
Related Party Advisory Services Agreement			175	259
Majority Shareholder | Underwriting Activities | Covea
Related Party Transaction [Line Items]
Reinsurance balances receivable		3,169
Non-life reserves		95,013
Life and health reserves		1,175
Unearned premiums		571
Majority Shareholder | Private equity funds | Exor
Related Party Transaction [Line Items]
Investment carrying value			468,000
Net realized and unrealized gain (loss) on related party investment	$ 34,000	72,000	115,000
Majority Shareholder | Other invested assets | Exor
Related Party Transaction [Line Items]
Investment carrying value			51,000
Transaction amount			51,000
Majority Shareholder | Public equity funds | Exor
Related Party Transaction [Line Items]
Investment carrying value			1,154,000
Payments to acquire investments					$ 500,000
Transaction amount	772,000
Net realized and unrealized gain (loss) on related party investment	24,000	40,000	115,000	91,000
Realized gain (loss) on related party investment	$ 450,000
Retained earnings
Related Party Transaction [Line Items]
Dividends on common shares		177,894	106,667	$ 50,000
Retained earnings | Majority Shareholder | Exor
Related Party Transaction [Line Items]
Dividends on common shares		$ 178,000	$ 107,000

Segment Information (Narrative)

Segment Information (Narrative) (Details) - 12 months ended Dec. 31, 2022	Total	Segment
Segment Reporting [Abstract]
Number of worldwide business segments	3	3

Segment Information (Results by

Segment Information (Results by Segment) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Segment Reporting [Line Items]
Gross premiums written	$ 8,689,279		$ 8,203,925	$ 6,875,925
Net premiums written	7,544,195		7,134,018	6,300,858
(Increase) decrease in unearned premiums	(287,078)		(177,496)	235,968
Net premiums earned	7,257,117		6,956,522	6,536,826
Losses and loss expenses	(4,747,000)		(4,884,000)	(5,335,000)
Acquisition costs	(1,540,681)		(1,386,832)	(1,356,118)
Technical result	969,000		686,000	(154,000)
Other income	40,492		28,748	13,491
Other expenses	(414,876)		(398,542)	(355,647)
Underwriting result	594,000		316,000	(497,000)
Net investment income	398,348		376,469	360,668
Net realized and unrealized investment (losses) gains	(1,969,014)		37,797	454,319
Interest expense	(55,185)		(55,606)	(39,200)
Amortization of intangible assets	(8,912)		(8,861)	(9,988)
Net foreign exchange (gains) losses	(29,402)		(30,883)	(51,964)
Income tax (expense) benefit	(31,334)		(38,219)	13,091
Interest in earnings of equity method investments	10,821		126,795	23,611
Net (loss) income	(1,090,029)		723,404	254,189
Non Life
Segment Reporting [Line Items]
Gross premiums written	7,015,422		6,557,055	5,376,703
Net premiums written	5,898,750		5,510,828	4,825,919
(Increase) decrease in unearned premiums	(288,000)		(181,000)	229,000
Net premiums earned	5,611,452		5,329,556	5,054,529
Losses and loss expenses	(3,313,000)		(3,443,000)	(4,017,000)
Acquisition costs	(1,430,000)		(1,279,000)	(1,254,000)
Technical result	868,000		608,000	(216,000)
Other income	0		0	(1,000)
Other expenses	(119,000)		(101,000)	(87,000)
Underwriting result	$ 749,000		$ 507,000	$ (304,000)
Reinsurance Ratios [Abstract]
Loss ratio	59%	[1]	64.60%	79.50%
Acquisition ratio	25.50%	[2]	24%	24.80%
Technical ratio	84.50%	[3]	88.60%	104.30%
Other expense ratio	2.10%	[4]	1.90%	1.70%
Combined Ratio	86.60%	[5]	90.50%	106%
Non Life | P&C
Segment Reporting [Line Items]
Gross premiums written	$ 5,025,000		$ 4,541,000	$ 3,442,000
Net premiums written	4,234,000		3,722,000	3,044,000
(Increase) decrease in unearned premiums	(293,000)		(194,000)	119,000
Net premiums earned	3,941,000		3,528,000	3,163,000
Losses and loss expenses	(2,410,000)		(2,391,000)	(2,389,000)
Acquisition costs	(995,000)		(864,000)	(784,000)
Technical result	536,000		273,000	(10,000)
Other income	0		0	(1,000)
Other expenses	(84,000)		(71,000)	(61,000)
Underwriting result	$ 452,000		$ 202,000	$ (72,000)
Reinsurance Ratios [Abstract]
Loss ratio	61.20%	[1]	67.80%	75.50%
Acquisition ratio	25.20%	[2]	24.50%	24.80%
Technical ratio	86.40%	[3]	92.30%	100.30%
Other expense ratio	2.10%	[4]	2%	1.90%
Combined Ratio	88.50%	[5]	94.30%	102.20%
Non Life | Specialty
Segment Reporting [Line Items]
Gross premiums written	$ 1,990,000		$ 2,016,000	$ 1,935,000
Net premiums written	1,665,000		1,789,000	1,782,000
(Increase) decrease in unearned premiums	5,000		13,000	110,000
Net premiums earned	1,670,000		1,802,000	1,892,000
Losses and loss expenses	(903,000)		(1,052,000)	(1,628,000)
Acquisition costs	(435,000)		(415,000)	(470,000)
Technical result	332,000		335,000	(206,000)
Other income	0		0	0
Other expenses	(35,000)		(30,000)	(26,000)
Underwriting result	$ 297,000		$ 305,000	$ (232,000)
Reinsurance Ratios [Abstract]
Loss ratio	54.10%	[1]	58.40%	86%
Acquisition ratio	26%	[2]	23%	24.80%
Technical ratio	80.10%	[3]	81.40%	110.80%
Other expense ratio	2.10%	[4]	1.70%	1.40%
Combined Ratio	82.20%	[5]	83.10%	112.20%
Life and Health
Segment Reporting [Line Items]
Gross premiums written	$ 1,673,857		$ 1,646,870	$ 1,499,222
Net premiums written	1,645,445		1,623,190	1,474,939
(Increase) decrease in unearned premiums	1,000		4,000	7,000
Net premiums earned	1,645,665		1,626,966	1,482,297
Losses and loss expenses	(1,434,000)		(1,441,000)	(1,318,000)
Acquisition costs	(111,000)		(108,000)	(102,000)
Technical result	101,000		78,000	62,000
Other income	39,000		26,000	13,000
Other expenses	(93,000)		(88,000)	(73,000)
Underwriting result	47,000		16,000	2,000
Net investment income	74,000		81,000	68,000
Allocated underwriting result	121,000		97,000	70,000
Corporate and Other
Segment Reporting [Line Items]
Gross premiums written	0		0	0
Net premiums written	0		0	0
(Increase) decrease in unearned premiums	0		0	0
Net premiums earned	0		0	0
Losses and loss expenses	0		0	0
Acquisition costs	0		0	0
Technical result	0		0	0
Other income	1,000		3,000	1,000
Other expenses	(203,000)		(210,000)	(196,000)
Net investment income	324,000		295,000	293,000
Net realized and unrealized investment (losses) gains	(1,969,000)		38,000	454,000
Interest expense	(55,000)		(56,000)	(39,000)
Amortization of intangible assets	(9,000)		(9,000)	(10,000)
Net foreign exchange (gains) losses	(29,000)		(31,000)	(52,000)
Income tax (expense) benefit	(31,000)		(38,000)	13,000
Interest in earnings of equity method investments	$ 11,000		$ 127,000	$ 24,000
[1]Loss ratio is obtained by dividing losses and loss expenses by net premiums earned.[2]Acquisition ratio is obtained by dividing acquisition costs by net premiums earned.[3]Technical ratio is defined as the sum of the loss ratio and the acquisition ratio.[4]Other expense ratio is obtained by dividing other expenses by net premiums earned.[5]Combined ratio is defined as the sum of the technical ratio and the other expense ratio.

Segment Information (Distributi

Segment Information (Distribution of gross and net written premium) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 8,689,279	$ 8,203,925	$ 6,875,925
Percentage Distribution of gross premiums written	100%	100%	100%
North America
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 5,040,000	$ 4,649,000	$ 3,794,000
Percentage Distribution of gross premiums written	58%	57%	55%
Europe
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 2,592,000	$ 2,410,000	$ 1,921,000
Percentage Distribution of gross premiums written	30%	29%	28%
Asia, Australia and New Zealand
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 720,000	$ 814,000	$ 806,000
Percentage Distribution of gross premiums written	8%	10%	12%
Latin America and the Caribbean
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 223,000	$ 189,000	$ 220,000
Percentage Distribution of gross premiums written	3%	2%	3%
Middle East, Africa, Russia and the Commonwealth of Independent States (CIS)
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 114,000	$ 142,000	$ 135,000
Percentage Distribution of gross premiums written	1%	2%	2%
P&C
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 5,025,000	$ 4,541,000	$ 3,442,000
P&C | Casualty
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	2,777,000	2,145,000	1,430,000
P&C | Catastrophe
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	933,000	924,000	545,000
P&C | Property
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	764,000	809,000	641,000
P&C | US Health
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	355,000	351,000	379,000
P&C | Multiline & Other
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	119,000	183,000	289,000
P&C | Motor
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	77,000	129,000	158,000
Specialty
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	1,990,000	2,016,000	1,935,000
Specialty | Casualty
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	0	0	4,000
Specialty | Property
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	240,000	277,000	173,000
Specialty | Multiline & Other
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	45,000	20,000	152,000
Specialty | Financial Risks
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	634,000	510,000	568,000
Specialty | Aviation & space
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	362,000	416,000	219,000
Specialty | Energy Reinsurance
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	346,000	314,000	192,000
Specialty | Agriculture
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	101,000	205,000	468,000
Specialty | Marine
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	223,000	174,000	142,000
Specialty | Engineering
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	39,000	100,000	17,000
Life and Health
Distribution Of Gross Premiums Written [Line Items]
Gross premiums written	$ 1,673,857	$ 1,646,870	$ 1,499,222

Segment Information (Broker det

Segment Information (Broker details) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Economic Dependence [Line Items]
Cedant Percentage Of Gross Written Premium	5%	5%	5%
Gross Premiums Written | Customer Concentration Risk | Marsh & McLennan Companies, Inc
Economic Dependence [Line Items]
Concentration Risk, Percentage	30%	28%	30%
Gross Premiums Written | Customer Concentration Risk | Aon PLC
Economic Dependence [Line Items]
Concentration Risk, Percentage	26%	24%	21%
Gross Premiums Written | Customer Concentration Risk | Non Life | P&C | Two Significant Brokers
Economic Dependence [Line Items]
Concentration Risk, Percentage	67%	63%	64%
Gross Premiums Written | Customer Concentration Risk | Non Life | Specialty | Two Significant Brokers
Economic Dependence [Line Items]
Concentration Risk, Percentage	70%	66%	64%
Gross Premiums Written | Customer Concentration Risk | Life and Health | Two Significant Brokers
Economic Dependence [Line Items]
Concentration Risk, Percentage	6%	6%	6%

Subsequent Events (Details)

Subsequent Events (Details) - Series J Preferred Stock - $ / shares			12 Months Ended
	Feb. 16, 2023	Mar. 15, 2021	Dec. 31, 2022
Subsequent Event [Line Items]
Preferred shares, dividend rate		4.875%	4.875%
Subsequent Event
Subsequent Event [Line Items]
Dividends declared (per share)	$ 0.3046875

SCHEDULE I - Consolidated Sum_2

SCHEDULE I - Consolidated Summary of Investments Other Than Investments in Related Parties (Details) $ in Thousands	Dec. 31, 2022 USD ($)
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Fair Value	$ 17,593,171
Amount at which shown in the balance sheet	17,888,400
Fixed maturities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	14,925,319
Fair Value	13,021,914
Amount at which shown in the balance sheet	13,021,914
U.S. government and government sponsored enterprises
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	2,106,556	[1]
Fair Value	1,797,934
Amount at which shown in the balance sheet	1,797,934
U.S. states, territories and municipalities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	58,707	[1]
Fair Value	58,873
Amount at which shown in the balance sheet	58,873
Non US sovereign government supranational and government related
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	1,834,025	[1]
Fair Value	1,654,532
Amount at which shown in the balance sheet	1,654,532
Corporate bonds
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	6,477,064	[1]
Fair Value	5,759,149
Amount at which shown in the balance sheet	5,759,149
Asset-backed securities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	28,550
Fair Value	28,364
Amount at which shown in the balance sheet	28,364
Residential mortgage-backed securities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	4,420,417	[1]
Fair Value	3,723,062
Amount at which shown in the balance sheet	3,723,062
Equities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	586,107	[1]
Fair Value	929,886
Amount at which shown in the balance sheet	929,886
Banks, trust and insurance companies
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	88,584	[1]
Fair Value	61,873
Amount at which shown in the balance sheet	61,873
Industrial, miscellaneous and all other
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	487,726	[1]
Fair Value	854,431
Amount at which shown in the balance sheet	854,431
Nonredeemable Preferred Stock
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	9,797	[1]
Fair Value	13,582
Amount at which shown in the balance sheet	13,582
Short-term investments
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost	536,139	[1]
Fair Value	523,510
Amount at which shown in the balance sheet	523,510
Other invested assets
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Fair Value	3,117,861	[2]
Amount at which shown in the balance sheet	3,355,106
Equity method investments	237,000
Real Estate Investment
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Fair Value	0	[3]
Amount at which shown in the balance sheet	$ 57,984	[3]
[1]Original cost of fixed maturities reduced by repayments and adjusted for amortization of premiums or accrual of discounts. Original cost of equity securities.[2]Other invested assets shown in the Consolidated Balance Sheets in Item 18 also includes the Company’s investments accounted for using the equity method of accounting of $237 million.[3]Investments in real estate are carried at original cost less any impairments.

SCHEDULE II - Condensed Balance

SCHEDULE II - Condensed Balance Sheets - Parent Company Only (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	May 03, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Nov. 30, 2006
Assets
Fixed maturities, at fair value (amortized cost: 2022, $90,171; 2021, $85,811)		$ 13,021,914	$ 14,071,274
Other assets		203,119	208,652
Total assets		27,272,413	28,029,871
Liabilities
Accounts payable, accrued expenses and other		488,594	560,561
Total liabilities		$ 20,984,063	$ 20,485,885
Common stock, shares outstanding		100,000,000	100,000,000
Liabilities and Equity
Common shares (par value $0.00000001; issued and outstanding: 100,000,000 shares)		$ 0	$ 0
Preferred shares (par value $1.00; issued and outstanding: 8,000,000 shares; aggregate liquidation value: $200,000)		8,000	8,000
Additional paid-in capital		1,929,934	1,929,934
Accumulated other comprehensive loss		(7,669)	(29,706)
Retained earnings		4,358,085	5,635,758
Total shareholders’ equity		6,288,350	7,543,986		$ 7,326,997
Total liabilities and shareholders’ equity		27,272,413	28,029,871
Other information
Amortized cost of trading securities, debt		$ 14,925,319	$ 14,181,310
Common shares, par value		$ 0.00	$ 0.00
Common shares, shares issued		100,000,000	100,000,000
Preferred shares, par value per share		$ 1	$ 1
Preferred shares, shares issued		8,000,000	8,000,000
Preferred shares, shares outstanding		8,000,000	8,000,000
Aggregate liquidation preference		$ 200,000	$ 200,000	$ 637,000
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc
Other information
Commitment		61,924	62,000					$ 250,000
Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC
Other information
Stated interest rate of debt instrument						4.50%
Commitment						$ 500,000
Parent Company
Assets
Fixed maturities, at fair value (amortized cost: 2022, $90,171; 2021, $85,811)		73,642	85,111
Cash and cash equivalents		3,814	1,988		$ 10,020		$ 4,512
Investment in subsidiaries		8,640,997	9,757,268
Intercompany loans and balances receivable		18,546	24,834
Other assets		21,042	19,906
Total assets		8,758,041	9,889,107
Liabilities
Intercompany loans and balances payable	[1]	2,423,951	2,297,350
Accounts payable, accrued expenses and other		45,740	47,771
Total liabilities		$ 2,469,691	$ 2,345,121
Common stock, shares outstanding		100,000,000	100,000,000
Liabilities and Equity
Common shares (par value $0.00000001; issued and outstanding: 100,000,000 shares)		$ 0	$ 0
Preferred shares (par value $1.00; issued and outstanding: 8,000,000 shares; aggregate liquidation value: $200,000)		8,000	8,000
Additional paid-in capital		1,929,934	1,929,934
Accumulated other comprehensive loss		(7,669)	(29,706)
Retained earnings		4,358,085	5,635,758
Total shareholders’ equity		6,288,350	7,543,986
Total liabilities and shareholders’ equity		8,758,041	9,889,107
Other information
Amortized cost of trading securities, debt		$ 90,171	$ 85,811
Common shares, par value		$ 0.00	$ 0.00
Common shares, shares issued		100,000,000	100,000,000
Preferred shares, par value per share		$ 1	$ 1
Preferred shares, shares issued		8,000,000	8,000,000
Preferred shares, shares outstanding		8,000,000	8,000,000
Aggregate liquidation preference		$ 200,000	$ 200,000
Subsidiary Issuer | Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance II Inc
Other information
Aggregate principal amount of guarantee obligations		$ 62,000
Subsidiary Issuer | Junior Subordinated Debt [Member] | Notes Issued By PartnerRe Finance B LLC
Other information
Stated interest rate of debt instrument		4.50%
Commitment		$ 500,000
Subsidiary Issuer | PartnerRe Finance B LLC
Other information
Percentage ownership		100%
Subsidiary Issuer | PartnerRe Finance B LLC | Senior Notes | 3.7% notes maturing 2029 Issued By PartnerRe Finance B LLC
Other information
Stated interest rate of debt instrument		3.70%
Subsidiary Issuer | PartnerRe Finance Ireland DAC
Other information
Percentage ownership		100%
Subsidiary Issuer | PartnerRe Finance Ireland DAC | Senior Notes | 2016 Euro Senior Notes
Other information
Stated interest rate of debt instrument		1.25%
Subsidiary Issuer | PartnerRe Finance II Inc
Other information
Percentage ownership		100%
[1]The parent has fully and unconditionally guaranteed all obligations of PartnerRe Finance B LLC and PartnerRe Finance Ireland DAC, a direct 100% owned subsidiary of the parent, related to the issuance of the 3.700% senior notes and 1.250% senior notes, respectively. The parent’s obligations under these guarantees are senior and unsecured and rank equally with all other senior unsecured indebtedness of the parent.The parent has also fully and unconditionally guaranteed all obligations of PartnerRe Finance II Inc. and PartnerRe Finance B LLC, both indirect 100% owned finance subsidiaries of the parent, related to the remaining $62 million aggregate principal amount of Fixed-to-Floating Rate junior subordinated CENts, with an annual rate of 3-month LIBOR plus a margin equal to 2.325%, and $500 million aggregate principal amount of 4.500% Fixed-Rate Reset junior subordinated notes, respectively. The parent’s obligations under these guarantees are unsecured junior subordinated obligations and rank junior in right of payment to all of the parent's outstanding and future senior indebtedness, and equally in right of payment with all outstanding and future unsecured indebtedness that is by its terms equal in right of payment to the junior subordinated notes.

SCHEDULE II - Condensed Stateme

SCHEDULE II - Condensed Statements of Operations - Parent Company Only (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Income Statements, Captions [Line Items]
Net investment income	$ 398,348	$ 376,469	$ 360,668
Net realized and unrealized investment (losses) gains	(1,969,014)	37,797	454,319
Other income	40,492	28,748	13,491
Total revenues	5,726,943	7,399,536	7,365,304
Other expenses	414,876	398,542	355,647
Net foreign exchange losses	29,402	30,883	51,964
Net (loss) income	(1,090,029)	723,404	254,189
Preferred dividends	9,750	22,693	45,990
Loss on redemption of preferred shares	0	21,234	2,341
Net (loss) income available to common shareholder	(1,099,779)	679,477	205,858
Other comprehensive income (loss)	22,037	66,299	(20,080)
Comprehensive (loss) income	(1,067,992)	789,703	234,109
Parent Company
Condensed Income Statements, Captions [Line Items]
Net investment income	1,851	2,496	2,094
Net realized and unrealized investment (losses) gains	(15,406)	(16,730)	641
Other income	106	148	113
Total revenues	(13,449)	(14,086)	2,848
Other expenses	73,046	55,996	53,458
Interest expense on intercompany loans	33,408	35,204	17,188
Net foreign exchange losses	(65,165)	(79,696)	82,986
Total expenses	41,289	11,504	153,632
Loss before equity in net (loss) income of subsidiaries	(54,738)	(25,590)	(150,784)
Equity in net (loss) income of subsidiaries	(1,035,291)	748,994	404,973
Net (loss) income	(1,090,029)	723,404	254,189
Preferred dividends	9,750	22,693	45,990
Loss on redemption of preferred shares	0	21,234	2,341
Net (loss) income available to common shareholder	(1,099,779)	679,477	205,858
Other comprehensive income (loss)	22,037	66,299	(20,080)
Comprehensive (loss) income	$ (1,067,992)	$ 789,703	$ 234,109

SCHEDULE II - Condensed State_2

SCHEDULE II - Condensed Statements of Cash Flows - Parent Company Only (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
		Mar. 15, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 03, 2021
Cash flows from operating activities
Net (loss) income			$ (1,090,029)	$ 723,404	$ 254,189
Adjustments to reconcile net income to net cash used in operating activities:
Other, net			63,433	23,801	55,004
Net cash provided by operating activities			1,468,409	1,232,590	1,124,893
Cash flows from investing activities
Purchases of fixed maturities			(2,940,597)	(8,141,246)	(8,962,066)
Purchases of short-term investments			(867,605)	(372,901)	(5,006,397)
Other, net			11,679	(31,903)	23,431
Net cash used in investing activities			(664,825)	(2,329,122)	(632,748)
Cash flows from financing activities
Redemption of Class B common shares	[1]		(6,346)	(581)	(5,157)
Issuance of preferred shares			0	193,887	0
Redemption of preferred shares			0	(637,241)	(66,985)
Net cash used in financing activities			(194,550)	(573,295)	328,362
Effect of foreign exchange rate changes on cash			(18,335)	(20,109)	45,863
Increase (decrease) in cash and cash equivalents			590,699	$ (1,689,936)	866,370
Supplemental cash flow information:
Non-cash exchange of intercompany balances			103,000		204,000
non-cash exchange intercompany loan			$ 744,000
Preferred shares, par value per share			$ 1	$ 1
Aggregate liquidation preference			$ 200,000	$ 200,000		$ 637,000
Underwriting discounts and commissions						$ 21,000
Series J Preferred Stock
Supplemental cash flow information:
Shares issued during the period (in shares)		8,000,000
Annual dividend rate		4.875%	4.875%
Preferred shares, par value per share		$ 1
Aggregate liquidation preference		$ 200,000
Underwriting discounts and commissions		$ 6,000
Preferred shares, redemption price per share (in dollars per share)		$ 25
Series G 6.5% cumulative
Supplemental cash flow information:
Preferred shares, redemption price per share (in dollars per share)						$ 25
Series I 5.875% non-cumulative
Supplemental cash flow information:
Preferred shares, redemption price per share (in dollars per share)						25
Series H 7.25% cumulative
Supplemental cash flow information:
Preferred shares, redemption price per share (in dollars per share)						$ 25
December 1, 2016 - December 1, 2066 | Notes Issued By PartnerRe Finance II Inc | Junior Subordinated Debt [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Spread on variable rate (as a percent)			2.325%
Parent Company
Cash flows from operating activities
Net (loss) income			$ (1,090,029)	723,404	254,189
Adjustments to reconcile net income to net cash used in operating activities:
Equity in net loss (income) of subsidiaries			1,035,291	(748,994)	(404,973)
Other, net			41,810	(51,783)	87,789
Net cash provided by operating activities			(12,928)	(77,373)	(62,995)
Cash flows from investing activities
Advances to/from subsidiaries, net (1)	[2]		22,213	100,426	73,738
Net issue of intercompany loans receivable and payable (1) (2)	[2],[3]		0	0	458,489
Sales and redemptions of fixed maturities			11,290	481,015	32,230
Sales and redemptions of short-term investments			5,173	0	43,899
Purchases of fixed maturities			(15,984)	(62,239)	(496,139)
Purchases of short-term investments			(5,173)	0	(39,913)
Other, net			(3,341)	(8,465)	(3,987)
Net cash used in investing activities			14,178	510,737	68,317
Cash flows from financing activities
Issuance of preferred shares	[4]		0	193,887	0
Redemption of preferred shares	[4]		0	(637,241)	0
Net cash used in financing activities			0	(443,354)	0
Effect of foreign exchange rate changes on cash			576	1,958	186
Increase (decrease) in cash and cash equivalents			1,826	(8,032)	5,508
Cash and cash equivalents—beginning of year			1,988	10,020	4,512
Cash and cash equivalents—end of year			$ 3,814	$ 1,988	10,020
Supplemental cash flow information:
Preferred shares, par value per share			$ 1	$ 1
Aggregate liquidation preference			$ 200,000	$ 200,000
Subsidiaries
Cash flows from financing activities
Redemption of preferred shares					(67,000)
Supplemental cash flow information:
Payment of dividends by subsidiary on behalf of parent			188,000	129,000	96,000
Non-cash dividends received from subsidiaries			630,000	$ 350,000
Non-cash capital contributions to subsidiaries			$ 527,000		25,000
Notes Issued					$ 458,000
[1]Class B shares are liability-accounted on the Company's Consolidated Balance Sheet. See Note 13 for further details.[2]The following non-cash transactions were excluded from the Condensed Statement of Cash Flows - Parent Company Only: a. During 2020, the parent recorded a non-cash exchange related to a reduction of intercompany loans and balances receivable of $204 million and a corresponding reduction of intercompany loans and balances payable of $204 million. b. During 2022, 2021 and 2020, dividends paid to common and preferred shareholders of $188 million, $129 million and $96 million, respectively, were paid by a Bermuda subsidiary on behalf of the parent, with a corresponding increase to intercompany balances payable. During 2020, the redemption of Series F preferred shares of $67 million in 2020 was also paid by a Bermuda subsidiary on behalf of the parent, with a corresponding increase to intercompany balances payable. c. During 2021, the parent recorded a non-cash dividend received from a subsidiary of $350 million, with a corresponding change to intercompany balances payable. During 2020, the parent recorded a non-cash capital contribution to a subsidiary of $25 million, with a corresponding change to the intercompany balances payable. d. During 2022, the parent recorded a non-cash exchange of certain intercompany balances payable for an intercompany loan payable of $744 million. e. During 2022, the parent recorded non-cash dividends received from subsidiaries of $630 million, non-cash capital contributions to subsidiaries of $527 million and a corresponding decrease in intercompany balances payable of $103 million.

SCHEDULE III - Supplementary _2

SCHEDULE III - Supplementary Insurance Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Deferred Policy Acquisition Costs		$ 1,012,850	$ 920,779	$ 819,971
Gross Reserves		12,725,631	12,047,792	11,395,321
Unearned Premiums		2,745,371	2,501,161	2,265,214
Other Benefits Payable		2,510,293	2,638,086	2,704,229
Premium Revenue		7,257,117	6,956,522	6,536,826
Net Investment Income (1)	[1]	398,348	376,469	360,668
Losses Incurred		4,747,403	4,883,984	5,334,900
Amortization of DAC		1,540,681	1,386,832	1,356,118
Other Expenses (2)	[2]	414,876	398,542	355,647
Premiums Written		7,544,195	7,134,018	6,300,858
Non Life
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Deferred Policy Acquisition Costs		700,694	617,537	543,416
Gross Reserves		12,725,631	12,047,792	11,395,321
Unearned Premiums		2,743,406	2,498,426	2,257,441
Other Benefits Payable		0	0	0
Premium Revenue		5,611,452	5,329,556	5,054,529
Losses Incurred		3,313,234	3,443,245	4,016,704
Amortization of DAC		1,430,121	1,279,039	1,254,067
Other Expenses (2)	[2]	119,274	100,635	87,163
Premiums Written		5,898,750	5,510,828	4,825,919
Life and Health
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Deferred Policy Acquisition Costs		312,156	303,242	276,555
Gross Reserves		0	0	0
Unearned Premiums		1,965	2,735	7,773
Other Benefits Payable		2,510,293	2,638,086	2,704,229
Premium Revenue		1,645,665	1,626,966	1,482,297
Net Investment Income (1)	[1]	73,656	81,226	68,259
Losses Incurred		1,434,169	1,440,739	1,318,196
Amortization of DAC		110,560	107,793	102,051
Other Expenses (2)	[2]	92,919	88,069	73,105
Premiums Written		1,645,445	1,623,190	1,474,939
Corporate and Other
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Deferred Policy Acquisition Costs		0	0	0
Gross Reserves		0	0	0
Unearned Premiums		0	0	0
Other Benefits Payable		0	0	0
Premium Revenue		0	0	0
Net Investment Income (1)	[1]	324,692	295,243	292,409
Losses Incurred		0	0	0
Amortization of DAC		0	0	0
Other Expenses (2)	[2]	202,683	209,838	195,379
Premiums Written		$ 0	$ 0	$ 0
[1]Because the Company does not manage its assets by segment, net investment income is not allocated to the Non-life business of the reinsurance operations. However, because of the interest-sensitive nature of some of the Company’s Life products, net investment income is considered in management’s assessment of the profitability of the Life and Health segment.[2]Other expenses are a component of underwriting result for the Non-life business and Life and Health segment as the Company allocates certain other expenses to its operating segments that vary with business written.

SCHEDULE IV - Reinsurance (Deta

SCHEDULE IV - Reinsurance (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Life reinsurance in force
Gross amount	[1]	$ 0	$ 0	$ 0
Ceded to other companies	[1]	20,301,849	19,383,794	18,764,660
Assumed from other companies	[1]	529,438,861	453,373,378	398,443,383
Net amount	[1]	$ 509,137,012	$ 433,989,584	$ 379,678,723
Percentage of amount assumed to net	[1]	104%	104%	105%
Reinsurance Premiums For Insurance Companies By Product Segment Net Amount [Abstract]
Gross amount		$ 377,380	$ 318,058	$ 269,691
Ceded to other companies		1,113,743	969,381	540,194
Assumed from other companies		7,993,480	7,607,845	6,807,329
Net premiums earned		$ 7,257,117	$ 6,956,522	$ 6,536,826
Percentage of amount assumed to net		110%	109%	104%
Life
Reinsurance Premiums For Insurance Companies By Product Segment Net Amount [Abstract]
Gross amount		$ 0	$ 0	$ 0
Ceded to other companies		28,426	24,519	23,522
Assumed from other companies		1,648,455	1,620,130	1,483,298
Net premiums earned		$ 1,620,029	$ 1,595,611	$ 1,459,776
Percentage of amount assumed to net		102%	102%	102%
Accident and health
Reinsurance Premiums For Insurance Companies By Product Segment Net Amount [Abstract]
Gross amount		$ 0	$ 0	$ 0
Ceded to other companies		0	0	0
Assumed from other companies		25,636	31,355	22,521
Net premiums earned		$ 25,636	$ 31,355	$ 22,521
Percentage of amount assumed to net		100%	100%	100%
Property and casualty
Reinsurance Premiums For Insurance Companies By Product Segment Net Amount [Abstract]
Gross amount	[2]	$ 377,380	$ 318,058	$ 269,691
Ceded to other companies	[2]	1,085,317	944,862	516,672
Assumed from other companies	[2]	6,319,389	5,956,360	5,301,510
Net premiums earned	[2]	$ 5,611,452	$ 5,329,556	$ 5,054,529
Percentage of amount assumed to net	[2]	113%	112%	105%
[1]Life reinsurance in force excludes products that do not pass risk transfer.[2]P&C includes Specialty and U.S. health premiums.

SCHEDULE VI - Supplemental In_2

SCHEDULE VI - Supplemental Information Concerning Property-Casualty Insurance Operations (Details) - Non Life - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Supplemental Information Concerning Property-Casualty Insurance Operations [Line Items]
Deferred Policy Acquisition Costs	[1]	$ 700,694	$ 617,537	$ 543,416
Liability for Unpaid Losses and Loss Expenses	[1]	12,725,631	12,047,792	11,395,321
Unearned Premiums	[1]	2,743,406	2,498,426	2,257,441
Premiums Earned	[1]	5,611,452	5,329,556	5,054,529
Losses and Loss Expenses Incurred Related to - Current year	[1]	3,533,087	3,637,671	3,945,248
Losses and Loss Expenses Incurred Related to - Prior year	[1]	(219,853)	(194,426)	71,456
Acquisition Costs	[1]	1,430,121	1,279,039	1,254,067
Paid Losses and Loss Expenses	[1]	2,658,136	2,972,995	3,232,604
Premiums Written	[1]	$ 5,898,750	$ 5,510,828	$ 4,825,919
[1](1) Includes the Company's P&C and Specialty segments.